BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 3228] [Cited by in F6Publishing: 2973] [Article Influence: 645.6] [Reference Citation Analysis]
Number Citing Articles
1 Patel AH, Peddu D, Amin S, Elsaid MI, Minacapelli CD, Chandler TM, Catalano C, Rustgi VK. Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment. J Clin Transl Hepatol 2023;11:502-15. [PMID: 36643037 DOI: 10.14218/JCTH.2022.00204] [Reference Citation Analysis]
2 Shen W, Middleton MS, Cunha GM, Delgado TI, Wolfson T, Gamst A, Fowler KJ, Alazraki A, Trout AT, Ohliger MA, Shah SN, Bashir MR, Kleiner DE, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Zhou J, Sirlin CB, Lavine JE. Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis. J Hepatol 2023;78:238-46. [PMID: 36368598 DOI: 10.1016/j.jhep.2022.10.027] [Reference Citation Analysis]
3 Hassoun S, Bruckmann C, Ciardullo S, Perseghin G, Di Gaudio F, Broccolo F. Setting up of a machine learning algorithm for the identification of severe liver fibrosis profile in the general US population cohort. Int J Med Inform 2023;170:104932. [PMID: 36459836 DOI: 10.1016/j.ijmedinf.2022.104932] [Reference Citation Analysis]
4 Zhang Y, Fu Q, Wu T, Liu K, Xiao Y, Liao Q, Qi X, Li Y, Zhou L. 5-Methoxyflavone ameliorates non-alcoholic fatty liver disease through targeting the cytochrome P450 1A1. Free Radic Biol Med 2023;195:178-91. [PMID: 36587922 DOI: 10.1016/j.freeradbiomed.2022.12.093] [Reference Citation Analysis]
5 Indira Chandran V, Wernberg CW, Lauridsen MM, Skytthe MK, Bendixen SM, Larsen FT, Hansen CD, Grønkjær LL, Siersbæk MS, Caterino TD, Detlefsen S, Møller HJ, Grøntved L, Ravnskjaer K, Moestrup SK, Thiele MS, Krag A, Graversen JH. Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness. Hepatology 2023;77:558-72. [PMID: 35712786 DOI: 10.1002/hep.32620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Pericàs JM, Tacke F, Anstee QM, Di Prospero NA, Kjær MS, Mesenbrink P, Koenig F, Genescà J, Ratziu V; EU-PEARL NASH Investigators. Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons. J Hepatol 2023;78:442-7. [PMID: 36216134 DOI: 10.1016/j.jhep.2022.09.021] [Reference Citation Analysis]
7 Huangfu G, Jaltotage B, Pang J, Lan NSR, Abraham A, Otto J, Ihdayhid AR, Rankin JM, Chow BJW, Watts GF, Ayonrinde OT, Dwivedi G. Hepatic fat as a novel marker for high-risk coronary atherosclerotic plaque features in familial hypercholesterolaemia. Metabolism 2023;139:155370. [PMID: 36464035 DOI: 10.1016/j.metabol.2022.155370] [Reference Citation Analysis]
8 Newberry C, Kumar S. Dietary and nutrition considerations in caring for patients with nonalcoholic fatty liver disease: Updates for the practicing clinician. Nutr Clin Pract 2023;38:70-9. [PMID: 36183354 DOI: 10.1002/ncp.10917] [Reference Citation Analysis]
9 Lin D, Sun Q, Liu Z, Pan J, Zhu J, Wang S, Jia S, Zheng M, Li X, Gong F. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice. Free Radic Biol Med 2023;195:199-218. [PMID: 36586452 DOI: 10.1016/j.freeradbiomed.2022.12.087] [Reference Citation Analysis]
10 Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. Clin Gastroenterol Hepatol 2023;21:370-9. [PMID: 35051649 DOI: 10.1016/j.cgh.2022.01.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
11 Ciardullo S, Perseghin G. Trends in prevalence of probable fibrotic non-alcoholic steatohepatitis in the United States, 1999-2016. Liver Int 2023;43:340-4. [PMID: 36565051 DOI: 10.1111/liv.15503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tamaki N, Imajo K, Sharpton SR, Jung J, Sutter N, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Kurosaki M, Izumi N, Nakajima A, Loomba R. Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD. Clin Gastroenterol Hepatol 2023;21:380-387.e3. [PMID: 35123096 DOI: 10.1016/j.cgh.2022.01.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Chen J, Ruan X, Sun Y, Li X, Yuan S, Larsson SC. Plasma phospholipid arachidonic acid in relation to non-alcoholic fatty liver disease: Mendelian randomization study. Nutrition 2023;106:111910. [PMID: 36459845 DOI: 10.1016/j.nut.2022.111910] [Reference Citation Analysis]
14 Yao JM, Ying HZ, Zhang HH, Qiu FS, Wu JQ, Yu CH. Exosomal RBP4 potentiated hepatic lipid accumulation and inflammation in high-fat-diet-fed mice by promoting M1 polarization of Kupffer cells. Free Radic Biol Med 2023;195:58-73. [PMID: 36572267 DOI: 10.1016/j.freeradbiomed.2022.12.085] [Reference Citation Analysis]
15 Zhang Z, Wang L, Lin Z, Yan W, Chen J, Zhang X, Ye W, Li J, Li Z. Dietary inflammatory index and risk of non-alcoholic fatty liver disease and advanced hepatic fibrosis in US adults. Front Nutr 2023;10. [DOI: 10.3389/fnut.2023.1102660] [Reference Citation Analysis]
16 Liao Y, Wang L, Liu F, Zhou Y, Lin X, Zhao Z, Xu S, Tang D, Jiao Y, Yang L, Yu W, Gao P. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis. Front Endocrinol 2023;14. [DOI: 10.3389/fendo.2023.1078149] [Reference Citation Analysis]
17 Dahmus J, Hummer B, Rivas G, Schmitz K, Caldwell SH, Argo CK, Schreibman I, Stine JG. Patients with Nonalcoholic Steatohepatitis and Advanced Liver Disease Have the Lowest Cardiorespiratory Fitness. Dig Dis Sci 2023. [PMID: 36692803 DOI: 10.1007/s10620-022-07809-w] [Reference Citation Analysis]
18 Kamari N, Moradinazar M, Qasemi M, Khosravy T, Samadi M, Abdolahzad H. Combination of the effect of ginger and anti‐inflammatory diet on children with obesity with nonalcoholic fatty liver disease: A randomized clinical trial. Food Science & Nutrition 2023. [DOI: 10.1002/fsn3.3218] [Reference Citation Analysis]
19 Jin L, Xu M. Characterization of gut dominant microbiota in obese patients with nonalcoholic fatty liver disease. Front Cell Infect Microbiol 2023;13. [DOI: 10.3389/fcimb.2023.1113643] [Reference Citation Analysis]
20 Gu Y, Sun L, He Y, Yang L, Deng C, Zhou R, Kong T, Zhang W, Chen Y, Li J, Shi J. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials. Expert Rev Gastroenterol Hepatol 2023. [PMID: 36689199 DOI: 10.1080/17474124.2023.2172397] [Reference Citation Analysis]
21 Bullón-Vela V, Xu Y, Razquin C, Abete I, Zulet MA, Martínez-González MA, Buil-Corsiales P, Vitelli-Storelli F, Martín Sánchez V, Vazquez-Ruíz Z, Sayón-Orea C, Domínguez-Fernández M, Cid C, Estruch R, Lamuela-Raventós RM, Fitó M, Blanchart G, Babio N, Salas-Salvadó J, Tinahones FJ, Tur JA, Romaguera D, Konieczna J, Pintó X, Daimiel L, Rodriguez-Mateos A, Martínez JA. Health associations of liver enzymes and inflammatory scores with urinary citrus flavonoid metabolites. Food Funct 2023;14:1011-23. [PMID: 36562455 DOI: 10.1039/d2fo02846h] [Reference Citation Analysis]
22 Amin NB, Saxena AR, Somayaji V, Dullea R. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology. Clin Ther 2023:S0149-2918(22)00414-3. [PMID: 36690550 DOI: 10.1016/j.clinthera.2022.12.008] [Reference Citation Analysis]
23 Pal SC, Méndez-Sánchez N. Screening for MAFLD: who, when and how? Ther Adv Endocrinol Metab 2023;14:20420188221145650. [PMID: 36699945 DOI: 10.1177/20420188221145650] [Reference Citation Analysis]
24 Zheng J, Li X, Zhang Y, Miao Y, Zhang Q. Hyperuricemia as an effect modifier of the association between metabolic phenotypes and nonalcoholic fatty liver disease in Chinese population. J Transl Med 2023;21:39. [PMID: 36681819 DOI: 10.1186/s12967-022-03850-5] [Reference Citation Analysis]
25 Pickhardt PJ, Correale L, Hassan C. AI-based opportunistic CT screening of incidental cardiovascular disease, osteoporosis, and sarcopenia: cost-effectiveness analysis. Abdom Radiol (NY) 2023. [PMID: 36670245 DOI: 10.1007/s00261-023-03800-9] [Reference Citation Analysis]
26 Sanyal A, Shankar S, Yates K, Bolognese J, Daly E, Dehn C, Neuschwander-tetri B, Kowdley K, Vuppalanchi R, Behling CA, Tonascia J, Samir A, Sirlin C, Sherlock S, Fowler K, Heymann H, Kamphaus T, Loomba R, Calle R. The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis.. [DOI: 10.21203/rs.3.rs-2492725/v1] [Reference Citation Analysis]
27 Belfort-DeAguiar R, Lomonaco R, Cusi K. Approach to the Patient With Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab 2023;108:483-95. [PMID: 36305273 DOI: 10.1210/clinem/dgac624] [Reference Citation Analysis]
28 Barbieri E, Santoro N, Umano GR. Clinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity. Front Endocrinol 2023;14. [DOI: 10.3389/fendo.2023.1062341] [Reference Citation Analysis]
29 Ciardullo S, Muraca E, Bianconi E, Cannistraci R, Perra S, Zerbini F, Perseghin G. Diabetes Mellitus is Associated With Higher Serum Neurofilament Light Chain Levels in the General US Population. J Clin Endocrinol Metab 2023;108:361-7. [PMID: 36196647 DOI: 10.1210/clinem/dgac580] [Reference Citation Analysis]
30 Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, Guo J. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol 2023;13. [DOI: 10.3389/fendo.2022.1087260] [Reference Citation Analysis]
31 Nam H, Yoo JJ, Cho Y, Kang SH, Ahn SB, Lee HW, Jun DW, Song DS, Choi M. Effect of exercise-based interventions in nonalcoholic fatty liver disease: A systematic review with meta-analysis. Dig Liver Dis 2023:S1590-8658(22)00861-1. [PMID: 36653265 DOI: 10.1016/j.dld.2022.12.013] [Reference Citation Analysis]
32 Song W, Yoo SH, Jang J, Baik SJ, Lee BK, Lee HW, Park JS. Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis. Gut Liver 2023;17:130-8. [PMID: 36472070 DOI: 10.5009/gnl220041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Tovo CV, de Mattos AZ, Coral GP, Sartori GDP, Nogueira LV, Both GT, Villela-Nogueira CA, de Mattos AA. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. World J Gastroenterol 2023; 29(2): 343-356 [DOI: 10.3748/wjg.v29.i2.343] [Reference Citation Analysis]
34 Cernea S, Onișor D. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. World J Gastroenterol 2023; 29(2): 286-309 [DOI: 10.3748/wjg.v29.i2.286] [Reference Citation Analysis]
35 Julián MT, Ballesta S, Pera G, Pérez-montes de Oca A, Soldevila B, Caballería L, Morillas R, Expósito C, Martínez–escudé A, Puig-domingo M, Franch-nadal J, Torán P, Cusi K, Julve J, Mauricio D, Alonso N. Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study. Front Endocrinol 2023;13. [DOI: 10.3389/fendo.2022.1051958] [Reference Citation Analysis]
36 Li Y, Wang Q, Li J, Li A, Wang Q, Zhang Q, Chen Y. Therapeutic modulation of V Set and Ig domain-containing 4 (VSIG4) signaling in immune and inflammatory diseases. Cytotherapy 2023:S1465-3249(22)01074-X. [PMID: 36642683 DOI: 10.1016/j.jcyt.2022.12.004] [Reference Citation Analysis]
37 Yang Z, Tian R, Zhang X, Cai J, She Z, Li H. Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction. Front Cardiovasc Med 2023;9. [DOI: 10.3389/fcvm.2022.1120085] [Reference Citation Analysis]
38 Gao W, Zhang L, Wu J, Xu Y, Qi S, Liu W, Liu P, Shi S, Wang H, Zhang Q, Wang Y, Wang S. Extraction, characterization, and anti-nonalcoholic steatohepatitis activity of a (1,3) (1,6)-β-D-glucan from the Polyporus umbellatus (Pers.) Fries. Int J Biol Macromol 2023;230:123252. [PMID: 36639082 DOI: 10.1016/j.ijbiomac.2023.123252] [Reference Citation Analysis]
39 Yang Y, Wu C. The linkage of gut microbiota and the property theory of traditional Chinese medicine (TCM): Cold-natured and sweet-flavored TCMs as an example. J Ethnopharmacol 2023;306:116167. [PMID: 36641107 DOI: 10.1016/j.jep.2023.116167] [Reference Citation Analysis]
40 Li J, Wu N, Yang Y, Zhai X, Yuan F, Zhang F, Yu N, Li D, Wang R, Wang J, Zhang L, Shi Y, He G, Liu B. Unique genetic variants of lean nonalcoholic fatty liver disease: a retrospective cohort study. BMC Endocr Disord 2023;23:11. [PMID: 36627697 DOI: 10.1186/s12902-022-01234-w] [Reference Citation Analysis]
41 Barrientos-Riosalido A, Real M, Bertran L, Aguilar C, Martínez S, Parada D, Vives M, Sabench F, Riesco D, Castillo DD, Richart C, Auguet T. Increased Hepatic ATG7 mRNA and ATG7 Protein Expression in Nonalcoholic Steatohepatitis Associated with Obesity. Int J Mol Sci 2023;24. [PMID: 36674839 DOI: 10.3390/ijms24021324] [Reference Citation Analysis]
42 Shahryari M, Keller S, Meierhofer D, Wallach I, Safraou Y, Guo J, Marticorena Garcia SR, Braun J, Makowski MR, Sack I, Berndt N. On the relationship between metabolic capacities and in vivo viscoelastic properties of the liver. Front Bioeng Biotechnol 2022;10:1042711. [PMID: 36698634 DOI: 10.3389/fbioe.2022.1042711] [Reference Citation Analysis]
43 Jirapinyo P, Zucker SD, Thompson CC. Regression of Hepatic Fibrosis After Endoscopic Gastric Plication in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2023. [PMID: 36597405 DOI: 10.14309/ajg.0000000000002087] [Reference Citation Analysis]
44 Şendur HN, Cerit MN, Fatullayeva T, Erdal ZS, Karabörk Kılıç AC, Özhan Oktar S. Do Ultrasound Based Quantitative Hepatic Fat Content Measurements Have Differences Between Respiratory Phases? Acad Radiol 2023:S1076-6332(22)00662-6. [PMID: 36628802 DOI: 10.1016/j.acra.2022.12.021] [Reference Citation Analysis]
45 Kiens O, Taalberg E, Ivanova V, Veeväli K, Laurits T, Tamm R, Ottas A, Kilk K, Soomets U, Altraja A. Apnoea-hypopnoea index of 5 events·h(-1) as a metabolomic threshold in patients with sleep complaints. ERJ Open Res 2023;9:00325-2022. [PMID: 36632170 DOI: 10.1183/23120541.00325-2022] [Reference Citation Analysis]
46 Jin D, Cui Z, Jin S, Zhou T, Guo B, Gao P, Li G. Comparison of efficacy of anti-diabetics on non-diabetic NAFLD: A network meta-analysis. Front Pharmacol 2022;13:1096064. [PMID: 36699084 DOI: 10.3389/fphar.2022.1096064] [Reference Citation Analysis]
47 Zhang M, Lin Y, Chen R, Yu H, Li Y, Chen M, Dou C, Yin P, Zhang L, Tang P. Ghost messages: cell death signals spread. Cell Commun Signal 2023;21:6. [PMID: 36624476 DOI: 10.1186/s12964-022-01004-0] [Reference Citation Analysis]
48 Jeeyavudeen MS, Khan SKA, Fouda S, Pappachan JM. Management of metabolic-associated fatty liver disease: The diabetology perspective. World J Gastroenterol 2023; 29(1): 126-143 [DOI: 10.3748/wjg.v29.i1.126] [Reference Citation Analysis]
49 Fu H, Yu H, Zhao Y, Chen J, Liu Z. Association Between Hypertension and the Prevalence of Liver Steatosis and Fibrosis.. [DOI: 10.21203/rs.3.rs-2400318/v1] [Reference Citation Analysis]
50 Zhang W, Wang X, Huang J, Wang S, Yao Q, Li H. Healthy Eating Index-2015 in relation to risk of metabolic dysfunction-associated fatty liver disease among US population: National Health and Nutrition Examination Survey 2017–2018. Front Nutr 2023;9. [DOI: 10.3389/fnut.2022.1043901] [Reference Citation Analysis]
51 Ravaioli F, Dajti E, Mantovani A, Newsome PN, Targher G, Colecchia A. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis. Gut 2023:gutjnl-2022-328689. [PMID: 36599683 DOI: 10.1136/gutjnl-2022-328689] [Reference Citation Analysis]
52 Villavicencio EA, Maldonado A, Crocker RM, Guan Y, Stallman C, Garcia DO. Communicating PNPLA3 genetic risk status for NAFLD among Mexican-origin men. Front Public Health 2022;10:1090101. [PMID: 36684893 DOI: 10.3389/fpubh.2022.1090101] [Reference Citation Analysis]
53 Handelsman Y, Butler J, Bakris GL, DeFronzo RA, Fonarow GC, Green JB, Grunberger G, Januzzi JL Jr, Klein S, Kushner PR, McGuire DK, Michos ED, Morales J, Pratley RE, Weir MR, Wright E, Fonseca VA. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications 2023;37:108389. [PMID: 36669322 DOI: 10.1016/j.jdiacomp.2022.108389] [Reference Citation Analysis]
54 Collins M, Patel K. Non‐Alcoholic Fatty Liver Disease. The Liver in Systemic Disease 2023. [DOI: 10.1002/9781119802181.ch17] [Reference Citation Analysis]
55 Schattenberg JM, Allen AM, Jarvis H, Zelber-Sagi S, Cusi K, Dillon JF, Caussy C, Francque SM, Younossi Z, Alkhouri N, Lazarus JV. A multistakeholder approach to innovations in NAFLD care. Commun Med (Lond) 2023;3:1. [PMID: 36596859 DOI: 10.1038/s43856-022-00228-y] [Reference Citation Analysis]
56 Khorasani S, Boike J, Duarte-Rojo A. Will noninvasive screening for fibrosis/steatosis open Pandora's box? Sharing the healthcare burden of state-of-the-art hepatology practice. Hepatology 2023. [PMID: 36680399 DOI: 10.1097/HEP.0000000000000235] [Reference Citation Analysis]
57 Ng CH, Chan KE, Muthiah M, Tan C, Tay P, Lim WH, Tan DJH, Fu CE, Yong JN, Wong ZY, Koh B, Chew NW, Syn N, Huang DQ, Young Dan Y, Siddiqui MS, Sanyal AJ, Noureddin M. Examining the interim proposal for name change to steatotic liver disease in the US population. Hepatology 2023. [PMID: 36645228 DOI: 10.1097/HEP.0000000000000043] [Reference Citation Analysis]
58 Ezpeleta M, Gabel K, Cienfuegos S, Kalam F, Lin S, Pavlou V, Song Z, Haus JM, Koppe S, Alexandria SJ, Tussing-Humphreys L, Varady KA. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial. Cell Metab 2023;35:56-70.e3. [PMID: 36549296 DOI: 10.1016/j.cmet.2022.12.001] [Reference Citation Analysis]
59 Siener R, Metzner C. Dietary weight loss strategies for kidney stone patients. World J Urol 2023. [PMID: 36593299 DOI: 10.1007/s00345-022-04268-w] [Reference Citation Analysis]
60 Sripongpun P, Kim WR, Mannalithara A, Charu V, Vidovszky A, Asch S, Desai M, Kim SH, Kwong AJ. The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care. Hepatology 2023;77:256-67. [PMID: 35477908 DOI: 10.1002/hep.32545] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
61 ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Cusi K, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46:S49-67. [PMID: 36507651 DOI: 10.2337/dc23-S004] [Reference Citation Analysis]
62 Barcelos STA, Silva-Sperb AS, Moraes HA, Longo L, de Moura BC, Michalczuk MT, Uribe-Cruz C, Cerski CTS, da Silveira TR, Dall'Alba V, Álvares-da-Silva MR. Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study. Ann Hepatol 2023;28:100769. [PMID: 36216309 DOI: 10.1016/j.aohep.2022.100769] [Reference Citation Analysis]
63 Shalimar, Sheikh SS, Biswas S, Vaishnav M, Pathak P, Pachisia AV, Narang H, Prasad S, Mehta S, Dhooria A, Swaroop S, Golla R, Agarwal A, Kumar R, Acharya SK. Incidence and Predictors of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol 2023;13:37-47. [PMID: 36647411 DOI: 10.1016/j.jceh.2022.09.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Reynolds JV, Donlon NE, Elliott JA, Moran B, Temperley H, Nugent TS, Davern M, King S, Conroy M, Lysaght J, Ravi N, Ryan C, Finn S, Norris S, Donohoe CL. Incidence and Impact of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent. World J Surg 2023;47:227-35. [PMID: 36264338 DOI: 10.1007/s00268-022-06781-w] [Reference Citation Analysis]
65 Pan J, Li Q, Sun Y, Gu Y, Ding Y, Pang N, Zhou Y, Pei L, Gao M, Ma S, Xiao Y, Wu F, Hu D, Chen Y, Yang L. Increased Serum Adipsin Correlates with MAFLD and Metabolic Risk Abnormalities. DMSO 2023;Volume 16:187-200. [DOI: 10.2147/dmso.s396335] [Reference Citation Analysis]
66 Yilmaz Y, Toraman AE, Alp C, Doğan Z, Keklikkiran C, Stepanova M, Younossi Z. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study. Aliment Pharmacol Ther 2023;57:215-23. [PMID: 36369643 DOI: 10.1111/apt.17301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
67 Pugliese N, Alfarone L, Arcari I, Giugliano S, Parigi TL, Rescigno M, Lleo A, Aghemo A. Clinical features and management issues of NAFLD-related HCC: what we know so far. Expert Rev Gastroenterol Hepatol 2023;17:31-43. [PMID: 36576057 DOI: 10.1080/17474124.2023.2162503] [Reference Citation Analysis]
68 Koseki M. Nonalcoholic fatty liver disease and cardiovascular disease. Cardio-Hepatology 2023. [DOI: 10.1016/b978-0-12-817394-7.00011-5] [Reference Citation Analysis]
69 Fasoula N, Karlas A, Prokopchuk O, Katsouli N, Bariotakis M, Liapis E, Goetz A, Kallmayer M, Reber J, Novotny A, Friess H, Ringelhan M, Schmid R, Eckstein H, Hofmann S, Ntziachristos V. Non-invasive multispectral optoacoustic tomography resolves intrahepatic lipids in patients with hepatic steatosis. Photoacoustics 2023. [DOI: 10.1016/j.pacs.2023.100454] [Reference Citation Analysis]
70 Priyadi H, Trimurtini I, Pontjosudargo FA. The Influence of Plum (Prunus salicina Lindl) Extract to Liver MDA Levels in Rats Induced by High Fat Diet. Proceedings of The 13th Annual Scientific Conference of Medical Faculty, Universitas Jenderal Achmad Yani (ASCMF 2022) 2023. [DOI: 10.2991/978-94-6463-060-2_19] [Reference Citation Analysis]
71 Pan Y, Zhang X. Diet Modulates Gut Microbiome and Metabolites in Non-alcoholic Fatty Liver Diseases. Microbiome in Gastrointestinal Cancer 2023. [DOI: 10.1007/978-981-19-4492-5_9] [Reference Citation Analysis]
72 Singh SP, Anirvan P. NAFLD in Indians: A Myopic Yet Alarming Perspective. J Clin Exp Hepatol 2023;13:7-9. [PMID: 36647401 DOI: 10.1016/j.jceh.2022.11.016] [Reference Citation Analysis]
73 Lawitz EJ, Bhandari BR, Ruane PJ, Kohli A, Harting E, Ding D, Chuang JC, Huss RS, Chung C, Myers RP, Loomba R. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. Clin Gastroenterol Hepatol 2023;21:143-152.e3. [PMID: 34999207 DOI: 10.1016/j.cgh.2021.12.044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
74 Amangurbanova M, Huang DQ, Loomba R. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. Aliment Pharmacol Ther 2023;57:37-51. [PMID: 36349732 DOI: 10.1111/apt.17292] [Reference Citation Analysis]
75 Li Y, Lei R, Lei H, Xiong Q, Xie F, Yao C, Feng P. Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Eur J Gastroenterol Hepatol 2023;35:1-14. [PMID: 36468565 DOI: 10.1097/MEG.0000000000002471] [Reference Citation Analysis]
76 Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, Tan DJH, Tang ASP, Tay P, Xiao J, Yong JN, Zeng RW, Chew NWS, Nah B, Kulkarni A, Siddiqui MS, Dan YY, Wong VW, Sanyal AJ, Noureddin M, Muthiah M, Ng CH. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2023;8:20-30. [PMID: 36400097 DOI: 10.1016/S2468-1253(22)00317-X] [Reference Citation Analysis]
77 Schwenger KJP, Alali M, Ghorbani Y, Fischer SE, Jackson TD, Okrainec A, Allard JP. Reliability of Non-invasive Liver Fibrosis Assessment Tools Versus Biopsy in Pre- and Post-bariatric Surgery Patients with Non-alcoholic Fatty Liver Disease. Obes Surg 2023;33:247-55. [PMID: 36464738 DOI: 10.1007/s11695-022-06380-7] [Reference Citation Analysis]
78 Shah PA, Patil R, Harrison SA. NAFLD-related hepatocellular carcinoma: The growing challenge. Hepatology 2023;77:323-38. [PMID: 35478412 DOI: 10.1002/hep.32542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
79 Tian H, Fang Y, Liu W, Wang J, Zhao J, Tang H, Yin Y, Hu Y, Peng J. Inhibition on XBP1s-driven lipogenesis by Qushi Huayu Decoction contributes to amelioration of hepatic steatosis induced by fructose. Journal of Ethnopharmacology 2023;301:115806. [DOI: 10.1016/j.jep.2022.115806] [Reference Citation Analysis]
80 Xiao J, Ng CH, Chan KE, Tang ASP, Teh R, Ling AHZ, Yong JN, Lim WH, Tan DJH, Tan C, Win KM, Bwa AH, Chew NWS, Huang D, Dan YY, Noureddin M, Siddiqui MS, Sanyal A, Tamaki N, Muthiah M. Complete alcohol abstinence increases the risk of NAFLD but not severity. A population analysis with transient elastography. Scand J Gastroenterol 2023;58:76-82. [PMID: 35944527 DOI: 10.1080/00365521.2022.2105168] [Reference Citation Analysis]
81 Contreras D, González-Rocha A, Clark P, Barquera S, Denova-Gutiérrez E. Diagnostic accuracy of blood biomarkers and non-invasive scores for the diagnosis of NAFLD and NASH: Systematic review and meta-analysis. Ann Hepatol 2023;28:100873. [PMID: 36371077 DOI: 10.1016/j.aohep.2022.100873] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Zheng M, Ai Z, Guo Y, Chen Y, Xie P, An W. Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma. Oncogene 2023;42:308-21. [PMID: 36434180 DOI: 10.1038/s41388-022-02549-7] [Reference Citation Analysis]
83 Berná G, López-bermudo L, Escudero-lópez B, Martín F. We are what we eat: The role of lipids in metabolic diseases. Advances in Food and Nutrition Research 2023. [DOI: 10.1016/bs.afnr.2022.11.004] [Reference Citation Analysis]
84 Heinrich B. [Innate and adaptive immunity in the context of non-alcoholic fatty liver disease]. Z Gastroenterol 2023;61:76-82. [PMID: 36623545 DOI: 10.1055/a-1993-3519] [Reference Citation Analysis]
85 Draijer L, Voorhoeve M, Troelstra M, Holleboom A, Beuers U, Kusters M, Nederveen A, Benninga M, Koot B. A natural history study of pediatric non-alcoholic fatty liver disease over 10 years. JHEP Reports 2023. [DOI: 10.1016/j.jhepr.2023.100685] [Reference Citation Analysis]
86 Brown EA, Minnich A, Sanyal AJ, Loomba R, Du S, Schwarz J, Ehman RL, Karsdal M, Leeming DJ, Cizza G, Charles ED. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. JHEP Reports 2023. [DOI: 10.1016/j.jhepr.2022.100661] [Reference Citation Analysis]
87 Park Y, Sinn DH, Kim K, Gwak GY. The association of non-alcoholic fatty liver disease between parents and adolescent children. Aliment Pharmacol Ther 2023;57:245-52. [PMID: 36271616 DOI: 10.1111/apt.17257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
88 Zhang J, Xie H, Yao J, Jin W, Pan H, Pan Z, Xie D, Xie D. TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination. Hum Cell 2023;36:209-22. [PMID: 36417114 DOI: 10.1007/s13577-022-00820-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Zou CY, Sun Y, Liang J. Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis(,). Clin Res Hepatol Gastroenterol 2023;47:102053. [PMID: 36403941 DOI: 10.1016/j.clinre.2022.102053] [Reference Citation Analysis]
90 Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol 2023;29:77-98. [PMID: 36226471 DOI: 10.3350/cmh.2022.0237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 de Mutsert R, Després J. Overall, abdominal, and visceral obesity in men and women: an introduction. Visceral and Ectopic Fat 2023. [DOI: 10.1016/b978-0-12-822186-0.00017-1] [Reference Citation Analysis]
92 Mao Y, Ying M, Xu G. Identification of hub genes and small molecule therapeutic drugs related to simple steatosis with secondary analysis of existing microarray data. All Life 2022;15:921-932. [DOI: 10.1080/26895293.2022.2114550] [Reference Citation Analysis]
93 Morishita A, Oura K, Takuma K, Nakahara M, Tadokoro T, Fujita K, Tani J, Shi T, Himoto T, Tatsuta M, Moriya A, Senoo T, Tsutsui A, Nagano T, Takaguchi K, Ono M, Masaki T. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatol Int 2022. [PMID: 36583842 DOI: 10.1007/s12072-022-10453-1] [Reference Citation Analysis]
94 Kwon OY, Kim SU, Ahn SH, Jang Y. Self-Management and Associated Factors among Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study. Int J Environ Res Public Health 2022;20. [PMID: 36612985 DOI: 10.3390/ijerph20010667] [Reference Citation Analysis]
95 Bao J, Lv Y, Wang K, Wang Q, Chen Y, Dong Y, Zhu Y, Wang W. A Comparative Study of Ultrasound Attenuation Imaging, Controlled Attenuation Parameters, and Magnetic Resonance Spectroscopy for the Detection of Hepatic Steatosis. J Ultrasound Med 2022. [PMID: 36583414 DOI: 10.1002/jum.16158] [Reference Citation Analysis]
96 Feldman F, Koudoufio M, El-Jalbout R, Sauvé MF, Ahmarani L, Sané AT, Ould-Chikh NE, N'Timbane T, Patey N, Desjardins Y, Stintzi A, Spahis S, Levy E. Cranberry Proanthocyanidins as a Therapeutic Strategy to Curb Metabolic Syndrome and Fatty Liver-Associated Disorders. Antioxidants (Basel) 2022;12. [PMID: 36670951 DOI: 10.3390/antiox12010090] [Reference Citation Analysis]
97 Guo Z, Kong D, Du H, Yun Z, Zhang J, Li X, Ye Y. Association of type 2 diabetes mellitus and other glycemic traits with the risk of NAFLD.. [DOI: 10.21203/rs.3.rs-2377438/v1] [Reference Citation Analysis]
98 Bukke VN, Moola A, Serviddio G, Vendemiale G, Bellanti F. Nuclear factor erythroid 2-related factor 2-mediated signaling and metabolic associated fatty liver disease. World J Gastroenterol 2022; 28(48): 6909-6921 [DOI: 10.3748/wjg.v28.i48.6909] [Reference Citation Analysis]
99 Mantovani A, Csermely A, Taverna A, Cappelli D, Benfari G, Bonapace S, Byrne CD, Targher G. Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes. Diabetes Metab 2022;49:101416. [PMID: 36586476 DOI: 10.1016/j.diabet.2022.101416] [Reference Citation Analysis]
100 Canivet CM, Boursier J. Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022? Diagnostics (Basel) 2022;13. [PMID: 36611384 DOI: 10.3390/diagnostics13010091] [Reference Citation Analysis]
101 Chong SE, Chang F, Chuah KH, Sthaneshwar P, Mustapha NRN, Mahadeva S, Chan WK. Validation of the Hepamet fibrosis score in a multi-ethnic Asian population. Ann Hepatol 2022;:100888. [PMID: 36586588 DOI: 10.1016/j.aohep.2022.100888] [Reference Citation Analysis]
102 Wang Z, Zhu Y, Xia L, Li J, Song M, Yang C. Exercise-Induced ADAR2 Protects against Nonalcoholic Fatty Liver Disease through miR-34a. Nutrients 2022;15. [PMID: 36615779 DOI: 10.3390/nu15010121] [Reference Citation Analysis]
103 Zhang Z, Chen C, Wang Y, Wang N, Chen Y, Lu Y, Xia F. The associations of total testosterone with probable nonalcoholic steatohepatitis and nonalcoholic fatty liver disease fibrotic progression in men with type 2 diabetes: a cross-sectional study. Eur J Med Res 2022;27:307. [PMID: 36572925 DOI: 10.1186/s40001-022-00958-8] [Reference Citation Analysis]
104 Genua I, Iruzubieta P, Rodríguez-Duque JC, Pérez A, Crespo J. NAFLD and type 2 diabetes: A practical guide for the joint management. Gastroenterol Hepatol 2022:S0210-5705(22)00311-9. [PMID: 36584750 DOI: 10.1016/j.gastrohep.2022.12.002] [Reference Citation Analysis]
105 Okada A, Yamada G, Kimura T, Hagiwara Y, Yamaguchi S, Kurakawa KI, Nangaku M, Yamauchi T, Matsuyama Y, Kadowaki T. Diagnostic ability using fatty liver and metabolic markers for metabolic-associated fatty liver disease stratified by metabolic/glycemic abnormalities. J Diabetes Investig 2022. [PMID: 36566480 DOI: 10.1111/jdi.13966] [Reference Citation Analysis]
106 Lønsmann I, Steen Pedersen J, Krag A, Hansen T, Karsdal M, Julie Leeming D, Juul Nielsen M, Bendtsen F. Biomarkers reflecting pericellular fibrosis improve together with liver histology after bariatric surgery in early non-alcoholic fatty liver disease. Clin Biochem 2022;113:29-35. [PMID: 36574896 DOI: 10.1016/j.clinbiochem.2022.12.012] [Reference Citation Analysis]
107 Park J, Kim G, Kim H, Lee J, Jin SM, Kim JH. The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study. Cardiovasc Diabetol 2022;21:287. [PMID: 36564787 DOI: 10.1186/s12933-022-01725-z] [Reference Citation Analysis]
108 Gjurašin B, Jeličić M, Kutleša M, Papić N. The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes. Life (Basel) 2022;13. [PMID: 36675985 DOI: 10.3390/life13010036] [Reference Citation Analysis]
109 Pervez MA, Khan DA, Gilani STA, Fatima S, Ijaz A, Nida S. Hepato-Protective Effects of Delta-Tocotrienol and Alpha-Tocopherol in Patients with Non-Alcoholic Fatty Liver Disease: Regulation of Circulating MicroRNA Expression. Int J Mol Sci 2022;24. [PMID: 36613525 DOI: 10.3390/ijms24010079] [Reference Citation Analysis]
110 Prieto Ortíz JE, Sánchez Luque CB, Ortega Quiróz RJ. Hígado graso (parte 1): aspectos generales, epidemiología, fisiopatología e historia natural. Rev colomb Gastroenterol 2022;37:420-433. [DOI: 10.22516/25007440.952] [Reference Citation Analysis]
111 Vélez Aguirre JD, Yepez Barreto IDJ. Factores asociados a la masa y la fuerza muscular en pacientes con cirrosis hepática: un estudio transversal. Rev colomb Gastroenterol 2022;37:410-419. [DOI: 10.22516/25007440.936] [Reference Citation Analysis]
112 Cheng X, Fu Z, Xie W, Zhu L, Meng J. Preoperative circulating peroxiredoxin 1 levels as a predictor of non-alcoholic fatty liver disease remission after laparoscopic bariatric surgery. Front Endocrinol (Lausanne) 2022;13:1072513. [PMID: 36619535 DOI: 10.3389/fendo.2022.1072513] [Reference Citation Analysis]
113 Carretero-Gómez J, Carrasco-Sánchez FJ, Fernández-Rodríguez JM, Casado-Escribano P, Miramontes-González JP, Seguí-Ripoll JM, Ena J, Arévalo-Lorido JC; Diabetes Obesity and Nutrition Working Group of the Spanish Society of Internal Medicine (SEMI). Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity. Rev Clin Esp (Barc) 2022:S2254-8874(22)00104-7. [PMID: 36549643 DOI: 10.1016/j.rceng.2022.12.001] [Reference Citation Analysis]
114 Price JC, Ma Y, Kuniholm MH, Adimora AA, Fischl M, French AL, Golub ET, Konkle-Parker D, Minkoff H, Ofotokun I, Plankey M, Sharma A, Tien PC. Human Immunodeficiency Virus Is Associated With Elevated FibroScan-Aspartate Aminotransferase (FAST) Score. Clin Infect Dis 2022;75:2119-27. [PMID: 35511608 DOI: 10.1093/cid/ciac337] [Reference Citation Analysis]
115 Raahimi MM, Livesey A, Hamilton J, Shipman AR, Aspinall RJ. Liver fibrosis for the dermatologist: a review. Clinical and Experimental Dermatology 2022. [DOI: 10.1093/ced/llac083] [Reference Citation Analysis]
116 Antwi SO, Craver EC, Nartey YA, Sartorius K, Patel T. Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study. Cancers (Basel) 2022;14. [PMID: 36551719 DOI: 10.3390/cancers14246234] [Reference Citation Analysis]
117 Fan H, Xu C, Li W, Huang Y, Hua R, Xiong Y, Yang Y, Feng X, Wang Z, Yuan Z, Zhou J. Ideal Cardiovascular Health Metrics Are Associated with Reduced Severity of Hepatic Steatosis and Liver Fibrosis Detected by Transient Elastography. Nutrients 2022;14. [PMID: 36558503 DOI: 10.3390/nu14245344] [Reference Citation Analysis]
118 Seko Y, Takahashi H, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Nakajima A, Itoh Y; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: Multicenter study. Hepatol Res 2022. [PMID: 36524984 DOI: 10.1111/hepr.13871] [Reference Citation Analysis]
119 Wang S, Li X, Xu W, Gao J, Wang Y, Jia X, Li G, Pan Q, Chen K. Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1. Int J Mol Sci 2022;23. [PMID: 36555703 DOI: 10.3390/ijms232416063] [Reference Citation Analysis]
120 Ting YW, Jalaludin MY, Zaini AA, Mohamed R. Triglyceride to high-density lipoprotein cholesterol ratio is an independent predictor of liver fibrosis among pediatrics non-alcoholic fatty liver disease. Front Endocrinol (Lausanne) 2022;13:1071350. [PMID: 36589844 DOI: 10.3389/fendo.2022.1071350] [Reference Citation Analysis]
121 Lee HA, Moon H, Kim Y, Lee HA, Kim HY. Effect of 12-week intermittent calorie restriction on liver fat content in comparison with standard-of-care in patients with nonalcoholic fatty liver disease: a study protocol for a randomized controlled trial (FLICR).. [DOI: 10.21203/rs.3.rs-2224684/v1] [Reference Citation Analysis]
122 Peloso A, Tihy M, Moeckli B, Rubbia-Brandt L, Toso C. Clearing Steatosis Prior to Liver Surgery for Colorectal Metastasis: A Narrative Review and Case Illustration. Nutrients 2022;14. [PMID: 36558499 DOI: 10.3390/nu14245340] [Reference Citation Analysis]
123 Saxena AR, Lyle SA, Khavandi K, Qiu R, Whitlock M, Esler WP, Kim AM. A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes Obes Metab 2022. [PMID: 36515213 DOI: 10.1111/dom.14946] [Reference Citation Analysis]
124 Sanyal AJ, Williams SA, Lavine JE, Neuschwander-Tetri BA, Alexander L, Ostroff R, Biegel H, Kowdley KV, Chalasani N, Dasarathy S, Diehl AM, Loomba R, Hameed B, Behling C, Kleiner DE, Karpen SJ, Williams J, Jia Y, Yates KP, Tonascia J. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. J Hepatol 2022:S0168-8278(22)03326-8. [PMID: 36528237 DOI: 10.1016/j.jhep.2022.11.029] [Reference Citation Analysis]
125 Choi SW, Kweon SS, Lee YH, Ryu SY, Nam HS, Shin MH. Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: The Dong-gu study. PLoS One 2022;17:e0277729. [PMID: 36512564 DOI: 10.1371/journal.pone.0277729] [Reference Citation Analysis]
126 He W, Huang C, Wang L, Su W, Wang S, Huang P, Zhang X, Huang Y, Zhao Y, Lin M, Shi X, Li X. The correlation between triiodothyronine and the severity of liver fibrosis. BMC Endocr Disord 2022;22:313. [PMID: 36503486 DOI: 10.1186/s12902-022-01228-8] [Reference Citation Analysis]
127 Gawrieh S, Karns R, Kleiner DE, Olivier M, Jenkins T, Inge TH, Chalasani NP, Xanthakos S. Comparative Analysis of Global Hepatic Gene Expression in Adolescents and Adults with Non-alcoholic Fatty Liver Disease.. [DOI: 10.1101/2022.12.08.519606] [Reference Citation Analysis]
128 Chen H, Zhan Y, Zhang J, Cheng S, Zhou Y, Chen L, Zeng Z. The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019. JMIR Public Health Surveill 2022;8:e34809. [PMID: 36508249 DOI: 10.2196/34809] [Reference Citation Analysis]
129 Xue C, Wu L, Rao C, Huang X, Chen S, Li F. Transcriptomic Insight Based on Network Analysis Reveals the Effect of Ursolic Acid on Non-Alcoholic Steatohepatitis.. [DOI: 10.21203/rs.3.rs-2356611/v1] [Reference Citation Analysis]
130 Roca-fernandez A, Banerjee R, Thomaides-brears H, Telford A, Sanyal A, Neubauer S, Nichols TE, Raman B, Mccracken C, Petersen SE, Ntusi NA, Cuthbertson DJ, Lai M, Dennis A, Banerjee A. Liver disease is a significant risk factor for cardiovascular outcomes - a UK Biobank study.. [DOI: 10.1101/2022.12.08.22283242] [Reference Citation Analysis]
131 Huysentruyt K, Belza C, Wong-Sterling S, Chami R, Siddiqui I, Wales PW, Avitzur Y. Use of a combined transient elastography and biochemical strategy to determine liver fibrosis in pediatric intestinal failure. Clin Nutr 2022;42:136-42. [PMID: 36563562 DOI: 10.1016/j.clnu.2022.12.002] [Reference Citation Analysis]
132 Huang CY, Chen HW, Lo CW, Wang YR, Li CC, Liu KL, Lii CK. Luteolin ameliorates palmitate-induced lipotoxicity in hepatocytes by mediating endoplasmic reticulum stress and autophagy. Food Chem Toxicol 2022;:113554. [PMID: 36509263 DOI: 10.1016/j.fct.2022.113554] [Reference Citation Analysis]
133 Song J, Liu Y, Chen J, Yang J, Wen J, Gao J, Shao C, Wang W, Tang YD. Fibrosis-4 stage of liver fibrosis predicts cardiovascular outcomes in acute coronary syndrome patients with and without type 2 diabetes mellitus. Diabetes Res Clin Pract 2022;195:110206. [PMID: 36502890 DOI: 10.1016/j.diabres.2022.110206] [Reference Citation Analysis]
134 Rice BA, Naimi TS, Long MT. Nonheavy Alcohol Use Associates With Liver Fibrosis and Nonalcoholic Steatohepatitis in the Framingham Heart Study. Clin Gastroenterol Hepatol 2022:S1542-3565(22)01125-9. [PMID: 36503167 DOI: 10.1016/j.cgh.2022.10.039] [Reference Citation Analysis]
135 Ferraioli G, Roccarina D. Update on the role of elastography in liver disease. Therap Adv Gastroenterol 2022;15:17562848221140657. [PMID: 36506750 DOI: 10.1177/17562848221140657] [Reference Citation Analysis]
136 Tatoli R, Tirelli S, Lampignano L, Castellana F, Bortone I, Zupo R, Sborgia G, Lozupone M, Panza F, Giannelli G, Quaranta N, Boeing H, Sardone R. Liver Fibrosis and Hearing Loss in an Older Mediterranean Population: Results from the Salus in Apulia Study. J Clin Med 2022;11. [PMID: 36498787 DOI: 10.3390/jcm11237213] [Reference Citation Analysis]
137 Elhini SH, Wahsh EA, Elberry AA, El Ameen NF, Abdelfadil Saedii A, Refaie SM, Elsayed AA, Rabea HM. The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals (Basel) 2022;15. [PMID: 36558967 DOI: 10.3390/ph15121516] [Reference Citation Analysis]
138 Kamada Y, Nakamura T, Isobe S, Hosono K, Suama Y, Ohtakaki Y, Nauchi A, Yasuda N, Mitsuta S, Miura K, Yamamoto T, Hosono T, Yoshida A, Kawanishi I, Fukushima H, Kinoshita M, Umeda A, Kinoshita Y, Fukami K, Miyawaki T, Fujii H, Yoshida Y, Kawanaka M, Hyogo H, Morishita A, Hayashi H, Tobita H, Tomita K, Ikegami T, Takahashi H, Yoneda M, Jun DW, Sumida Y, Okanoue T, Nakajima A; JANIT Forum. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum. J Gastroenterol 2023;58:79-97. [PMID: 36469127 DOI: 10.1007/s00535-022-01932-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Zhou XD, Cai J, Targher G, Byrne CD, Shapiro MD, Sung KC, Somers VK, Chahal CAA, George J, Chen LL, Zhou Y, Zheng MH; CHESS-MAFLD consortium. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol 2022;21:270. [PMID: 36463192 DOI: 10.1186/s12933-022-01697-0] [Reference Citation Analysis]
140 Wu P, Zhang J, Xiao J, Huang G, Li J, Zhou Z. Efficacy and safety of Yinchenwuling Powder for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2022;101:e32088. [PMID: 36482550 DOI: 10.1097/MD.0000000000032088] [Reference Citation Analysis]
141 Smirnova E, Muthiah MD, Narayan N, Siddiqui MS, Puri P, Luketic VA, Contos MJ, Idowu M, Chuang JC, Billin AN, Huss RS, Myers RP, Boyett S, Seneshaw M, Min HK, Mirshahi F, Sanyal AJ. Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD. Hepatology 2022;76:1811-24. [PMID: 35561146 DOI: 10.1002/hep.32568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Younossi ZM, Paik JM, Golabi P, Younossi Y, Henry L, Nader F. The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005-2010 and 2017-2018. Liver Int 2022;42:2646-61. [PMID: 36161464 DOI: 10.1111/liv.15437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Yi M, Peng W, Teng F, Kong Q, Chen Z. The role of noninvasive scoring systems for predicting cardiovascular disease risk in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2022;34:1277-84. [PMID: 36317774 DOI: 10.1097/MEG.0000000000002462] [Reference Citation Analysis]
144 Roeb E. NAFLD – Prävention und ernährungsmedizinische Behandlungsmöglichkeiten. Ernährung & Medizin 2022;37:167-172. [DOI: 10.1055/a-1917-8335] [Reference Citation Analysis]
145 Qu B, Liu X, Liang Y, Zheng K, Zhang C, Lu L. Salidroside in the Treatment of NAFLD/NASH. Chem Biodivers 2022;19:e202200401. [PMID: 36210339 DOI: 10.1002/cbdv.202200401] [Reference Citation Analysis]
146 Xu Z, Wu FW, Niu X, Lu XP, Li YR, Zhang ST, Ou JZ, Wang XM. Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease. Pharm Biol 2022;60:1819-38. [PMID: 36124995 DOI: 10.1080/13880209.2022.2106250] [Reference Citation Analysis]
147 Wang S, Li X, Ji H, Shen L. Modulation of gut microbiota by glycyrrhizic acid may contribute to its anti-NAFLD effect in rats fed a high-fat diet. Life Sciences 2022;310:121110. [DOI: 10.1016/j.lfs.2022.121110] [Reference Citation Analysis]
148 Yuri M, Nishimura T, Tada T, Yoshida M, Fujiwara A, Kawata S, Yoshihara K, Yoshioka R, Ota S, Nakano R, Yuri Y, Takashima T, Aizawa N, Ikeda N, Shiomi H, Ide YH, Enomoto H, Yasuhiro F, Yano H, Iijima H. Diagnosis of hepatic steatosis based on ultrasound attenuation imaging is not influenced by liver fibrosis. Hepatol Res 2022;52:1009-19. [PMID: 36018852 DOI: 10.1111/hepr.13831] [Reference Citation Analysis]
149 Lee J, Kim J, Lee R, Lee E, Choi TG, Lee AS, Yoon Y, Park G, Namgoong J, Lee S, Tak E. Therapeutic strategies for liver diseases based on redox control systems. Biomedicine & Pharmacotherapy 2022;156:113764. [DOI: 10.1016/j.biopha.2022.113764] [Reference Citation Analysis]
150 Testino G, Pellicano R. Metabolic associated liver disease. Panminerva Med 2022;64. [DOI: 10.23736/s0031-0808.22.04730-9] [Reference Citation Analysis]
151 Adrian T, Hornum M, Knop FK, Lotte Gluud L. Incidental finding of non-alcoholic steatohepatitis-cirrhosis. Endocrinol Diabetes Metab Case Rep 2022;2022:22-0350. [PMID: 36571477 DOI: 10.1530/EDM-22-0350] [Reference Citation Analysis]
152 Ma W, Zhang S, Li Y, Chen T, Yang Q, Feng X. Adiponectin alleviates non-alcoholic fatty liver injury via regulating oxidative stress in liver cells. Minerva Med 2022;113:990-9. [PMID: 32996726 DOI: 10.23736/S0026-4806.20.06734-8] [Reference Citation Analysis]
153 Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatology 2022;76:1880-97. [PMID: 35239194 DOI: 10.1002/hep.32439] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
154 Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q, Huang DQ, Zhao C, Zhang J, Liu C, Chang N, Xing F, Yan S, Wan ZH, Tang NSY, Mayumi M, Liu X, Liu C, Rui F, Yang H, Yang Y, Jin R, Le RHX, Xu Y, Le DM, Barnett S, Stave CD, Cheung R, Zhu Q, Nguyen MH. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022;20:2809-2817.e28. [PMID: 34890795 DOI: 10.1016/j.cgh.2021.12.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 62.0] [Reference Citation Analysis]
155 Ozlu T, Yilmaz Y, Gunes FE. The effects of dietary intervention on fibrosis and biochemical parameters in metabolic-associated fatty liver disease. Minerva Gastroenterol (Torino) 2022;68:426-33. [PMID: 33829726 DOI: 10.23736/S2724-5985.21.02809-9] [Reference Citation Analysis]
156 Park J, Kim G, Kim BS, Han KD, Yoon Kwon S, Hee Park S, Lee YB, Jin SM, Hyeon Kim J. The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study. Diabetes Res Clin Pract 2022;194:110191. [PMID: 36471549 DOI: 10.1016/j.diabres.2022.110191] [Reference Citation Analysis]
157 Theodoridis X, Kalopitas G, Vadarlis A, Bakaloudi DR, Gkiourtzis Ν, Dionysopoulos G, Karanika E, Tsekitsidi E, Chourdakis M. Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: A systematic review and network meta-analysis. Pharmacol Ther 2022;240:108294. [PMID: 36183848 DOI: 10.1016/j.pharmthera.2022.108294] [Reference Citation Analysis]
158 Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res 2022;11:1349-63. [PMID: 36317935 DOI: 10.2217/cer-2021-0194] [Reference Citation Analysis]
159 Tu H, Yin X, Wen J, Wu W, Zhai B, Li J, Jiang H. Glutaminase 1 blockade alleviates nonalcoholic steatohepatitis via promoting proline metabolism. Biochemical and Biophysical Research Communications 2022;634:1-9. [DOI: 10.1016/j.bbrc.2022.10.007] [Reference Citation Analysis]
160 Attia D, Abdel Alem S, El-Akel W, Abdel-Razek W, Eslam M, Fouad Y, Waked I. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study. Aliment Pharmacol Ther 2022;56:1581-90. [PMID: 36168675 DOI: 10.1111/apt.17233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Piercy DL, Kreider KE, Coviello A, Patel YA, Thompson JA. Implementing Screening for Nonalcoholic Fatty Liver Disease in Endocrinology Clinics. The Journal for Nurse Practitioners 2022. [DOI: 10.1016/j.nurpra.2022.10.012] [Reference Citation Analysis]
162 Yuan S, Chen J, Vujkovic M, Chang K, Li X, Larsson SC, Gill D. Effects of metabolic traits, lifestyle factors, and pharmacological interventions on liver fat: mendelian randomisation study. bmjmed 2022;1:e000277. [DOI: 10.1136/bmjmed-2022-000277] [Reference Citation Analysis]
163 Huang K, Lee C, Cheng Y, Gau S, Tsai T, Chung N, Lee C. Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: A real-world cohort study. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1027484] [Reference Citation Analysis]
164 Navadurong H, Prasoppokakorn T, Srisawat N, Chaiteerakij R, Komolmit P, Tangkijvanich P, Treeprasertsuk S. Urinary neutrophil gelatinase‐associated lipocalin: A novel biomarker for predicting chronic kidney disease in patients with nonalcoholic fatty liver disease. Portal Hypertension & Cirrhosis 2022. [DOI: 10.1002/poh2.32] [Reference Citation Analysis]
165 Pitisuttithum P, Treeprasertsuk S. Nonalcoholic fatty liver disease (NAFLD) among older adults. Portal Hypertension & Cirrhosis 2022. [DOI: 10.1002/poh2.31] [Reference Citation Analysis]
166 Sokolowska KE, Maciejewska-Markiewicz D, Bińkowski J, Palma J, Taryma-Leśniak O, Kozlowska-Petriczko K, Borowski K, Baśkiewicz-Hałasa M, Hawryłkowicz V, Załęcka P, Ufnal M, Strapagiel D, Jarczak J, Skonieczna-Żydecka K, Ryterska K, Machaliński B, Wojdacz TK, Stachowska E. Identified in blood diet-related methylation changes stratify liver biopsies of NAFLD patients according to fibrosis grade. Clin Epigenetics 2022;14:157. [PMID: 36447285 DOI: 10.1186/s13148-022-01377-6] [Reference Citation Analysis]
167 Che W, Zhao M, Li X, Li C, Cho WC, Yu S. Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1002916] [Reference Citation Analysis]
168 Takahashi H, Kawanaka M, Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguch T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T. Association of serum albumin levels and long-term prognosis in patients with biopsy- confirmed nonalcoholic fatty liver disease.. [DOI: 10.21203/rs.3.rs-2303193/v1] [Reference Citation Analysis]
169 Juárez-hernández E, Velázquez-alemán AP, Castro-narro G, Uribe M, López-méndez I. Bariatric endoscopic-surgical therapies for NAFLD. Should they be considered viable options among current treatments? Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1026444] [Reference Citation Analysis]
170 Lin Y, Feng X, Cao X, Miao R, Sun Y, Li R, Ye J, Zhong B. Age patterns of nonalcoholic fatty liver disease incidence: heterogeneous associations with metabolic changes. Diabetol Metab Syndr 2022;14:181. [DOI: 10.1186/s13098-022-00930-w] [Reference Citation Analysis]
171 Doustmohammadian A, Amirkalali B, Gholizadeh E, Khoonsari M, Faraji AH, Nikkhah M, Maadi M, Motamed N, Mansourian MR, Hajjar M, Clark CCT, Chaibakhsh S, Tameshkel FS, Afzali A, Zamani F. Mediators of dietary diversity score (DDS) on NAFLD in Iranian adults: a structural equation modeling study. Eur J Clin Nutr 2022. [DOI: 10.1038/s41430-022-01240-0] [Reference Citation Analysis]
172 Liang M, Huo M, Guo Y, Zhang Y, Xiao X, Xv J, Fang L, Li T, Wang H, Dong S, Jiang X, Yu W. Aqueous extract of Artemisia capillaris improves non-alcoholic fatty liver and obesity in mice induced by high-fat diet. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1084435] [Reference Citation Analysis]
173 Siener R, Ernsten C, Bitterlich N, Alteheld B, Metzner C. Effect of Two Different Dietary Weight Loss Strategies on Risk Factors for Urinary Stone Formation and Cardiometabolic Risk Profile in Overweight Women. Nutrients 2022;14. [PMID: 36501084 DOI: 10.3390/nu14235054] [Reference Citation Analysis]
174 Ha J, Yim SY, Karagozian R. Mortality and Liver-Related Events in Lean Versus Non-Lean Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022:S1542-3565(22)01099-0. [PMID: 36442727 DOI: 10.1016/j.cgh.2022.11.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Josloff K, Beiriger J, Khan A, Gawel RJ, Kirby RS, Kendrick AD, Rao AK, Wang RX, Schafer MM, Pearce ME, Chauhan K, Shah YB, Marhefka GD, Halegoua-DeMarzio D. Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. J Cardiovasc Dev Dis 2022;9. [PMID: 36547416 DOI: 10.3390/jcdd9120419] [Reference Citation Analysis]
176 Choo BP, Goh GB, Chia SY, Oh HC, Tan NC, Tan JYL, Ang TL, Bee YM, Wong YJ. Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: A cost-effectiveness and price threshold analysis. Ann Acad Med Singap 2022;51:686-694. [DOI: 10.47102/annals-acadmedsg.2022284] [Reference Citation Analysis]
177 Pansa CC, Molica LR, Moraes KCM. Non-alcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology. Scand J Gastroenterol 2022;:1-13. [PMID: 36426638 DOI: 10.1080/00365521.2022.2148835] [Reference Citation Analysis]
178 Theys C, Lauwers D, Perez-Novo C, Vanden Berghe W. PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs? Biomedicines 2022;10. [PMID: 36551797 DOI: 10.3390/biomedicines10123041] [Reference Citation Analysis]
179 Šamadan L, Papić N, Mijić M, Knežević Štromar I, Gašparov S, Vince A. Do Semaphorins Play a Role in Development of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease? Biomedicines 2022;10. [PMID: 36551769 DOI: 10.3390/biomedicines10123014] [Reference Citation Analysis]
180 Zhang S, Wang L, Yu M, Guan W, Yuan J. Fat mass index as a screening tool for the assessment of non-alcoholic fatty liver disease. Sci Rep 2022;12:20219. [PMID: 36418352 DOI: 10.1038/s41598-022-23729-1] [Reference Citation Analysis]
181 Yin G, Liang H, Sun W, Zhang S, Feng Y, Liang P, Chen S, Liu X, Pan W, Zhang F. Shuangyu Tiaozhi decoction alleviates non-alcoholic fatty liver disease by improving lipid deposition, insulin resistance, and inflammation in vitro and in vivo. Front Pharmacol 2022;13:1016745. [PMID: 36506575 DOI: 10.3389/fphar.2022.1016745] [Reference Citation Analysis]
182 Di Ciaula A, Bonfrate L, Baj J, Khalil M, Garruti G, Stellaard F, Wang HH, Wang DQ, Portincasa P. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling. Nutrients 2022;14. [PMID: 36500979 DOI: 10.3390/nu14234950] [Reference Citation Analysis]
183 Chen X, Tian F, Wu J, Liu L, Li Y, Yu G, Duan H, Jiang Y, Liu S, He Y, Luo Y, Song C, Li H, Liang Y, Wan H, Shen J. Associations of phthalates with NAFLD and liver fibrosis: A nationally representative cross-sectional study from NHANES 2017 to 2018. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.1059675] [Reference Citation Analysis]
184 Fan S, Zhou Z, Ye J, Li Y, Huang K, Ke X. Integration of Lipidomics and Transcriptomics Reveals the Efficacy and Mechanism of Qige Decoction on NAFLD. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-13. [DOI: 10.1155/2022/9739032] [Reference Citation Analysis]
185 Sheng W, Ji G, Zhang L. Management of non-alcoholic fatty liver disease patients with sleep apnea syndrome. World J Gastroenterol 2022; 28(43): 6099-6108 [DOI: 10.3748/wjg.v28.i43.6099] [Reference Citation Analysis]
186 Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, Madamba E, Bettencourt R, Richards L, Behling C, Sirlin CB, Loomba R. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol 2022:S0168-8278(22)03302-5. [PMID: 36410554 DOI: 10.1016/j.jhep.2022.11.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
187 Liu Q, Zhao G, Li Q, Wu W, Zhang Y, Bian H. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study. BMC Gastroenterol 2022;22:471. [DOI: 10.1186/s12876-022-02576-4] [Reference Citation Analysis]
188 Luo F, Yu Y, Li M, Chen Y, Zhang P, Xiao C, Lv G. Polymeric nanomedicines for the treatment of hepatic diseases. J Nanobiotechnol 2022;20:488. [DOI: 10.1186/s12951-022-01708-y] [Reference Citation Analysis]
189 Li C, Yu R, Ding Y. Association between Porphyromonas Gingivalis and systemic diseases: Focus on T cells-mediated adaptive immunity. Front Cell Infect Microbiol 2022;12. [DOI: 10.3389/fcimb.2022.1026457] [Reference Citation Analysis]
190 Tong X, Lin L, Hu P, Cao R, Zhang Y, Olick-Gibson J, Wang LV. Non-Invasive 3D Photoacoustic Tomography of Angiographic Anatomy and Hemodynamics of Fatty Livers in Rats. Adv Sci (Weinh) 2023;10:e2205759. [PMID: 36394162 DOI: 10.1002/advs.202205759] [Reference Citation Analysis]
191 Zhao H, Gao X, Liu Z, Zhang L, Fang X, Sun J, Zhang Z, Sun Y. Sodium Alginate Prevents Non-Alcoholic Fatty Liver Disease by Modulating the Gut-Liver Axis in High-Fat Diet-Fed Rats. Nutrients 2022;14. [PMID: 36432531 DOI: 10.3390/nu14224846] [Reference Citation Analysis]
192 Pichon C, Nachit M, Gillard J, Vande Velde G, Lanthier N, Leclercq IA. Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.1051157] [Reference Citation Analysis]
193 Crudele L, De Matteis C, Piccinin E, Gadaleta RM, Cariello M, Di Buduo E, Piazzolla G, Suppressa P, Berardi E, Sabbà C, Moschetta A. Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis. JHEP Rep 2023;5:100627. [PMID: 36561127 DOI: 10.1016/j.jhepr.2022.100627] [Reference Citation Analysis]
194 Yang TY, Yu MH, Wu YL, Hong CC, Chen CS, Chan KC, Wang CJ. Mulberry Leaf (Morus alba L.) Extracts and Its Chlorogenic Acid Isomer Component Improve Glucolipotoxicity-Induced Hepatic Lipid Accumulation via Downregulating miR-34a and Decreased Inflammation. Nutrients 2022;14. [PMID: 36432495 DOI: 10.3390/nu14224808] [Reference Citation Analysis]
195 Yeh CH, Shen ZQ, Lin CC, Lu CK, Tsai TF. Rejuvenation: Turning Back Time by Enhancing CISD2. Int J Mol Sci 2022;23. [PMID: 36430496 DOI: 10.3390/ijms232214014] [Reference Citation Analysis]
196 Drożdż K, Nabrdalik K, Kwiendacz H, Hendel M, Olejarz A, Tomasik A, Bartman W, Nalepa J, Gumprecht J, Lip GYH. Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach. Cardiovasc Diabetol 2022;21:240. [PMID: 36371249 DOI: 10.1186/s12933-022-01672-9] [Reference Citation Analysis]
197 Rojano A, Sena E, Manzano-nuñez R, Pericàs JM, Ciudin A. NAFLD as the metabolic hallmark of obesity. Intern Emerg Med 2022. [DOI: 10.1007/s11739-022-03139-x] [Reference Citation Analysis]
198 Chen X, Chen Z, Jiang L, Huang J, Zhu Y, Lin S. MAFLD is associated with increased all-cause mortality in low cardiovascular-risk individuals but not in intermediate to high-risk individuals. Nutr Metab Cardiovasc Dis 2022:S0939-4753(22)00449-5. [PMID: 36599780 DOI: 10.1016/j.numecd.2022.11.007] [Reference Citation Analysis]
199 Yang B, Yang X, Tan X, Lu L, Fan W, Barbier-torres L, Steggerda J, Liu T, Yang H. Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-18. [DOI: 10.1155/2022/6799414] [Reference Citation Analysis]
200 Seeberg KA, Hofsø D, Borgeraas H, Grimnes JO, Fatima F, Seeberg LT, Kvan NP, Svanevik M, Hertel JK, Hjelmesæth J. Association between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study. BMC Gastroenterol 2022;22:448. [PMID: 36336684 DOI: 10.1186/s12876-022-02550-0] [Reference Citation Analysis]
201 Ciardullo S, Rea F, Cannistraci R, Muraca E, Perra S, Zerbini F, Mortara A, Perseghin G. NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population. Cardiovasc Diabetol 2022;21:236. [DOI: 10.1186/s12933-022-01671-w] [Reference Citation Analysis]
202 Sfikas G, Valsamidis I. Therapeutic Approach to NAFLD-NASH. Non-alcoholic Fatty Liver Disease - New-Insight and Glance Into Disease Pathogenesis [Working Title] 2022. [DOI: 10.5772/intechopen.107487] [Reference Citation Analysis]
203 Iwadare T, Kimura T, Kunimoto H, Tanaka N, Wakabayashi S, Yamazaki T, Okumura T, Kobayashi H, Yamashita Y, Sugiura A, Joshita S, Umemura T. Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD. Biomedicines 2022;10:2806. [DOI: 10.3390/biomedicines10112806] [Reference Citation Analysis]
204 Qi X, Lai J. Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH). IJMS 2022;23:13501. [DOI: 10.3390/ijms232113501] [Reference Citation Analysis]
205 Abdallah HR, Youness ER, Bedeir MM, Abouelnaga MW, Ezzat WM, Elhosary Y, El-hariri HM, Hussein MAE, Ahmed HR, Eladawy R. Clinical and Diagnostic characteristics of Non-Alcoholic Fatty Liver Disease among Egyptian children and adolescents with type1 diabetes.. [DOI: 10.21203/rs.3.rs-2214921/v1] [Reference Citation Analysis]
206 Park H, Yoon EL, Kim M, Lee J, Cho S, Jun DW, Nah E. Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1024836] [Reference Citation Analysis]
207 Houttu V, Bouts J, Vali Y, Daams J, Grefhorst A, Nieuwdorp M, Holleboom AG. Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1032164] [Reference Citation Analysis]
208 Almomani A, Kumar P, Onwuzo S, Boustany A, Krishtopaytis E, Hitawala A, Alshaikh D, Albakri A, Hussein L, Hussein E, Asaad I. Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature. J Gastroenterol Hepatol 2022. [PMID: 36328950 DOI: 10.1111/jgh.16049] [Reference Citation Analysis]
209 Lavallee CM, Bruno A, Ma C, Raman M. The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative Review. Nutrients 2022;14:4655. [DOI: 10.3390/nu14214655] [Reference Citation Analysis]
210 Fu Y, Zhou Y, Shen L, Li X, Zhang H, Cui Y, Zhang K, Li W, Chen W, Zhao S, Li Y, Ye W. Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.973366] [Reference Citation Analysis]
211 Kim K, Lee YJ, Kwon SC, Min YS, Lee HK, Baek G, Kim SH, Jang EC. Correlation between shift work and non-alcoholic fatty liver disease among male workers in the steel manufacturing company of Korea: a cross-sectional study. Ann Occup Environ Med 2022;34:e33. [PMID: 36544884 DOI: 10.35371/aoem.2022.34.e33] [Reference Citation Analysis]
212 Wan Q, Peng H, Lyu J, Liu F, Cheng C, Qiao Y, Deng J, Zheng H, Wang Y, Zou C, Liu X. Water Specific MRI T1 Mapping for Evaluating Liver Inflammation Activity Grades in Rats With Methionine-Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease. J Magn Reson Imaging 2022;56:1429-36. [PMID: 35212074 DOI: 10.1002/jmri.28131] [Reference Citation Analysis]
213 Li J, Huang L, Xiong W, Gu C, Zhang S, Xue X. Effect of aerobic exercise on GRP78 and ATF6 expressions in mice with non-alcoholic fatty liver disease. Sports Medicine and Health Science 2022. [DOI: 10.1016/j.smhs.2022.11.002] [Reference Citation Analysis]
214 Gumussoy M, Koc O, Karatas G, Ozercan M, Ellik Z, Duman S, Kiremitci S, Gokcan H, Elhan AH, Savas B, Idilman R. Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study. Eur J Gastroenterol Hepatol 2022;34:1172-7. [PMID: 36170687 DOI: 10.1097/MEG.0000000000002448] [Reference Citation Analysis]
215 Pervez MA, Khan DA, Mirza SA, Slehria AUR, Nisar U, Aamir M. Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: A randomized double-blind active-controlled trial. Complement Ther Med 2022;70:102866. [PMID: 35933083 DOI: 10.1016/j.ctim.2022.102866] [Reference Citation Analysis]
216 Kardashian A, Dodge JL, Terrault NA. Racial and ethnic differences in diet quality and food insecurity among adults with fatty liver and significant fibrosis: a U.S. population-based study. Aliment Pharmacol Ther 2022;56:1383-93. [PMID: 36173037 DOI: 10.1111/apt.17219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Andersson A, Kelly M, Imajo K, Nakajima A, Fallowfield JA, Hirschfield G, Pavlides M, Sanyal AJ, Noureddin M, Banerjee R, Dennis A, Harrison S. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. Clin Gastroenterol Hepatol 2022;20:2451-2461.e3. [PMID: 34626833 DOI: 10.1016/j.cgh.2021.09.041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
218 Toh JZK, Pan XH, Tay PWL, Ng CH, Yong JN, Xiao J, Koh JH, Tan EY, Tan EXX, Dan YY, Loh PH, Foo R, Chew NWS, Sanyal AJ, Muthiah MD, Siddiqui MS. A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2022;20:2462-2473.e10. [PMID: 34560278 DOI: 10.1016/j.cgh.2021.09.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
219 Zhang X, Wong GL, Yip TC, Cheung JTK, Tse YK, Hui VW, Lin H, Lai JC, Chan HL, Kong AP, Wong VW. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. Hepatology 2022;76:1409-22. [PMID: 35334125 DOI: 10.1002/hep.32476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
220 Nobuharu Tamaki, Noora Ahlholm, Panu K. Luukkonen, Kimmo Porthan, Suzanne R. Sharpton, Veeral Ajmera, Yuko Kono, Shravan Dave, Aijaz Ahmed, Vinay Sundaram, Michael J. Wilkinson, Heather Patton, Hersh Gupta, Vanessa Cervantes, Christie Hernandez, Scarlett J. Lopez, Ria Loomba, Amanda Baumgartner, Lisa Richards, Perttu E.T. Arkkila, Katriina Nemes, Helena Isoniemi, Hannele Yki-Järvinen, Rohit Loomba. Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. J Clin Invest;132:e162513. [PMID: 36317632 DOI: 10.1172/JCI162513] [Reference Citation Analysis]
221 Yang N, Gong F, Ge J, Wang L, Wang G, Cheng L. Advances in responsive liquid metal composites for cancer therapy. Materials Today Nano 2022. [DOI: 10.1016/j.mtnano.2022.100285] [Reference Citation Analysis]
222 Chang X, Bian H, Xia M, Zhu X, Sun X, Yang X, Gao J, Lin H, Yan H, Gao X. Postprandial glucose is correlated with an increasing risk of liver fibrosis in Chinese patients with nonalcoholic fatty liver disease. Diabetes & Metabolism 2022;48:101377. [DOI: 10.1016/j.diabet.2022.101377] [Reference Citation Analysis]
223 Zhou Y, Tian N, Li P, He Y, Tong L, Xie W. The correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with nonalcoholic fatty liver disease: a cross-sectional study. Eur J Gastroenterol Hepatol 2022;34:1158-64. [PMID: 36170685 DOI: 10.1097/MEG.0000000000002439] [Reference Citation Analysis]
224 Carrillo-larco RM, Guzman-vilca WC, Castillo-cara M, Alvizuri-gómez C, Alqahtani S, Garcia-larsen V. Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality: unsupervised machine learning analysis of NHANES III. BMJ Open 2022;12:e067203. [DOI: 10.1136/bmjopen-2022-067203] [Reference Citation Analysis]
225 Isaacs S. Nonalcoholic Fatty Liver Disease. Endocrinology and Metabolism Clinics of North America 2022. [DOI: 10.1016/j.ecl.2022.06.007] [Reference Citation Analysis]
226 Klang E, Soffer S, Alper L, Shimon O, Barash Y, Davidov Y, Likhter M, Cohen‐ezra O, Ben Yakov G, Ben‐ari Z. Research trends analysis of chronic hepatitis C versus nonalcoholic fatty liver disease: A literature review text‐mining analysis of publications. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.805] [Reference Citation Analysis]
227 Hidalgo I, Ortiz-Flores M, Villarreal F, Fonseca-Coronado S, Ceballos G, Meaney E, Nájera N. Is it possible to treat nonalcoholic liver disease using a flavanol-based nutraceutical approach? Basic and clinical data. J Basic Clin Physiol Pharmacol 2022;33:703-14. [PMID: 35119232 DOI: 10.1515/jbcpp-2021-0285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
228 DiBattista JV, Burkholder DA, Lok AS, Chen VL. Accuracy of Non-invasive Indices for Diagnosing Hepatic Steatosis Compared to Imaging in a Real-World Cohort. Dig Dis Sci 2022;67:5300-8. [PMID: 35166966 DOI: 10.1007/s10620-022-07415-w] [Reference Citation Analysis]
229 van Kleef LA, de Knegt RJ. The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach? Hepatology 2022;76:1243-5. [PMID: 35503710 DOI: 10.1002/hep.32552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
230 Moore MP, Cunningham RP, Meers GM, Johnson SA, Wheeler AA, Ganga RR, Spencer NM, Pitt JB, Diaz-Arias A, Swi AIA, Hammoud GM, Ibdah JA, Parks EJ, Rector RS. Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD. Hepatology 2022;76:1452-65. [PMID: 35000203 DOI: 10.1002/hep.32324] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
231 Shamseddeen H, Vuppalanchi R, Gromski MA. Duodenal mucosal resurfacing for nonalcoholic fatty liver disease. Clinical Liver Disease 2022;20:166-169. [DOI: 10.1002/cld.1255] [Reference Citation Analysis]
232 Du X, Li H, Han X, Ma W. Mesenchymal stem cells-derived exosomal miR-24-3p ameliorates non-alcohol fatty liver disease by targeting Keap-1. Biochemical and Biophysical Research Communications 2022. [DOI: 10.1016/j.bbrc.2022.11.012] [Reference Citation Analysis]
233 Phung HH, Lee CH. Mouse models of nonalcoholic steatohepatitis and their application to new drug development. Arch Pharm Res 2022. [DOI: 10.1007/s12272-022-01410-5] [Reference Citation Analysis]
234 McHenry S, Park Y, Davidson NO. Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population. Clin Gastroenterol Hepatol 2022;20:2638-40. [PMID: 34044131 DOI: 10.1016/j.cgh.2021.05.035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
235 Chen B, Tang WHW, Rodriguez M, Corey KE, Sanyal AJ, Kamath PS, Bozkurt B, Virk HUH, Pressman GS, Lazarus JV, El-Serag HB, Krittanawong C. NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity? Semin Liver Dis 2022;42:465-74. [PMID: 36241194 DOI: 10.1055/s-0042-1757712] [Reference Citation Analysis]
236 Gallego-durán R, Albillos A, Ampuero J, Arechederra M, Bañares R, Blas-garcía A, Berná G, Caparrós E, Delgado TC, Falcón-pérez JM, Francés R, Fernández-barrena MG, Graupera I, Iruzubieta P, Nevzorova YA, Nogueiras R, Macías RI, Martín F, Sabio G, Soriano G, Vaquero J, Cubero FJ, Gracia-sancho J. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). Gastroenterología y Hepatología (English Edition) 2022;45:724-734. [DOI: 10.1016/j.gastre.2022.02.004] [Reference Citation Analysis]
237 Sharpton SR, Oh TG, Madamba E, Wang C, Yu RT, Atkins AR, Huan T, Downes M, Evans RM, Loomba R. Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis. Aliment Pharmacol Ther 2022;56:1475-85. [PMID: 36164267 DOI: 10.1111/apt.17236] [Reference Citation Analysis]
238 Pan X, Peng H, Zhang J, Wu Y, Hu Z, Peng XE. Genetic variants in promoter region of TFR2 is associated with the risk of non-alcoholic fatty liver disease in a Chinese Han population: a case-control study. Gastroenterol Rep (Oxf) 2022;10:goac060. [PMID: 36324614 DOI: 10.1093/gastro/goac060] [Reference Citation Analysis]
239 Marcinkiewicz K, Horodnicka-józwa A, Jackowski T, Strączek K, Biczysko-mokosa A, Walczak M, Petriczko E. Nonalcoholic fatty liver disease in children with obesity– observations from one clinical centre in the Western Pomerania region. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.992264] [Reference Citation Analysis]
240 Koo D, Lee W. The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence? CPP 2022;4:132-141. [DOI: 10.36011/cpp.2022.4.e17] [Reference Citation Analysis]
241 Bjørnå ER, Engelsen MT, El-Serag HB, Ness-Jensen E. Prevalence and risk factors of nonalcoholic fatty liver disease in a general population, the HUNT study. Scand J Gastroenterol 2022;:1-7. [PMID: 36314512 DOI: 10.1080/00365521.2022.2139633] [Reference Citation Analysis]
242 Radonjić T, Dukić M, Jovanović I, Zdravković M, Mandić O, Popadić V, Popović M, Nikolić N, Klašnja S, Divac A, Todorović Z, Branković M. Aging of Liver in Its Different Diseases. IJMS 2022;23:13085. [DOI: 10.3390/ijms232113085] [Reference Citation Analysis]
243 Jiang Y, Cao H, Chen X, Yu G, Song C, Duan H, Tian F, Wan H, Shen J. Associations of serum folate and vitamin C levels with metabolic dysfunction-associated fatty liver disease in US adults: A nationwide cross-sectional study. Front Public Health 2022;10. [DOI: 10.3389/fpubh.2022.1022928] [Reference Citation Analysis]
244 Sebastiani G, Paisible N, Costiniuk C, Cox J, Kablawi D, Klein MB, Kronfli N, Routy J, Falutz J, Lebouché B, Guaraldi G. The Relationship between Visceral Adiposity and Nonalcoholic Fatty Liver Disease Diagnosed by Controlled Attenuation Parameter in People with HIV: A Pilot Study. Diagnostics 2022;12:2590. [DOI: 10.3390/diagnostics12112590] [Reference Citation Analysis]
245 Lan Y, Lu Y, Li J, Hu S, Chen S, Wang Y, Yuan X, Liu H, Wang X, Wu S, Wang L. Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in China. Hepatol Commun 2022;6:3393-405. [PMID: 36281973 DOI: 10.1002/hep4.2081] [Reference Citation Analysis]
246 Karády J, Ferencik M, Mayrhofer T, Meyersohn NM, Bittner DO, Staziaki PV, Szilveszter B, Hallett TR, Lu MT, Puchner SB, Simon TG, Foldyna B, Ginsburg GS, McGarrah RW, Voora D, Shah SH, Douglas PS, Hoffmann U, Corey KE. Risk factors for cardiovascular disease among individuals with hepatic steatosis. Hepatol Commun 2022;6:3406-20. [PMID: 36281983 DOI: 10.1002/hep4.2090] [Reference Citation Analysis]
247 Zhu Y, Yang H, Liang S, Zhang H, Mo Y, Rao S, Zhang Y, Zhang Z, Wang W, Yang W. Higher Adherence to Healthy Lifestyle Score Is Associated with Lower Odds of Non-Alcoholic Fatty Liver Disease. Nutrients 2022;14:4462. [DOI: 10.3390/nu14214462] [Reference Citation Analysis]
248 Sveinbjornsson G, Ulfarsson MO, Thorolfsdottir RB, Jonsson BA, Einarsson E, Gunnlaugsson G, Rognvaldsson S, Arnar DO, Baldvinsson M, Bjarnason RG, Eiriksdottir T, Erikstrup C, Ferkingstad E, Halldorsson GH, Helgason H, Helgadottir A, Hindhede L, Hjorleifsson G, Jones D, Knowlton KU, Lund SH, Melsted P, Norland K, Olafsson I, Olafsson S, Oskarsson GR, Ostrowski SR, Pedersen OB, Snaebjarnarson AS, Sigurdsson E, Steinthorsdottir V, Schwinn M, Thorgeirsson G, Thorleifsson G, Jonsdottir I, Bundgaard H, Nadauld L, Bjornsson ES, Rulifson IC, Rafnar T, Norddahl GL, Thorsteinsdottir U, Sulem P, Gudbjartsson DF, Holm H, Stefansson K, DBDS Genomic consortium. Multiomics study of nonalcoholic fatty liver disease. Nat Genet 2022. [DOI: 10.1038/s41588-022-01199-5] [Reference Citation Analysis]
249 Li X, Liu Z, Li L, Wang H, Wang H. TM6SF2 rs58542926 is related to hepatic steatosis, fibrosis and serum lipids both in adults and children: A meta-analysis. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1026901] [Reference Citation Analysis]
250 Ding H, Zhang Y, Ma X, Zhang Z, Xu Q, Liu C, Li B, Dong S, Li L, Zhu J, Zhong M, Zhang G. Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1016635] [Reference Citation Analysis]
251 Khalifa O, H. Mroue K, Mall R, Ullah E, S. Al-akl N, Arredouani A. Investigation of the Effect of Exendin-4 on Oleic Acid-Induced Steatosis in HepG2 Cells Using Fourier Transform Infrared Spectroscopy. Biomedicines 2022;10:2652. [DOI: 10.3390/biomedicines10102652] [Reference Citation Analysis]
252 Seko Y, Yamaguchi K, Yano K, Takahashi Y, Takeuchi K, Kataoka S, Moriguchi M, Itoh Y. The additive effect of genetic and metabolic factors in the pathogenesis of nonalcoholic fatty liver disease. Sci Rep 2022;12:17608. [PMID: 36266438 DOI: 10.1038/s41598-022-22729-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Hagemann CA, Legart C, Møllerhøj MB, Madsen MR, Hansen HH, Kønig MJ, Helgstrand F, Hjørne FP, Toxværd A, Langhoff JL, Kielgast UL, Gluud LL, Ægidius H, Rigbolt KTG, Vilsbøll T, Jelsing J, Knop FK. A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity. PLoS One 2022;17:e0275901. [PMID: 36260611 DOI: 10.1371/journal.pone.0275901] [Reference Citation Analysis]
254 Hamada Y, Hirano E. Regulation of Iron Metabolism in NAFLD/NASH. Non-alcoholic Fatty Liver Disease - New-Insight and Glance Into Disease Pathogenesis [Working Title] 2022. [DOI: 10.5772/intechopen.107221] [Reference Citation Analysis]
255 Azargoonjahromi A. Diminution of Liver Aminotransferase Enzymes Levels in Nonalcoholic Fatty Liver Disease by Silymarin: A Case Report.. [DOI: 10.21203/rs.3.rs-2179570/v1] [Reference Citation Analysis]
256 Chen L, Lv X, Kan M, Wang R, Wang H, Zang H. Critical Overview of Hepatic Factors That Link Non-Alcoholic Fatty Liver Disease and Acute Kidney Injury: Physiology and Therapeutic Implications. IJMS 2022;23:12464. [DOI: 10.3390/ijms232012464] [Reference Citation Analysis]
257 Kwan AC, Sun N, Driver M, Botting P, Navarrette J, Ouyang D, Hussain SK, Noureddin M, Li D, Ebinger JE, Berman DS, Cheng S. Cardiovascular and hepatic disease associations by magnetic resonance imaging: A retrospective cohort study. Front Cardiovasc Med 2022;9:1009474. [DOI: 10.3389/fcvm.2022.1009474] [Reference Citation Analysis]
258 Jacobson IM, Wong VW, Castera L, Anstee QM, Noureddin M, Cusi K, Harrison SA, Bugianesi E, Younossi ZM. Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis. J Clin Gastroenterol 2022. [PMID: 36251413 DOI: 10.1097/MCG.0000000000001780] [Reference Citation Analysis]
259 Hong SB, Lee NK, Kim S, Um K, Kim K, Kim IJ. Hepatic Fat Quantification with the Multi-Material Decomposition Algorithm by Using Low-Dose Non-Contrast Material-Enhanced Dual-Energy Computed Tomography in a Prospectively Enrolled Cohort. Medicina (Kaunas) 2022;58. [PMID: 36295617 DOI: 10.3390/medicina58101459] [Reference Citation Analysis]
260 Conde de la Rosa L, Goicoechea L, Torres S, Garcia-ruiz C, Fernandez-checa JC. Role of Oxidative Stress in Liver Disorders. Livers 2022;2:283-314. [DOI: 10.3390/livers2040023] [Reference Citation Analysis]
261 Zeng L, Liu J, Zhang T, Liu Y, Liao L, Chen X, Dong S. Study on the protective mechanism of dexmedetomidine on the liver of perioperative diabetic patients: A randomized controlled trial. Medicine 2022;101:e30899. [DOI: 10.1097/md.0000000000030899] [Reference Citation Analysis]
262 Gijbels A, Schutte S, Esser D, Wopereis S, Gonzales GB, Afman LA. Effects of a 12-week whole-grain or refined wheat intervention on plasma acylcarnitines, bile acids and signaling lipids, and association with liver fat: A post-hoc metabolomics study of a randomized controlled trial. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.1026213] [Reference Citation Analysis]
263 Li Y, Zhou Y, Wang L, Lin X, Mao M, Yin S, Zhu L, Jiao Y, Yu W, Gao P, Yang L. Emerging trends and hotspots in the links between the gut microbiota and MAFLD from 2002 to 2021: A bibliometric analysis. Front Endocrinol 2022;13:990953. [DOI: 10.3389/fendo.2022.990953] [Reference Citation Analysis]
264 Catena C, Brosolo G, Da Porto A, Donnini D, Bulfone L, Vacca A, Soardo G, Sechi LA. Association of non-alcoholic fatty liver disease with left ventricular changes in treatment-naive patients with uncomplicated hypertension. Front Cardiovasc Med 2022;9:1030968. [PMID: 36312275 DOI: 10.3389/fcvm.2022.1030968] [Reference Citation Analysis]
265 Gagnon E, Pelletier W, Gobeil É, Bourgault J, Manikpurage HD, Maltais-Payette I, Abner E, Taba N, Esko T, Mitchell PL, Ghodsian N, Després JP, Vohl MC, Tchernof A, Thériault S, Arsenault BJ. Mendelian randomization prioritizes abdominal adiposity as an independent causal factor for liver fat accumulation and cardiometabolic diseases. Commun Med (Lond) 2022;2:130. [PMID: 36249462 DOI: 10.1038/s43856-022-00196-3] [Reference Citation Analysis]
266 Wang M, Li L, Xu Y, Du J, Ling C. Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis. Front Pharmacol 2022;13:958428. [DOI: 10.3389/fphar.2022.958428] [Reference Citation Analysis]
267 Wang H, Li Y, Bian Y, Li X, Wang Y, Wu K, Liu C, Liu Y, Wang X. Potential hepatoprotective effects of Cistanche deserticola Y.C. Ma: Integrated phytochemical analysis using UPLC-Q-TOF-MS/MS, target network analysis, and experimental assessment. Front Pharmacol 2022;13:1018572. [DOI: 10.3389/fphar.2022.1018572] [Reference Citation Analysis]
268 Ogasawara Y, Kogiso T, Horiuchi K, Taniai M, Tokushige K. Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality.. [DOI: 10.21203/rs.3.rs-2110374/v1] [Reference Citation Analysis]
269 Young JR, Schoen S, Kumar V, Thomenius K, Samir AE. SoundAI: Improved Imaging with Learned Sound Speed Maps. 2022 IEEE International Ultrasonics Symposium (IUS) 2022. [DOI: 10.1109/ius54386.2022.9958284] [Reference Citation Analysis]
270 Abbas D, Fix OK, Evon DM, Barritt AS 4th. Tangible Resources for Multidisciplinary Treatment of Patients With Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2022. [PMID: 36066462 DOI: 10.14309/ajg.0000000000001989] [Reference Citation Analysis]
271 Trifan A, Stafie R, Rotaru A, Stratina E, Zenovia S, Nastasa R, Huiban L, Cuciureanu T, Muzica C, Chiriac S, Girleanu I, Singeap AM, Sfarti C, Cojocariu C, Petrea O, Stanciu C. Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter. J Clin Med 2022;11. [PMID: 36233826 DOI: 10.3390/jcm11195959] [Reference Citation Analysis]
272 Khan A, Ross HM, Parra NS, Chen SL, Chauhan K, Wang M, Yan B, Magagna J, Beiriger J, Shah Y, Shahzad T, Halegoua-demarzio D. Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD). Livers 2022;2:264-282. [DOI: 10.3390/livers2040022] [Reference Citation Analysis]
273 Okovityi SV, Raikhelson KL, Prikhodko VA. Combined hepatoprotective pharmacotherapy for liver disease. jour 2022. [DOI: 10.31146/1682-8658-ecg-203-7-5-20] [Reference Citation Analysis]
274 Elsaid MI, Li Y, Bridges JFP, Brock G, Minacapelli CD, Rustgi VK. Association of Bariatric Surgery With Cardiovascular Outcomes in Adults With Severe Obesity and Nonalcoholic Fatty Liver Disease. JAMA Netw Open 2022;5:e2235003. [PMID: 36205997 DOI: 10.1001/jamanetworkopen.2022.35003] [Reference Citation Analysis]
275 Ng CH, Xiao J, Chew NWS, Chin YH, Chan KE, Quek J, Lim WH, Tan DJH, Loke RWK, Tan C, Tang ASP, Goh XL, Nah B, Syn N, Young DY, Tamaki N, Huang DQ, Siddiqui MS, Noureddin M, Sanyal A, Muthiah M. Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality. Front Med (Lausanne) 2022;9:985803. [PMID: 36275825 DOI: 10.3389/fmed.2022.985803] [Reference Citation Analysis]
276 Kannangara KKDSD, Dehigolla MR, Gunathilaka CMJU, Maddumage RS, Dulshika GDS, Karunarathna WAC, Epa WA, Bulugahapitiya U, Jayasekara JMKB. Correlation between Liver Fat Indices and Ultrasonography to Determine Non-alcoholic Fatty Liver Disease among Diabetic Patients in Sri Lanka. GJMPBU 2022;17:15. [DOI: 10.25259/gjmpbu_63_2022] [Reference Citation Analysis]
277 Santoro N, Feldstein AE. The role of oxidized lipid species in insulin resistance and NASH in children. Front Endocrinol 2022;13:1019204. [DOI: 10.3389/fendo.2022.1019204] [Reference Citation Analysis]
278 Kobayashi T, Iwaki M, Nakajima A, Nogami A, Yoneda M. Current Research on the Pathogenesis of NAFLD/NASH and the Gut-Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome. Int J Mol Sci 2022;23:11689. [PMID: 36232990 DOI: 10.3390/ijms231911689] [Reference Citation Analysis]
279 Yang B, Luo W, Wang M, Tang Y, Zhu W, Jin L, Wang M, Wang Y, Zhang Y, Zuo W, Huang LJ, Zhao Y, Liang G. Macrophage-specific MyD88 deletion and pharmacological inhibition prevents liver damage in non-alcoholic fatty liver disease via reducing inflammatory response. Biochim Biophys Acta Mol Basis Dis 2022;1868:166480. [PMID: 35811033 DOI: 10.1016/j.bbadis.2022.166480] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
280 Pai RK, Jairath V, Hogan M, Zou G, Adeyi OA, Anstee QM, Aqel BA, Behling C, Carey EJ, Clouston AD, Corey K, Feagan BG, Kleiner DE, Ma C, McFarlane SC, Noureddin M, Ratziu V, Valasek MA, Younossi ZM, Harrison SA, Loomba R. Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology 2022;76:1150-63. [PMID: 35332569 DOI: 10.1002/hep.32475] [Reference Citation Analysis]
281 He K, Guo LL, Tang H, Peng X, Li J, Feng S, Bie C, Chen W, Li Y, Wang M, Tang S. A Freshwater Fish-Based Diet Alleviates Liver Steatosis by Modulating Gut Microbiota and Metabolites: A Clinical Randomized Controlled Trial in Chinese Participants With Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2022;117:1621-31. [PMID: 35973188 DOI: 10.14309/ajg.0000000000001885] [Reference Citation Analysis]
282 Ng CH, Huang DQ, Nguyen MH. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name. Clin Mol Hepatol 2022;28:790-801. [PMID: 35545437 DOI: 10.3350/cmh.2022.0070] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
283 Kim H, Lee CJ, Ahn SH, Lee KS, Lee BK, Baik SJ, Kim SU, Lee JI. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. Dig Dis Sci 2022;67:4919-28. [PMID: 35579799 DOI: 10.1007/s10620-022-07508-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
284 Eslam M, El-Serag HB, Francque S, Sarin SK, Wei L, Bugianesi E, George J. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol 2022;19:638-51. [PMID: 35710982 DOI: 10.1038/s41575-022-00635-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
285 Malespin MH, Barritt AS 4th, Watkins SE, Schoen C, Tincopa MA, Corbin KD, Mospan AR, Munoz B, Trinh HN, Weiss LM, Reddy KR, Loomba R, Kemmer N, Lok AS. Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort. Clin Gastroenterol Hepatol 2022;20:2393-2395.e4. [PMID: 33486083 DOI: 10.1016/j.cgh.2021.01.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
286 Mota AH, Wiltgen D, Gatelli LE, Rosa VJDAD, Machado YC, Mattos AAD, Tovo CV. Cardiac abnormalities in patients with nonalcoholic fatty liver disease. Rev Assoc Med Bras 2022;68:1394-1399. [DOI: 10.1590/1806-9282.20220263] [Reference Citation Analysis]
287 Hsieh YC, Wu PS, Lin YT, Huang YH, Hou MC, Lee KC, Lin HC. (Pro)renin receptor inhibition attenuated liver steatosis, inflammation, and fibrosis in mice with steatohepatitis. FASEB J 2022;36:e22526. [PMID: 36063123 DOI: 10.1096/fj.202200594R] [Reference Citation Analysis]
288 Unalp-Arida A, Ruhl CE. Transient Elastography Measures of Hepatic Steatosis and Fibrosis Are Associated With Body Composition Among US Adolescents. J Pediatr Gastroenterol Nutr 2022;75:497-505. [PMID: 35758468 DOI: 10.1097/MPG.0000000000003533] [Reference Citation Analysis]
289 Larion S, Padgett CA, Butcher JT, Mintz JD, Fulton DJ, Stepp DW. The biological clock enhancer nobiletin ameliorates steatosis in genetically obese mice by restoring aberrant hepatic circadian rhythm. Am J Physiol Gastrointest Liver Physiol 2022;323:G387-400. [PMID: 35997288 DOI: 10.1152/ajpgi.00130.2022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
290 Scheinberg AR, John BV. MAFLD Versus NAFLD: Which Better Predicts the Risk of Atherosclerotic Cardiovascular Disease? Dig Dis Sci 2022;67:4606-8. [PMID: 35579800 DOI: 10.1007/s10620-022-07512-w] [Reference Citation Analysis]
291 Miao L, Xu J, Targher G, Byrne CD, Zheng MH. Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review. Clin Mol Hepatol 2022;28:725-38. [PMID: 35286799 DOI: 10.3350/cmh.2022.0015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
292 Behari J. Needle-free Nonalcoholic Fatty Liver Disease Prognostication: Moving One Step Closer. Gastroenterology 2022;163:819-22. [PMID: 35944709 DOI: 10.1053/j.gastro.2022.07.078] [Reference Citation Analysis]
293 Ajmera V, Kim BK, Yang K, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Quach NE, Tu X, Zhang X, Noureddin M, Allen AM, Loomba R. Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants. Gastroenterology 2022;163:1079-1089.e5. [PMID: 35788349 DOI: 10.1053/j.gastro.2022.06.073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
294 Badmus OO, Hillhouse SA, Anderson CD, Hinds TD, Stec DE. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. Clin Sci (Lond) 2022;136:1347-66. [PMID: 36148775 DOI: 10.1042/CS20220572] [Reference Citation Analysis]
295 Li Z, Mao X, Cui X, Yu T, Zhang M, Li X, Li G. Evaluate the elasticity of carotid artery in the type 2 diabetes mellitus patients with nonalcoholic fatty liver disease by two-dimensional strain imaging. Medicine (Baltimore) 2022;101:e30738. [PMID: 36181039 DOI: 10.1097/MD.0000000000030738] [Reference Citation Analysis]
296 Ganguli SC, Russell LA, Tsoi KS. Implementation of a Whole Food Plant Based Diet in a Food as Prevention Program in a Resource Constrained Environment. J Lifestyle Med 2022;12:148-52. [PMID: 36628184 DOI: 10.15280/jlm.2022.12.3.148] [Reference Citation Analysis]
297 Ivashkin VT, Maevskaya MV, Zharkova MS, Kotovskaya YV, Tkacheva ON, Troshina EA, Shestakova MV, Maev IV, Breder VV, Gheivandova NI, Doshchitsin VL, Dudinskaya EN, Ershova EV, Kodzoeva KB, Komshilova KA, Korochanskaya NV, Mayorov AY, Mishina EE, Nadinskaya MY, Nikitin IG, Pogosova NV, Tarzimanova AI, Shamkhalova MS. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2022;32:104-140. [DOI: 10.22416/1382-4376-2022-32-4-104-140] [Reference Citation Analysis]
298 Islam KB, Brandman D, Chu JN, Goldman ML, Fox RK. Primary Care Providers and Nonalcoholic Fatty Liver Disease: A Needs Assessment Survey. Dig Dis Sci 2022. [PMID: 36178567 DOI: 10.1007/s10620-022-07706-2] [Reference Citation Analysis]
299 Yang B, Lu L, Zhou D, Fan W, Barbier-torres L, Steggerda J, Yang H, Yang X. Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis. Front Endocrinol 2022;13:1007944. [DOI: 10.3389/fendo.2022.1007944] [Reference Citation Analysis]
300 Unalp-Arida A, Ruhl CE. Prepandemic Prevalence Estimates of Fatty Liver Disease and Fibrosis Defined by Liver Elastography in the United States. Dig Dis Sci 2022;:1-16. [PMID: 36173583 DOI: 10.1007/s10620-022-07707-1] [Reference Citation Analysis]
301 Fu CE, Ng CH, Chew NWS, Heng ZEQ, Chin YH, Quek J, Lim WH, Xiao J, Chan KE, Tan DJH, Tan C, Zhang S, Koh TK, Nah B, Dan YY, Syn N, Siddiqui MS, Sanyal AJ, Noureddin M, Muthiah M. A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD). Front Med 2022;9. [DOI: 10.3389/fmed.2022.977552] [Reference Citation Analysis]
302 Fukushima M, Miyaaki H, Sasaki R, Haraguchi M, Miuma S, Hara T, Soyama A, Hidaka M, Eguchi S, Nakao K. Most Cases of Cryptogenic Cirrhosis May be Nonobese Nonalcoholic Steatohepatitis-Risk Factors of Liver Steatosis After Liver Transplantation for Cryptogenic Cirrhosis: A Retrospective Study. Intern Med 2022. [PMID: 36171128 DOI: 10.2169/internalmedicine.0514-22] [Reference Citation Analysis]
303 Yu H, Sheen J, Hou C, Lin I, Huang L, Tain Y, Cheng H, Lai Y, Lin Y, Tiao M, Tsai C. Effects of Maternal Gut Microbiota-Targeted Therapy on the Programming of Nonalcoholic Fatty Liver Disease in Dams and Fetuses, Related to a Prenatal High-Fat Diet. Nutrients 2022;14:4004. [DOI: 10.3390/nu14194004] [Reference Citation Analysis]
304 Zaman CF, Sultana J, Dey P, Dutta J, Mustarin S, Tamanna N, Roy A, Bhowmick N, Khanam M, Sultana S, Chowdhury S, Khanam F, Sakibuzzaman M, Dutta P. A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review. Cureus 2022. [DOI: 10.7759/cureus.29657] [Reference Citation Analysis]
305 Nakagawa C, Yokoyama S, Hosomi K. Association of Statin Adherence With the Development of Nonalcoholic Fatty Liver Disease: A Nested Case-Control Study Using a Japanese Claims Database. Ann Pharmacother 2022;:10600280221126971. [PMID: 36168669 DOI: 10.1177/10600280221126971] [Reference Citation Analysis]
306 Borges-canha M, Neves J, Silva M, Mendonça F, Moreno T, Ribeiro S, Correa J, Vale C, Gonçalves J, Urbano Ferreira H, Gil-santos S, Guerreiro V, Sande A, B. Souto S, Pedro J, Freitas P, Carvalho D, CRIO Group. Waist-to-Hip Ratio and Inflammatory Parameters Are Associated with Risk of Non-Alcoholic Fatty Liver Disease in Patients with Morbid Obesity. Biomedicines 2022;10:2416. [DOI: 10.3390/biomedicines10102416] [Reference Citation Analysis]
307 Shen K, Singh AD, Modaresi Esfeh J, Wakim-Fleming J. Therapies for non-alcoholic fatty liver disease: A 2022 update. World J Hepatol 2022; 14(9): 1718-1729 [DOI: 10.4254/wjh.v14.i9.1718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
308 Lei F, Qin J, Song X, Liu Y, Chen M, Sun T, Huang X, Deng K, Zuo X, Yao D, Xu L, Lu H, Wang G, Liu F, Chen L, Luo J, Xia J, Wang L, Yang Q, Zhang P, Ji Y, Zhang X, She Z, Zeng Q, Li H, Cai J. The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China. Front Endocrinol 2022;13:1007171. [DOI: 10.3389/fendo.2022.1007171] [Reference Citation Analysis]
309 Ma W, Wu W, Wen W, Xu F, Han D, Lyu J, Huang Y. Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK Biobank. Ther Adv Chronic Dis 2022;13:20406223221122478. [PMID: 36159632 DOI: 10.1177/20406223221122478] [Reference Citation Analysis]
310 Mandour MO, El-Hassan M, Elkomi RM, Oben JA. Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future? World J Hepatol 2022; 14(9): 1704-1717 [DOI: 10.4254/wjh.v14.i9.1704] [Reference Citation Analysis]
311 Scutt P, Ban L, Card T, Crooks CJ, Guha N, West J, Morling JR. Liver blood marker testing in UK primary care: a UK wide cohort study, 2004-2016. BMJ Open 2022;12:e058967. [PMID: 36167394 DOI: 10.1136/bmjopen-2021-058967] [Reference Citation Analysis]
312 Rogalski JK, Subdys A, Gawlik-kotelnicka OE. The development of the Metabolic-associated Fatty Liver Disease during pharmacotherapy of mental disorders - a review. Current Problems of Psychiatry 2022;0. [DOI: 10.2478/cpp-2022-0013] [Reference Citation Analysis]
313 Wupperfeld D, Fricker G, Bois De Fer B, Frank L, Wehrle A, Popovic B. Essential phospholipids decrease apoptosis and increase membrane transport in human hepatocyte cell lines. Lipids Health Dis 2022;21. [DOI: 10.1186/s12944-022-01698-8] [Reference Citation Analysis]
314 Cazac G, Lăcătușu C, Mihai C, Grigorescu E, Onofriescu A, Mihai B. Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes. Biomedicines 2022;10:2375. [DOI: 10.3390/biomedicines10102375] [Reference Citation Analysis]
315 Damjanovska S, Karb DB, Tripathi A, Asirwatham J, Delozier S, Perez JA, Falck-ytter Y, Cohen S. Accuracy of Ultrasound Elastography and Fibrosis-4 Index (FIB-4) in Ruling Out Cirrhosis in Obese Non-Alcoholic Fatty Liver Disease (NAFLD) Patients. Cureus 2022. [DOI: 10.7759/cureus.29445] [Reference Citation Analysis]
316 Chrysavgis L, Giannakodimos I, Chatzigeorgiou A, Tziomalos K, Papatheodoridis G, Cholongitas E. The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2022;:1-15. [PMID: 36124827 DOI: 10.1080/17474124.2022.2127408] [Reference Citation Analysis]
317 Torre E, Di Matteo S, Bruno GM, Martinotti C, Valentino MC, Testino G, Rebora A, Bottaro LC, Colombo GL. Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives. Clinicoecon Outcomes Res 2022;14:607-18. [PMID: 36127889 DOI: 10.2147/CEOR.S371778] [Reference Citation Analysis]
318 Lazarus JV, Castera L, Mark HE, Allen AM, Adams LA, Anstee QM, Arrese M, Alqahtani SA, Bugianesi E, Colombo M, Cusi K, Hagström H, Loomba R, Romero-Gómez M, Schattenberg JM, Thiele M, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Francque SM, Tsochatzis EA. Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice. JHEP Rep 2023;5:100596. [PMID: 36644239 DOI: 10.1016/j.jhepr.2022.100596] [Reference Citation Analysis]
319 Suri J, Borja S, Lim JK. Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis. World J Gastroenterol 2022; 28(35): 5129-5140 [DOI: 10.3748/wjg.v28.i35.5129] [Reference Citation Analysis]
320 Xia Y, Ren M, Yang J, Cai C, Cheng W, Zhou X, Lu D, Ji F. Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality. Front Microbiol 2022;13:1003755. [DOI: 10.3389/fmicb.2022.1003755] [Reference Citation Analysis]
321 Andrade TG, Xavier LCD, Souza FF, Araújo RC. Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver disease – a survey in a university hospital in Brazil. Archives of Endocrinology and Metabolism 2022. [DOI: 10.20945/2359-3997000000514] [Reference Citation Analysis]
322 Liu Q, Zhao G, Li Q, Wu W, Zhang Y, Bian H. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China.. [DOI: 10.21203/rs.3.rs-1713068/v2] [Reference Citation Analysis]
323 Huang J, Zhang M, Wu Y, Wang M, Zhu Y, Lin S. Fatty liver disease reverses the obesity paradox in chronic kidney disease stages 3-5: A follow-up study of NHANES III. Hepatol Commun 2022;6:3132-9. [PMID: 36125132 DOI: 10.1002/hep4.2086] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
324 Nguyen XK, Zhang J, Chin KL, Bloom S, Nicoll AJ. Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver? Nutrients 2022;14:3875. [PMID: 36145251 DOI: 10.3390/nu14183875] [Reference Citation Analysis]
325 Liu J, Yao B, Gao L, Zhang Y, Huang S, Wang X. Emerging role of carboxylesterases in nonalcoholic fatty liver disease. Biochem Pharmacol 2022;205:115250. [PMID: 36130649 DOI: 10.1016/j.bcp.2022.115250] [Reference Citation Analysis]
326 Yin X, Chen Y, Ruze R, Xu R, Song J, Wang C, Xu Q. The evolving view of thermogenic fat and its implications in cancer and metabolic diseases. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-01178-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
327 Shen T, Wu C, Lee Y, Chang C. Prevalence, Trends, and Characteristics of Nonalcoholic Fatty Liver Disease among the US Population Aged 12–79 Years.. [DOI: 10.21203/rs.3.rs-2043909/v1] [Reference Citation Analysis]
328 Tharwat M, Medhat MA, El-Kassas M. The NAFLD-MAFLD debate through the lens of the Arab world. Saudi J Gastroenterol 2022;28:413-6. [PMID: 36124490 DOI: 10.4103/sjg.sjg_314_22] [Reference Citation Analysis]
329 Alencar RSSM, Oliveira CP, Chagas AL, Fonseca LGD, Maccali C, Saud LRDC, Xerfan MP, Stefano JT, Herman P, D'Albuquerque LAC, Alves VAF, Carrilho FJ. Hepatocellular carcinoma (HCC) in patients with Non-Alcoholic Fatty Liver Disease (NAFLD): screening, treatment and survival analysis in a Brazilian series. Clinics (Sao Paulo) 2022;77:100097. [PMID: 36088887 DOI: 10.1016/j.clinsp.2022.100097] [Reference Citation Analysis]
330 Javanbakht M, Fishman J, Moloney E, Rydqvist P, Ansaripour A. Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis. PharmacoEconomics Open. [DOI: 10.1007/s41669-022-00370-2] [Reference Citation Analysis]
331 Şendur HN, Özdemir Kalkan D, Cerit MN, Kalkan G, Şendur AB, Özhan Oktar S. Hepatic Fat Quantification With Novel Ultrasound Based Techniques: A Diagnostic Performance Study Using Magnetic Resonance Imaging Proton Density Fat Fraction as Reference Standard. Can Assoc Radiol J. [DOI: 10.1177/08465371221123696] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
332 Fetzer DT, Rosado-Mendez IM, Wang M, Robbin ML, Ozturk A, Wear KA, Ormachea J, Stiles TA, Fowlkes JB, Hall TJ, Samir AE. Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization. Radiology 2022;:212808. [PMID: 36098640 DOI: 10.1148/radiol.212808] [Reference Citation Analysis]
333 Lugnier C. The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches. IJMS 2022;23:10616. [DOI: 10.3390/ijms231810616] [Reference Citation Analysis]
334 Wu W, Feng A, Ma W, Li D, Zheng S, Xu F, Han D, Lyu J. Worldwide long-term trends in the incidence of nonalcoholic fatty liver disease during 1990–2019: A joinpoint and age-period-cohort analysis. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.891963] [Reference Citation Analysis]
335 Brozzetti S, D’alterio C, Bini S, Antimi J, Rocco B, Fassari A, Lucatelli P, Nardis P, Di Martino M, De Sanctis GM, Corona M, Bagni O, Cortesi E, Bezzi M, Catalano C. Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients—A Retrospective Observational Study. Cancers 2022;14:4422. [DOI: 10.3390/cancers14184422] [Reference Citation Analysis]
336 Kreve F, Callejas GH, Jimenez LS, Marques RA, Chaim FDM, Utrini MP, Gestic MA, Ramos AC, Chaim EA, Cazzo E. Trajectory of NAFLD characteristics after Roux-en-Y gastric bypass: a five-year historical cohort study. Sao Paulo Med J . [DOI: 10.1590/1516-3180.2021.0828.07012022] [Reference Citation Analysis]
337 Mobasheri N, Ghahremani L, Fallahzadeh Abarghooee E, Hassanzadeh J, Apte U. Lifestyle Intervention for Patients with Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial Based on the Theory of Planned Behavior. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/3465980] [Reference Citation Analysis]
338 Grigorescu E, Lăcătușu C, Floria M, Cazac G, Onofriescu A, Ceasovschih A, Crețu I, Mihai B, Șorodoc L. Association of Inflammatory and Metabolic Biomarkers with Mitral Annular Calcification in Type 2 Diabetes Patients. JPM 2022;12:1484. [DOI: 10.3390/jpm12091484] [Reference Citation Analysis]
339 Dellinger RW, Holmes HE, Hu-Seliger T, Butt RW, Harrison SA, Mozaffarian D, Chen O, Guarente L. Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial. Hepatology 2022. [PMID: 36082508 DOI: 10.1002/hep.32778] [Reference Citation Analysis]
340 De Nucci S, Castellana F, Zupo R, Lampignano L, Di Chito M, Rinaldi R, Giannuzzi V, Cozzolongo R, Piazzolla G, Giannelli G, Sardone R, De Pergola G. Associations between serum biomarkers and non-alcoholic liver disease: Results of a clinical study of Mediterranean patients with obesity. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.1002669] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
341 Bassegoda O, Rivera-Esteban J, Serra I, Morillas R, Broquetas T, Vergara M, Rodriguez A, Aracil C, Virolés S, Carrión JA, Pardo A, Rodríguez-Tajes S, Serra-Burriel M, Pericàs JM, Augustin S, Ginès P, Graupera I. High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study. Hepatol Commun 2022;6:3212-22. [PMID: 36073343 DOI: 10.1002/hep4.2056] [Reference Citation Analysis]
342 Sarno G, Schiavo L, Calabrese P, Álvarez Córdova L, Frias-toral E, Cucalón G, Garcia-velasquez E, Fuchs-tarlovsky V, Pilone V. The Impact of Bariatric-Surgery-Induced Weight Loss on Patients Undergoing Liver Transplant: A Focus on Metabolism, Pathophysiological Changes, and Outcome in Obese Patients Suffering NAFLD-Related Cirrhosis. JCM 2022;11:5293. [DOI: 10.3390/jcm11185293] [Reference Citation Analysis]
343 Kawai S, Yamakage H, Kotani K, Noda M, Satoh-Asahara N, Hashimoto K. Analysis of time-dependent changes in the FIB4 index in patients with obesity receiving weight reduction therapy. Sci Rep 2022;12:15219. [PMID: 36075942 DOI: 10.1038/s41598-022-19420-0] [Reference Citation Analysis]
344 Shibata Y, Fukuda T, Nobeyama Y, Asahina A. Evaluation of nonalcoholic fatty liver disease in Japanese patients with psoriasis: Chest CT imaging for screening purposes. J Dermatol 2022. [PMID: 36074651 DOI: 10.1111/1346-8138.16564] [Reference Citation Analysis]
345 Rastogi A, Rath I, Varadarajan A, Ramakrishna G, Bihari C, Maiwall R. Non-alcoholic fatty liver disease (NAFLD) in lean individuals - Single centre large cohort clinicopathologic and immunophenotypic study. Pathol Res Pract 2022;238:154112. [PMID: 36126451 DOI: 10.1016/j.prp.2022.154112] [Reference Citation Analysis]
346 Chen G, Yang JC, Zhang GX, Cheng Z, Du X. Evaluation of Six Noninvasive Methods for the Detection of Fibrosis in Chinese Patients with Obesity and Nonalcoholic Fatty Liver Disease. Obes Surg 2022. [PMID: 36070119 DOI: 10.1007/s11695-022-06251-1] [Reference Citation Analysis]
347 Orci LA, Jornayvaz FR, Toso C, Gariani K. Systematic Review and Meta-Analysis of the Usefulness of Epicardial Fat Thickness as a Non-Invasive Marker of the Presence and Severity of Nonalcoholic Fatty Liver Disease. Biomedicines 2022;10:2204. [DOI: 10.3390/biomedicines10092204] [Reference Citation Analysis]
348 Li YW, Jiao Y, Chen N, Gao Q, Chen YK, Zhang YF, Wen QP, Zhang ZM. How to select the quantitative magnetic resonance technique for subjects with fatty liver: A systematic review. World J Clin Cases 2022; 10(25): 8906-8921 [DOI: 10.12998/wjcc.v10.i25.8906] [Reference Citation Analysis]
349 Yip TC, Vilar-Gomez E, Petta S, Yilmaz Y, Wong GL, Adams LA, de Lédinghen V, Sookoian S, Wong VW. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology 2022. [PMID: 36062393 DOI: 10.1002/hep.32774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
350 Hu H, Han Y, Cao C, He Y. The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population. J Transl Med 2022;20:398. [PMID: 36064712 DOI: 10.1186/s12967-022-03611-4] [Reference Citation Analysis]
351 Jeong MK, Min BH, Choi YR, Hyun JY, Park HJ, Eom JA, Won SM, Jeong JJ, Oh KK, Gupta H, Ganesan R, Sharma SP, Yoon SJ, Choi MR, Kim DJ, Suk KT. Food and Gut Microbiota-Derived Metabolites in Nonalcoholic Fatty Liver Disease. Foods 2022;11:2703. [PMID: 36076888 DOI: 10.3390/foods11172703] [Reference Citation Analysis]
352 Zhou J, Pang J, Tripathi M, Ho JP, Widjaja AA, Shekeran SG, Cook SA, Suzuki A, Diehl AM, Petretto E, Singh BK, Yen PM. Spermidine-mediated hypusination of translation factor EIF5A improves mitochondrial fatty acid oxidation and prevents non-alcoholic steatohepatitis progression. Nat Commun 2022;13:5202. [PMID: 36057633 DOI: 10.1038/s41467-022-32788-x] [Reference Citation Analysis]
353 Yu S, Wang J, Zheng H, Wang R, Johnson N, Li T, Li P, Lin J, Li Y, Yan J, Zhang Y, Zhu Z, Ding X. Pathogenesis from Inflammation to Cancer in NASH-Derived HCC. J Hepatocell Carcinoma 2022;9:855-67. [PMID: 36051860 DOI: 10.2147/JHC.S377768] [Reference Citation Analysis]
354 Hung CT, Tsai YW, Wu YS, Yeh CF, Yang KC. The novel role of ER protein TXNDC5 in the pathogenesis of organ fibrosis: mechanistic insights and therapeutic implications. J Biomed Sci 2022;29:63. [PMID: 36050716 DOI: 10.1186/s12929-022-00850-x] [Reference Citation Analysis]
355 Wang Y, Yu Y, Zhang H, Chen C, Wan H, Chen Y, Xia F, Yu S, Wang N, Ye L, Lu Y. Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China. Front Endocrinol 2022;13:968766. [DOI: 10.3389/fendo.2022.968766] [Reference Citation Analysis]
356 Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther 2022;56:942-56. [PMID: 35880713 DOI: 10.1111/apt.17158] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
357 Zhang D, Wang H, He X, Feng D, Sun Y, Liu Z, Gao Y, Liu H. MAFLD was more easily diagnosed than NAFLD in liver transplantation recipients with abnormal liver function. iLIVER 2022. [DOI: 10.1016/j.iliver.2022.09.001] [Reference Citation Analysis]
358 Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut 2022;71:1867-75. [PMID: 34489307 DOI: 10.1136/gutjnl-2021-325724] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
359 Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology 2022;163:764-774.e1. [PMID: 35842345 DOI: 10.1053/j.gastro.2022.06.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
360 Authors, Collaborators:. Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF Registration No.: 021–025. Z Gastroenterol 2022;60:e733-e801. [DOI: 10.1055/a-1880-2388] [Reference Citation Analysis]
361 Fan L, Zhu X, Shingina A, Kabagambe EK, Shrubsole MJ, Dai Q. Racial Disparities in Associations of Alcohol Consumption With Liver Disease Mortality in a Predominantly Low-Income Population: A Report From the Southern Community Cohort Study. Am J Gastroenterol 2022;117:1523-9. [PMID: 35416798 DOI: 10.14309/ajg.0000000000001768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
362 Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C, Karlas T, Krawczyk M, Longerich T, Luedde T, Roden M, Schattenberg J, Sterneck M, Tannapfel A, Lorenz P, Tacke F; Collaborators:. Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025. Z Gastroenterol 2022;60:1346-421. [PMID: 36100202 DOI: 10.1055/a-1880-2283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
363 Pan H, Zhou M, Ju Z, Luo J, Jin J, Shen L, Zhou P, Huang R. Potential role of gut microbiota-LCA-INSR axis in high fat-diet-induced non-alcoholic fatty liver dysfunction: From perspective of radiation variation. Current Research in Food Science 2022. [DOI: 10.1016/j.crfs.2022.09.022] [Reference Citation Analysis]
364 Dai L, Wang Q, Wang P, Zhang S, Tai L, Xu X, Sun G, Duan M, Yuan H, Feng Z. Discovery of novel AdipoRon analogues as potent anti-inflammatory agents against nonalcoholic steatohepatitis. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114800] [Reference Citation Analysis]
365 Karjoo S, Auriemma A, Fraker T, Bays HE. Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 2022;3:100027. [DOI: 10.1016/j.obpill.2022.100027] [Reference Citation Analysis]
366 Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Damgaard LH, Buchholtz K, Kjær MS, Balendran C, Myers RP, Loomba R, Noureddin M. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. J Hepatol 2022;77:607-18. [PMID: 35439567 DOI: 10.1016/j.jhep.2022.04.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
367 Basu R, Noureddin M, Clark JM. Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers. Mayo Clin Proc 2022;97:1700-16. [PMID: 36058582 DOI: 10.1016/j.mayocp.2022.04.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
368 Aishwarya TS, Mounika N, Vishwakarma G, Adela R. Effect of obeticholic acid in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) patients: a systematic review and meta-analysis. RPS Pharmacy and Pharmacology Reports 2022;1. [DOI: 10.1093/rpsppr/rqac001] [Reference Citation Analysis]
369 Ngu M, Norhayati M, Rosnani Z, Zulkifli M. Curcumin as adjuvant treatment in patients with non-alcoholic fatty liver (NAFLD) disease: A systematic review and meta-analysis. Complementary Therapies in Medicine 2022;68:102843. [DOI: 10.1016/j.ctim.2022.102843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
370 Dunn W, Song X, Koestler D, Grdinovac K, Al-Hihi E, Chen J, Taylor R, Wilson J, Weinman SA. Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation. J Gastroenterol Hepatol 2022;37:1815-21. [PMID: 35613944 DOI: 10.1111/jgh.15900] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
371 Cao Y, Xiang L, Qi F, Zhang Y, Chen Y, Zhou X. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. eClinicalMedicine 2022;51:101547. [DOI: 10.1016/j.eclinm.2022.101547] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
372 Gkiourtzis Ν, Kalopitas G, Vadarlis A, Bakaloudi DR, Dionysopoulos G, Karanika E, Tsekitsidi E, Chourdakis M. The Benefit of Probiotics in Pediatric Nonalcoholic Fatty Liver Disease: A Meta-analysis of Randomized Control Trials. J Pediatr Gastroenterol Nutr 2022;75:e31-7. [PMID: 35758473 DOI: 10.1097/MPG.0000000000003537] [Reference Citation Analysis]
373 Xie Y, Kong W, Wang X, Wu Z. Association of glycated hemoglobin with non-alcoholic fatty liver disease patients and the severity of liver steatosis and fibrosis measured by transient elastography in adults without diabetes. BMC Endocr Disord 2022;22. [DOI: 10.1186/s12902-022-01134-z] [Reference Citation Analysis]
374 Diaconu C, Guja C. Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus—From Prevalence to Diagnostic Approach and Treatment Strategies. JCM 2022;11:5144. [DOI: 10.3390/jcm11175144] [Reference Citation Analysis]
375 Arai T, Atsukawa M, Tsubota A, Mikami S, Haruki U, Yoshikata K, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun 2022;6:3073-82. [PMID: 36039537 DOI: 10.1002/hep4.2069] [Reference Citation Analysis]
376 Wu QL, Zeng SX, Peng JY, Yuan Y, Zhu Z, Xie ZC, Huang ZH, Haung JS, Lai JM, Chen JA, Lin MH. Advances in metformin for the treatment of non-alcoholic fatty liver disease in children. Expert Rev Gastroenterol Hepatol 2022. [PMID: 36039840 DOI: 10.1080/17474124.2022.2118112] [Reference Citation Analysis]
377 Herrmann J, Petit P, Grabhorn E, Lenz A, Jürgens J, Franchi-Albella S. Liver cirrhosis in children - the role of imaging in the diagnostic pathway. Pediatr Radiol 2022. [PMID: 36040526 DOI: 10.1007/s00247-022-05480-x] [Reference Citation Analysis]
378 Zhou C, Zhang W, Lin H, Zhang L, Wu F, Wang Y, Yu S, Peng X, Cheng W, Li M, Pan X, Huang Z, Zhang W. Effect of theaflavin-3,3′-digallate on leptin-deficient induced nonalcoholic fatty liver disease might be related to lipid metabolism regulated by the Fads1/PPARδ/Fabp4 axis and gut microbiota. Front Pharmacol 2022;13:925264. [DOI: 10.3389/fphar.2022.925264] [Reference Citation Analysis]
379 Asaji N, Inoue J, Hayashi H, Tokunaga E, Shimamoto Y, Kinoshita M, Tanaka T, Sakai A, Yano Y, Ueda Y, Kodama Y. Constitution of mucosa‐associated microbiota in the lower digestive tract does not change in early stage of non‐alcoholic fatty liver disease with fecal dysbiosis. JGH Open 2022. [DOI: 10.1002/jgh3.12803] [Reference Citation Analysis]
380 Salgado Alvarez GA, Pinto Galvez SM, Garcia Mora U, Cano Contreras AD, Durán Rosas C, Priego-Parra BA, Triana Romero A, Amieva Balmori M, Roesch Dietlen F, Martinez Vazquez SE, Mendez Guerrero IO, Chi-Cervera LA, Bernal Reyes R, Martinez Roriguez LA, Icaza Chavez ME, Remes Troche JM. Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease. World J Hepatol 2022; 14(8): 1633-1642 [DOI: 10.4254/wjh.v14.i8.1633] [Reference Citation Analysis]
381 Ng CH, Teng ML, Chew NW, Chan KE, Yong JN, Quek J, Tan DJH, Lim WH, Lee GSJ, Wong J, Kaewdech A, Huang DQ, Wang J, Chan MY, Noureddin M, Siddiqui MS, Sanyal A, Muthiah M. Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individuals. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2119128] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Ismaiel A, Ciobanu OS, Ismaiel M, Leucuta D, Popa S, David L, Ensar D, Al Srouji N, Dumitrascu DL. Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Biomedicines 2022;10:2101. [DOI: 10.3390/biomedicines10092101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
383 Han L, Fu S, Li J, Liu D, Tan Y. Association between grip strength and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Front Med 2022;9. [DOI: 10.3389/fmed.2022.988566] [Reference Citation Analysis]
384 Song Q, Liu S, Ling Q, Gao Q, Yang R, Chen S, Wu S, Chen M, Cai J. Severity of Nonalcoholic Fatty Liver Disease is Associated With Cardiovascular Outcomes in Patients With Prehypertension or Hypertension: A Community–Based Cohort Study. Front Endocrinol 2022;13:942647. [DOI: 10.3389/fendo.2022.942647] [Reference Citation Analysis]
385 Nishio T, Ito T, Hata K, Taura K, Hatano E. Current status of liver transplantation for non-B non-C liver cirrhosis and hepatocellular carcinoma. Ann Gastroenterol Surg 2023;7:42-52. [PMID: 36643372 DOI: 10.1002/ags3.12612] [Reference Citation Analysis]
386 Koperska A, Wesołek A, Moszak M, Szulińska M. Berberine in Non-Alcoholic Fatty Liver Disease—A Review. Nutrients 2022;14:3459. [DOI: 10.3390/nu14173459] [Reference Citation Analysis]
387 Harrison SA, Ruane PJ, Freilich B, Neff G, Patil R, Behling C, Hu C, Shringarpure R, de Temple B, Fong E, Tillman EJ, Rolph T, Cheng A, Yale K. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Rep 2023;5:100563. [PMID: 36644237 DOI: 10.1016/j.jhepr.2022.100563] [Reference Citation Analysis]
388 Wu S, Yuan C, Yang Z, Liu S, Zhang Q, Zhang S, Zhu S. Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study. BMC Med 2022;20. [DOI: 10.1186/s12916-022-02460-8] [Reference Citation Analysis]
389 Zunica ERM, Heintz EC, Axelrod CL, Kirwan JP. Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:4051. [PMID: 36011044 DOI: 10.3390/cancers14164051] [Reference Citation Analysis]
390 Haam JH, Hur YI, Kim YS, Kim KK, Kang JH, Ko HJ, Cho YJ, Choi HI, Lee KR, Park JH, Cho SH, Kim JK, Lee T, Seo MJ, Yoon YS, Seo Y, Nam GE, Kim SH. Fatty Liver Change in Korean Adults in a Systematic Social Distancing System Amid the COVID-19 Pandemic: A Multicenter Analysis. Int J Environ Res Public Health 2022;19:10444. [PMID: 36012079 DOI: 10.3390/ijerph191610444] [Reference Citation Analysis]
391 Liu TT, Qiu H, Liu SY, Chien C, Wang JH, Wong MW, Yi CH, Lin L, Lei WY, Liang SW, Hung JS, Huang JF, Chen CL, Han MAT. Modifications decrease hepatic steatosis in Taiwanese with metabolic-associated fatty liver disease. Kaohsiung J Med Sci 2022. [PMID: 35993503 DOI: 10.1002/kjm2.12580] [Reference Citation Analysis]
392 Wong C, Dash A, Fredrickson J, Lewin-Koh N, Chen S, Yoshida K, Liu Y, Gutierrez J, Kunder R. Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial. Hepatology 2022. [PMID: 35993161 DOI: 10.1002/hep.32742] [Reference Citation Analysis]
393 Arredouani A. Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment. Lifestyle-Related Diseases and Metabolic Syndrome [Working Title] 2022. [DOI: 10.5772/intechopen.106445] [Reference Citation Analysis]
394 Yang L, Dai Y, He H, Liu Z, Liao S, Zhang Y, Liao G, An Z. Integrative analysis of gut microbiota and fecal metabolites in metabolic associated fatty liver disease patients. Front Microbiol 2022;13:969757. [DOI: 10.3389/fmicb.2022.969757] [Reference Citation Analysis]
395 Mboumba Bouassa RS, Sebastiani G, Di Marzo V, Jenabian MA, Costiniuk CT. Cannabinoids and Chronic Liver Diseases. Int J Mol Sci 2022;23:9423. [PMID: 36012687 DOI: 10.3390/ijms23169423] [Reference Citation Analysis]
396 Zhou S, You H, Qiu S, Yu D, Bai Y, He J, Cao H, Che Q, Guo J, Su Z. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR). Biomed Pharmacother 2022;154:113577. [PMID: 35988420 DOI: 10.1016/j.biopha.2022.113577] [Reference Citation Analysis]
397 Qiao P, Jia Y, Ma A, He J, Shao C, Li X, Wang S, Yang B, Zhou H. Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice. Front Pharmacol 2022;13:934136. [DOI: 10.3389/fphar.2022.934136] [Reference Citation Analysis]
398 Salmi A, di Filippo L, Ferrari C, Frara S, Giustina A. Ultrasound and FibroScan® Controlled Attenuation Parameter in patients with MAFLD: head to head comparison in assessing liver steatosis. Endocrine 2022. [PMID: 35980569 DOI: 10.1007/s12020-022-03157-x] [Reference Citation Analysis]
399 So B, Ji LL, Imdad S, Kang C. Proteomic analysis of the effect of high-fat-diet and voluntary physical activity on mouse liver. PLoS ONE 2022;17:e0273049. [DOI: 10.1371/journal.pone.0273049] [Reference Citation Analysis]
400 Xie J, Huang H, Liu Z, Li Y, Yu C, Xu L, Xu C. The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study. Hepatology 2022. [PMID: 35971878 DOI: 10.1002/hep.32728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
401 Renzulli M, Pecorelli A, Brandi N, Marasco G, Adduci F, Tovoli F, Stefanini B, Granito A, Golfieri R. Radiological Features of Microvascular Invasion of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. Gastroenterology Insights 2022;13:275-285. [DOI: 10.3390/gastroent13030028] [Reference Citation Analysis]
402 Abdelnabi MN, Flores Molina M, Soucy G, Quoc-Huy Trinh V, Bédard N, Mazouz S, Jouvet N, Dion J, Tran S, Bilodeau M, Estall JL, Shoukry NH. Sex-Dependent Hepatoprotective Role of IL-22 Receptor Signaling in Non-Alcoholic Fatty Liver Disease-Related Fibrosis. Cell Mol Gastroenterol Hepatol 2022;14:1269-94. [PMID: 35970323 DOI: 10.1016/j.jcmgh.2022.08.001] [Reference Citation Analysis]
403 Chen P, Zhao Y, Chen Y. A vegan diet improves insulin resistance in individuals with obesity: a systematic review and meta-analysis. Diabetol Metab Syndr 2022;14:114. [PMID: 35964120 DOI: 10.1186/s13098-022-00879-w] [Reference Citation Analysis]
404 Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022;7:287. [PMID: 35963848 DOI: 10.1038/s41392-022-01119-3] [Reference Citation Analysis]
405 Luo L, Ma Q, Lin L, Wang H, Ye J, Zhong B, Huang M. Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Disease Markers 2022;2022:1-12. [DOI: 10.1155/2022/8446170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
406 Xu J, Piao C, Qu Y, Liu T, Peng Y, Li Q, Zhao X, Li P, Wu X, Fan Y, Chen B, Yang J. Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial. Front Pharmacol 2022;13:924021. [DOI: 10.3389/fphar.2022.924021] [Reference Citation Analysis]
407 Bae J, Lee JY, Shin E, Lee M, Lee YH, Lee BW, Kang ES, Cha BS. The effects of the voglibose on non-alcoholic fatty liver disease in mice model. Sci Rep 2022;12:13595. [PMID: 35948569 DOI: 10.1038/s41598-022-15550-7] [Reference Citation Analysis]
408 Bhujade H, Mishra S, Butt AS, Kamani L, Premkumar M. Work-up for Incidentally Detected NAFLD: How Far is It Worth? Euroasian Journal of Hepato-Gastroenterology 2022;12:S26-S36. [DOI: 10.5005/jp-journals-10018-1364] [Reference Citation Analysis]
409 Al Mahtab M, Akbar SMF, Roy PP, Rahim MA, Yesmin SS, Islam SB. Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status. Euroasian Journal of Hepato-Gastroenterology 2022;12:S46-S50. [DOI: 10.5005/jp-journals-10018-1360] [Reference Citation Analysis]
410 Shrestha A, Pradhananga S. Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease. Euroasian Journal of Hepato-Gastroenterology 2022;12:S51-S58. [DOI: 10.5005/jp-journals-10018-1359] [Reference Citation Analysis]
411 Ozkan H, Ozercan AM. Vibration-controlled Transient Elastography in NAFLD: Review Study. Euroasian Journal of Hepato-Gastroenterology 2022;12:S41-S45. [DOI: 10.5005/jp-journals-10018-1365] [Reference Citation Analysis]
412 Scheffschick A, Babel J, Sperling S, Nerusch J, Herzog N, Seehofer D, Damm G. Primary-like Human Hepatocytes Genetically Engineered to Obtain Proliferation Competence as a Capable Application for Energy Metabolism Experiments in In Vitro Oncologic Liver Models. Biology 2022;11:1195. [DOI: 10.3390/biology11081195] [Reference Citation Analysis]
413 Li Q, Zhang X, Zhang C, Li Y, Zhang S, Chen Y. Risk Factors and Prediction Models for Nonalcoholic Fatty Liver Disease Based on Random Forest. Computational and Mathematical Methods in Medicine 2022;2022:1-7. [DOI: 10.1155/2022/8793659] [Reference Citation Analysis]
414 Carpi RZ, Barbalho SM, Sloan KP, Laurindo LF, Gonzaga HF, Grippa PC, Zutin TLM, Girio RJS, Repetti CSF, Detregiachi CRP, Bueno PCS, Mazuqueli Pereira ESB, Goulart RA, Haber JFDS. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review. Int J Mol Sci 2022;23:8805. [PMID: 35955942 DOI: 10.3390/ijms23158805] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
415 Ng CH, Wong ZY, Chew NWS, Chan KE, Xiao J, Sayed N, Lim WH, Tan DJH, Loke RWK, Tay PWL, Yong JN, Kong G, Huang DQ, Wang J, Chan M, Dalakoti M, Tamaki N, Noureddin M, Siddiqui MS, Sanyal AJ, Muthiah M. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.942753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
416 Jitrukthai S, Kositamongkol C, Boonchai P, Mepramoon E, Ariyakunaphan P, Nimitpunya P, Srivanichakorn W, Chaisathaphol T, Washirasaksiri C, Auesomwang C, Sitasuwan T, Tinmanee R, Sayabovorn N, Charatcharoenwitthaya P, Phisalprapa P. Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome. J Clin Med 2022;11:4627. [PMID: 35956240 DOI: 10.3390/jcm11154627] [Reference Citation Analysis]
417 Li DD, Ma JM, Li MJ, Gao LL, Fan YN, Zhang YN, Tao XJ, Yang JJ. Supplementation of Lycium barbarum Polysaccharide Combined with Aerobic Exercise Ameliorates High-Fat-Induced Nonalcoholic Steatohepatitis via AMPK/PPARα/PGC-1α Pathway. Nutrients 2022;14:3247. [PMID: 35956423 DOI: 10.3390/nu14153247] [Reference Citation Analysis]
418 Naseri K, Saadati S, Yari Z, Askari B, Mafi D, Hoseinian P, Asbaghi O, Hekmatdoost A, de Courten B. Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2022;14:3224. [PMID: 35956400 DOI: 10.3390/nu14153224] [Reference Citation Analysis]
419 Powell N, Liang T, Ipe J, Cao S, Skaar T, Desta Z, Qian H, Ebert P, Chen Y, Thomas M, Chalasani N. Clinically Important Alterations in Pharmacogene Expression in Histologically Severe Nonalcoholic Fatty Liver Disease.. [DOI: 10.21203/rs.3.rs-1878803/v1] [Reference Citation Analysis]
420 Calcaterra V, Magenes VC, Vandoni M, Berardo C, Marin L, Bianchi A, Cordaro E, Silvestro GS, Silvestri D, Carnevale Pellino V, Cereda C, Zuccotti G. Benefits of Physical Exercise as Approach to Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Children and Adolescents with Obesity. Children 2022;9:1174. [DOI: 10.3390/children9081174] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
421 Корнован Г, Синенко В, Колотвіна Л, Бажора Я, Лагода Д, Назарян В, Амірова Г, Паслар О. КОМОРБІДНА ПАТОЛОГІЯ ПЕЧІНКИ У ПАЦІЄНТІВ, ЯКІ ЖИВУТЬ З ОЖИРІННЯМ. GoS 2022. [DOI: 10.36074/grail-of-science.22.07.2022.073] [Reference Citation Analysis]
422 Nakashima M, Tanakaya M, Miyoshi T, Saito T, Katayama Y, Sakuragi S, Ito H. The Fibrosis-4 Index Predicts Cardiovascular Prognosis in Patients With Severe Isolated Tricuspid Regurgitation. Circ J 2022. [PMID: 35922937 DOI: 10.1253/circj.CJ-22-0109] [Reference Citation Analysis]
423 Cazac GD, Lăcătușu CM, Mihai C, Grigorescu ED, Onofriescu A, Mihai BM. New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis. Life (Basel) 2022;12:1189. [PMID: 36013368 DOI: 10.3390/life12081189] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
424 Kumar R, Arya JK, Rizvi SI. Chitosan reduces inflammation and protects against oxidative stress in a hyperlipidemic rat model: relevance to nonalcoholic fatty liver disease. Mol Biol Rep 2022. [PMID: 35925484 DOI: 10.1007/s11033-022-07810-6] [Reference Citation Analysis]
425 Pérez-mayorga M, Lopez-lopez JP, Chacon-manosalva MA, Castillo MG, Otero J, Martinez-bello D, Gomez-arbelaez D, Cohen DD, Lopez-jaramillo P, Ravaioli F. Insulin Resistance Markers to Detect Nonalcoholic Fatty Liver Disease in a Male Hispanic Population. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-7. [DOI: 10.1155/2022/1782221] [Reference Citation Analysis]
426 St Rose K, Yan J, Xu F, Williams J, Dweck V, Saxena D, Schwabe RF, Caviglia JM. Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3. Hepatol Commun 2022;6:2676-88. [PMID: 35923109 DOI: 10.1002/hep4.2035] [Reference Citation Analysis]
427 Lv W, Tan X, Chen X, Hu T, Jiang J, Li Q, Chen X, Tan H, Qian B. D ‐Limonene for regulating metabolism‐associated fatty liver disease (MAFLD) and analysis of the TCM constitution: A protocol for an exploratory, randomized, double‐blind, placebo‐controlled trial (DL‐MAFLD‐TCM). Food Frontiers. [DOI: 10.1002/fft2.171] [Reference Citation Analysis]
428 Hughey CC, Puchalska P, Crawford PA. Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesis. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2022. [DOI: 10.1016/j.bbalip.2022.159209] [Reference Citation Analysis]
429 Tan YY, Yue SR, Lu AP, Zhang L, Ji G, Liu BC, Wang RR. The improvement of nonalcoholic steatohepatitis by Poria cocos polysaccharides associated with gut microbiota and NF-κB/CCL3/CCR1 axis. Phytomedicine 2022;103:154208. [PMID: 35691078 DOI: 10.1016/j.phymed.2022.154208] [Reference Citation Analysis]
430 Sourianarayanane A, McCullough AJ. Accuracy of steatosis and fibrosis NAFLD scores in relation to vibration controlled transient elastography: An NHANES analysis. Clin Res Hepatol Gastroenterol 2022;46:101997. [PMID: 35842111 DOI: 10.1016/j.clinre.2022.101997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
431 Ha Y, Chon YE, Kim MN, Lee JH, Hwang SG. Gamma-glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2022;37:1624-32. [PMID: 35467042 DOI: 10.1111/jgh.15871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
432 Jang H, Lee YB, Moon H, Chung JW, Nam JY, Cho EJ, Lee JH, Yu SJ, Kim YJ, Lee J, Yoon JH. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology 2022;76:492-501. [PMID: 35100447 DOI: 10.1002/hep.32380] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
433 Boutari C, Pappas PD, Anastasilakis D, Mantzoros CS. Statins’ efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clinical Nutrition 2022. [DOI: 10.1016/j.clnu.2022.08.001] [Reference Citation Analysis]
434 Kumada T, Ogawa S, Goto T, Toyoda H, Yasuda S, Ito T, Yasuda E, Akita T, Tanaka J. Intra-individual Comparisons of the Ultrasound-Guided Attenuation Parameter and the Magnetic Resonance Imaging-Based Proton Density Fat Fraction Using Bias and Precision Statistics. Ultrasound Med Biol 2022;48:1537-46. [PMID: 35613974 DOI: 10.1016/j.ultrasmedbio.2022.03.019] [Reference Citation Analysis]
435 Mastromauro C, Polidori N, Giannini C. Metabolic dysfunction-associated fatty liver disease in obese youth with insulin resistance and type 2 diabetes. Curr Opin Pediatr 2022;34:414-22. [PMID: 35836399 DOI: 10.1097/MOP.0000000000001138] [Reference Citation Analysis]
436 Vos MB, Van Natta ML, Blondet NM, Dasarathy S, Fishbein M, Hertel P, Jain AK, Karpen SJ, Lavine JE, Mohammad S, Miriel LA, Molleston JP, Mouzaki M, Sanyal A, Sharkey EP, Schwimmer JB, Tonascia J, Wilson LA, Xanthakos SA; NASH Clinical Research Network. Randomized placebo-controlled trial of losartan for pediatric NAFLD. Hepatology 2022;76:429-44. [PMID: 35133671 DOI: 10.1002/hep.32403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
437 Kim HJ, Park SJ, Park HK, Byun DW, Suh K, Yoo MH. Association of thyroid autoimmunity with nonalcoholic fatty liver disease in euthyroid middle-aged subjects: A population-based study. J Gastroenterol Hepatol 2022;37:1617-23. [PMID: 35434848 DOI: 10.1111/jgh.15865] [Reference Citation Analysis]
438 Yu XD, Wang JW. Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives. Biochem Pharmacol 2022;202:115157. [PMID: 35777449 DOI: 10.1016/j.bcp.2022.115157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
439 Ni T, Han T, Li Y, Zhang C, Qin N, Wang Y, Duan H, Chen Y, Duan X. The isoxazole based flavonoid derivative 1 ameliorates non-alcoholic fatty liver disease in high-fat diet-induced obese mice by regulating lipid metabolism and inflammatory responses. Phytochemistry Letters 2022;50:112-7. [DOI: 10.1016/j.phytol.2022.06.005] [Reference Citation Analysis]
440 Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2022;42:1955-68. [PMID: 34459096 DOI: 10.1111/liv.15046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
441 Marie S, Frost KL, Hau RK, Martinez-guerrero L, Izu JM, Myers CM, Wright SH, Cherrington NJ. Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.08.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
442 Petrelli F, Manara M, Colombo S, De Santi G, Ghidini M, Mariani M, Iaculli A, Rausa E, Rampulla V, Arru M, Viti M, Lonati V, Ghidini A, Luciani A, Facciorusso A. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Neoplasia 2022;30:100809. [DOI: 10.1016/j.neo.2022.100809] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
443 Patel M. Evidence-based management of patients with nonalcoholic fatty liver disease. JAAPA 2022;35:20-24. [DOI: 10.1097/01.jaa.0000840492.53680.59] [Reference Citation Analysis]
444 Wang X, Li W, Fu J, Ni Y, Liu K, Liu F. Correlation between T-Lymphocyte Subsets, Regulatory T Cells, and Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-8. [DOI: 10.1155/2022/6250751] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
445 Sheng S, Yan S, Chen J, Zhang Y, Wang Y, Qin Q, Li W, Li T, Huang M, Ding S, Tang L. Gut microbiome is associated with metabolic syndrome accompanied by elevated gamma-glutamyl transpeptidase in men. Front Cell Infect Microbiol 2022;12:946757. [DOI: 10.3389/fcimb.2022.946757] [Reference Citation Analysis]
446 John K, Franck M, Al Aoua S, Rau M, Huber Y, Schattenberg JM, Geier A, Bahr MJ, Wedemeyer H, Schulze-osthoff K, Bantel H. Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4. JCM 2022;11:4394. [DOI: 10.3390/jcm11154394] [Reference Citation Analysis]
447 Ma J, Wei Z, Wang Q, Lu X, Zhou Z, Li R, Shu Q, Liu Y, Wang J, Liu N, Shi H. Association of serum creatinine with hepatic steatosis and fibrosis: a cross-sectional study. BMC Gastroenterol 2022;22:358. [PMID: 35896972 DOI: 10.1186/s12876-022-02437-0] [Reference Citation Analysis]
448 Curci R, Bianco A, Franco I, Campanella A, Mirizzi A, Bonfiglio C, Sorino P, Fucilli F, Di Giovanni G, Giampaolo N, Pesole PL, Osella AR. The Effect of Low Glycemic Index Mediterranean Diet and Combined Exercise Program on Metabolic-Associated Fatty Liver Disease: A Joint Modeling Approach. J Clin Med 2022;11:4339. [PMID: 35893431 DOI: 10.3390/jcm11154339] [Reference Citation Analysis]
449 Ma Y, Chen G, Yi J, Li Q, Tan Z, Fan W, Luo X, He Z, Si Z, Li J. IRX3 plays an important role in the pathogenesis of metabolic-associated fatty liver disease by regulating hepatic lipid metabolism. Front Endocrinol 2022;13:895593. [DOI: 10.3389/fendo.2022.895593] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
450 Jia S, Jin L, Cheng X, Wu J, Yao X, Shao J, Zhang C, Cen D, Cheng B, Wang J, Chen L, Yao X. Bicyclol alleviates high-fat diet-induced hepatic ER stress- and autophagy-associated non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis in mice. Drug Development and Industrial Pharmacy. [DOI: 10.1080/03639045.2022.2106238] [Reference Citation Analysis]
451 Tan L, Shin S. Effects of oily fish and its fatty acid intake on non-alcoholic fatty liver disease development among South Korean adults. Front Nutr 2022;9:876909. [DOI: 10.3389/fnut.2022.876909] [Reference Citation Analysis]
452 Razouki ZA, Zhang X, Hwang JP, Heredia NI. Clinical Factors Associated with Non-Obese Nonalcoholic Fatty Liver Disease Detected among US Adults in the NHANES 2017–2018. JCM 2022;11:4260. [DOI: 10.3390/jcm11154260] [Reference Citation Analysis]
453 Zhou L, Shen H, Li X, Wang H. Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease. Front Immunol 2022;13:951406. [DOI: 10.3389/fimmu.2022.951406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
454 Mandraffino G, Morace C, Franzè MS, Nassisi V, Sinicropi D, Cinquegrani M, Saitta C, Scoglio R, Marino S, Belvedere A, Cairo V, Lo Gullo A, Scuruchi M, Raimondo G, Squadrito G. Fatty Liver as Potential Biomarker of Atherosclerotic Damage in Familial Combined Hyperlipidemia. Biomedicines 2022;10:1770. [DOI: 10.3390/biomedicines10081770] [Reference Citation Analysis]
455 Maldonado SS, Grab J, Wang CW, Huddleston H, Cedars M, Sarkar M. Polycystic ovary syndrome is associated with nonalcoholic steatohepatitis in women of reproductive age. Hepatol Commun 2022. [PMID: 35861548 DOI: 10.1002/hep4.2039] [Reference Citation Analysis]
456 Ristic-Medic D, Bajerska J, Vucic V. Crosstalk between dietary patterns, obesity and nonalcoholic fatty liver disease. World J Gastroenterol 2022; 28(27): 3314-3333 [DOI: 10.3748/wjg.v28.i27.3314] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
457 Li Y, Nie JJ, Yang Y, Li J, Li J, Wu X, Liu X, Chen DF, Yang Z, Xu FJ, Yang Y. Redox-Unlockable Nanoparticle-Based MST1 Delivery System to Attenuate Hepatic Steatosis via the AMPK/SREBP-1c Signaling Axis. ACS Appl Mater Interfaces 2022. [PMID: 35858286 DOI: 10.1021/acsami.2c05889] [Reference Citation Analysis]
458 Liang C, Yu Z, Bai L, Hou W, Tang S, Zhang W, Chen X, Hu Z, Duan Z, Zheng S. Association of Serum Bilirubin With Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Endocrinol 2022;13:869579. [DOI: 10.3389/fendo.2022.869579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
459 Rieger TR, Allen RJ, Musante CJ. A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease. Front Pharmacol 2022;13:910789. [DOI: 10.3389/fphar.2022.910789] [Reference Citation Analysis]
460 Yagi C, Kusunoki Y, Tsunoda T, Murase T, Nakamura T, Osugi K, Ohigashi M, Morimoto A, Miyoshi A, Kakutani-Hatayama M, Kosaka-Hamamoto K, Kadoya M, Konishi K, Shoji T, Koyama H. Xanthine oxidoreductase activity is correlated with hepatic steatosis. Sci Rep 2022;12:12282. [PMID: 35854080 DOI: 10.1038/s41598-022-16688-0] [Reference Citation Analysis]
461 Filozof CM, Lackner C, Romero-gómez M, Imperial JC, Mcgee R, Dimick-santos L, Cummings O, Behling C, Johnson T, Sanyal A. Best Practices in Liver Biopsy Histologic Assessment for Nonalcoholic Steatohepatitis Clinical Trials: Expert Opinion. GastroHep 2022;2022:1-11. [DOI: 10.1155/2022/3538103] [Reference Citation Analysis]
462 Makri ES, Makri E, Polyzos SA. Combination Therapies for Nonalcoholic Fatty Liver Disease. JPM 2022;12:1166. [DOI: 10.3390/jpm12071166] [Reference Citation Analysis]
463 Cigrovski Berkovic M, Rezic T, Bilic-Curcic I, Mrzljak A. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum? World J Clin Cases 2022; 10(20): 6759-6768 [DOI: 10.12998/wjcc.v10.i20.6759] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
464 Orekondy N, Lee D, Malik R. Should patients with nonalcoholic steatohepatitis fibrosis undergo bariatric surgery as primary treatment? Clinical Liver Disease. [DOI: 10.1002/cld.1224] [Reference Citation Analysis]
465 Lonardo A, Mantovani A, Petta S, Carraro A, Byrne CD, Targher G. Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. Nat Rev Endocrinol 2022. [PMID: 35840803 DOI: 10.1038/s41574-022-00711-5] [Reference Citation Analysis]
466 Maev IV, Andreev DN, Kucheryavyy YA. Metabolically associated fatty liver disease – a disease of the 21st century: A review. Consilium Medicum 2022;24:325-332. [DOI: 10.26442/20751753.2022.5.201532] [Reference Citation Analysis]
467 Castera L, Boursier J. Noninvasive Algorithms for the Case Finding of "At-Risk" Patients with NAFLD. Semin Liver Dis 2022. [PMID: 35835440 DOI: 10.1055/s-0042-1751081] [Reference Citation Analysis]
468 Li D, Janmey PA, Wells RG. Local fat content determines global and local stiffness in fatty livers.. [DOI: 10.1101/2022.07.14.500092] [Reference Citation Analysis]
469 Yan H, Huang C, Shen X, Li J, Zhou S, Li W. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis. Front Endocrinol 2022;13:923606. [DOI: 10.3389/fendo.2022.923606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
470 Canivet CM, Costentin C, Irvine KM, Delamarre A, Lannes A, Sturm N, Oberti F, Patel PJ, Decaens T, Irles-Depé M, Fouchard I, Hermabessière P, Roux M, Barthelon J, Calès P, Powell EE, de Ledinghen V, Boursier J. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD. Hepatology 2022. [PMID: 35822302 DOI: 10.1002/hep.32665] [Reference Citation Analysis]
471 Udoh US, Rajan PK, Nakafuku Y, Finley R, Sanabria JR. Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma. IJMS 2022;23:7734. [DOI: 10.3390/ijms23147734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
472 Nguyen HD, Kim MS. Cadmium, lead, and mercury mixtures interact with non-alcoholic fatty liver diseases. Environ Pollut 2022;309:119780. [PMID: 35841990 DOI: 10.1016/j.envpol.2022.119780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
473 Mantovani A, Zusi C, Csermely A, Salvagno GL, Colecchia A, Lippi G, Maffeis C, Targher G. Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study. Hormones (Athens) 2022. [PMID: 35831700 DOI: 10.1007/s42000-022-00387-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
474 Dai Y, Zhao Z, Liu C. Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. Front Pharmacol 2022;13:942841. [DOI: 10.3389/fphar.2022.942841] [Reference Citation Analysis]
475 Samimi S, Rajabzadeh S, Rabizadeh S, Nakhjavani M, Nakhaei P, Avanaki FA, Esteghamati A. Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes. Eur J Med Res 2022;27:112. [PMID: 35818084 DOI: 10.1186/s40001-022-00731-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
476 Yu Q, Liu Y, Hu P, Gao F, Huang G. Performance of Imaging Techniques in Non-invasive Diagnosis of Non-alcoholic Fatty Liver Disease in Children: A Systematic Review and Meta-Analysis. Front Pediatr 2022;10:837116. [DOI: 10.3389/fped.2022.837116] [Reference Citation Analysis]
477 Wang S, Liu Z, Geng J, Li L, Feng X. An overview of ferroptosis in non-alcoholic fatty liver disease. Biomed Pharmacother 2022;153:113374. [PMID: 35834990 DOI: 10.1016/j.biopha.2022.113374] [Reference Citation Analysis]
478 Rinella M, Cryer DR, Articolo A, Fisher T, Schneider J, Nadolsky K. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02410-x] [Reference Citation Analysis]
479 Yan M, Man S, Ma L, Gao W. Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives. Metabolism 2022;134:155264. [PMID: 35810782 DOI: 10.1016/j.metabol.2022.155264] [Reference Citation Analysis]
480 Ishikawa H, Hayakawa M, Baatartsogt N, Kakizawa N, Ohto-Ozaki H, Maruyama T, Miura K, Suzuki K, Rikiyama T, Ohmori T. IκBζ regulates the development of nonalcoholic fatty liver disease through the attenuation of hepatic steatosis in mice. Sci Rep 2022;12:11634. [PMID: 35804007 DOI: 10.1038/s41598-022-15840-0] [Reference Citation Analysis]
481 Rodriguez-Diaz C, Taminiau B, García-García A, Cueto A, Robles-Díaz M, Ortega-Alonso A, Martín-Reyes F, Daube G, Sanabria-Cabrera J, Jimenez-Perez M, Isabel Lucena M, Andrade RJ, García-Fuentes E, García-Cortes M. Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. Pharmacol Res 2022;182:106348. [PMID: 35817360 DOI: 10.1016/j.phrs.2022.106348] [Reference Citation Analysis]
482 Wang R, Xue F, Wang L, Shi G, Qian G, Yang N, Chen X. Serum uric acid to creatinine ratio is associated with higher prevalence of NAFLD detected by FibroScan in the United States. J Clin Lab Anal 2022;:e24590. [PMID: 35808891 DOI: 10.1002/jcla.24590] [Reference Citation Analysis]
483 Shim S, Krishnaiah M, Sankham MR, Kim I, Lee Y, Shin I, Oh AR, Lee HJ, Vu TNL, Park J, Choi S, Park S, Kwon Y, Fang S, Kim DK. Discovery of (E)-3-(3-((2-Cyano-4'-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem 2022. [PMID: 35797110 DOI: 10.1021/acs.jmedchem.2c00641] [Reference Citation Analysis]
484 Shao G, Liu Y, Lu L, Zhang G, Zhou W, Wu T, Wang L, Xu H, Ji G. The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products. Front Pharmacol 2022;13:944088. [DOI: 10.3389/fphar.2022.944088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med 2022. [PMID: 35796150 DOI: 10.1111/joim.13531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
486 Leng J, Tian H, Fang Y, Hu Y, Peng J. Amelioration of Non-Alcoholic Steatohepatitis by Atractylodes macrocephala Polysaccharide, Chlorogenic Acid, and Geniposide Combination Is Associated With Reducing Endotoxin Gut Leakage. Front Cell Infect Microbiol 2022;12:827516. [DOI: 10.3389/fcimb.2022.827516] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
487 Waikar DY. Diagnosing Pediatric NAFLD. Annals of Pediatric Gastroenterology & Hepatology 2022;1:13-20. [DOI: 10.5005/jp-journals-11009-0022] [Reference Citation Analysis]
488 Yarra P, Dunn W, Younossi Z, Kuo YF, Singal AK. Association of Previous Gastric Bypass Surgery and Patient Outcomes in Alcohol-Associated Cirrhosis Hospitalizations. Dig Dis Sci 2022. [PMID: 35788931 DOI: 10.1007/s10620-022-07591-9] [Reference Citation Analysis]
489 Xue L, Deng Z, Luo W, He X, Chen Y. Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Front Cell Infect Microbiol 2022;12:759306. [DOI: 10.3389/fcimb.2022.759306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
490 Şendur HN, Cerit MN, Ibrahimkhanli N, Şendur AB, Özhan Oktar S. Interobserver Variability in Ultrasound-Based Liver Fat Quantification. J Ultrasound Med 2022. [PMID: 35778902 DOI: 10.1002/jum.16048] [Reference Citation Analysis]
491 Zhu Y, Ke Y, Hu Y, Wu K, Liu S, Hu J. Association of circulating vaspin levels and patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis. Lipids Health Dis 2022;21:57. [PMID: 35780150 DOI: 10.1186/s12944-022-01658-2] [Reference Citation Analysis]
492 Seike T, Boontem P, Yanagi M, Li S, Kido H, Yamamiya D, Nakagawa H, Okada H, Yamashita T, Harada K, Kikuchi M, Shiraishi Y, Ozaki N, Kaneko S, Yamashima T, Mizukoshi E. Hydroxynonenal Causes Hepatocyte Death by Disrupting Lysosomal Integrity in Nonalcoholic Steatohepatitis. Cell Mol Gastroenterol Hepatol 2022;14:925-44. [PMID: 35787976 DOI: 10.1016/j.jcmgh.2022.06.008] [Reference Citation Analysis]
493 Iwashita H, Shakado S, Yoshimaru N, Tanaka H, Koto F, Tanaka T, Takata K, Yokoyama K, Yamaguchi M, Irie M, Hirai F. Clinical Utility of Ultrasound-Guided Attenuation Parameter for the Detection and Quantification of Hepatic Steatosis in Patients with Fatty Liver Diagnosed by Computed Tomography. Ultrasound Med Biol 2022;48:1282-9. [PMID: 35397929 DOI: 10.1016/j.ultrasmedbio.2022.02.023] [Reference Citation Analysis]
494 Pariente A, Rosa I, Dharancy S, Hanslik B; Investigators of PERSEPT Study. Nonalcoholic fatty liver disease: opinions, population served, and management from a sample of French hepato(gastroentero)logists (PERSEPT study). Eur J Gastroenterol Hepatol 2022;34:791-800. [PMID: 35352691 DOI: 10.1097/MEG.0000000000002369] [Reference Citation Analysis]
495 Arai T, Atsukawa M, Tsubota A, Ono H, Kawano T, Yoshida Y, Okubo T, Hayama K, Nakagawa‐iwashita A, Itokawa N, Kondo C, Nagao M, Iwakiri K. Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. JGH Open 2022;6:503-511. [DOI: 10.1002/jgh3.12780] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
496 Vornoli A, Vizzarri F, Della Croce CM, Grande T, Palazzo M, Árvay J, Pucci L, Gabriele M, Matteucci M, Paolini M, Longo V, Pozzo L. The hypolipidemic, anti-inflammatory and antioxidant effect of Kavolì® aqueous extract, a mixture of Brassica oleracea leaves, in a rat model of NAFLD. Food Chem Toxicol 2022;:113261. [PMID: 35787436 DOI: 10.1016/j.fct.2022.113261] [Reference Citation Analysis]
497 Bierle DM, Wight EC, Ganesh R, Himes CP, Sundsted KK, Jacob AK, Mohabbat AB. Preoperative Evaluation and Management of Patients With Select Chronic Gastrointestinal, Liver, and Renal Diseases. Mayo Clin Proc 2022;97:1380-95. [PMID: 35787866 DOI: 10.1016/j.mayocp.2022.03.023] [Reference Citation Analysis]
498 Truong E, Noureddin M. Improvement in nonalcoholic fatty liver disease through bariatric surgery. Clin Liver Dis (Hoboken) 2022;20:13-7. [PMID: 35899237 DOI: 10.1002/cld.1229] [Reference Citation Analysis]
499 Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen A. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00165-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
500 Naglah A, Khalifa F, El-baz A, Gondim D. Conditional GANs based system for fibrosis detection and quantification in Hematoxylin and Eosin whole slide images. Medical Image Analysis 2022. [DOI: 10.1016/j.media.2022.102537] [Reference Citation Analysis]
501 Abdallah M, Brown L, Provenza J, Tariq R, Gowda S, Singal AK. Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials. Ann Hepatol 2022;27:100738. [PMID: 35781090 DOI: 10.1016/j.aohep.2022.100738] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
502 Wang S, Sun W, Zhou X. Bone metabolism discrepancy in type 2 diabetes mellitus patients with and without non-alcoholic fatty liver disease. Journal of Clinical Densitometry 2022. [DOI: 10.1016/j.jocd.2022.07.003] [Reference Citation Analysis]
503 Succurro E, Adelaide Marini M, Vanessa Fiorentino T, Perticone M, Sciacqua A, Andreozzi F, Sesti G. Sex‑specific differences in prevalence of nonalcoholic fatty liver disease in subjects with prediabetes and type 2 diabetes. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.110027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
504 Xie P, Peng Y, Qiu L. Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1. Carbohydrate Polymers 2022;288:119388. [DOI: 10.1016/j.carbpol.2022.119388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
505 Lee HA, Chang Y, Sung PS, Yoon EL, Lee HW, Yoo JJ, Lee YS, An J, Song DS, Cho YY, Kim SU, Kim YJ. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. Clin Mol Hepatol 2022;28:425-72. [PMID: 35850495 DOI: 10.3350/cmh.2022.0186] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
506 Stine JG, Schreibman IR, Faust AJ, Dahmus J, Stern B, Soriano C, Rivas G, Hummer B, Kimball SR, Geyer NR, Chinchilli VM, Loomba R, Schmitz K, Sciamanna C. NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH. Hepatology 2022;76:172-85. [PMID: 34890063 DOI: 10.1002/hep.32274] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
507 Kappus MR, Patel YA, Duarte-Rojo A. Improving the fitness of the NASH clinical trial: Standardizing the standard-of-care intervention. Hepatology 2022;76:12-4. [PMID: 35092072 DOI: 10.1002/hep.32369] [Reference Citation Analysis]
508 Khaoula B, Imene B, Wahiba G, Abdelkader G, Slimane L. Artificial Neural Networks Analysis of the Risk Factors for Aneurysm in the Population of the Setif Region in Algeria. WSEAS TRANSACTIONS ON BIOLOGY AND BIOMEDICINE 2022;19:163-167. [DOI: 10.37394/23208.2022.19.18] [Reference Citation Analysis]
509 Valenzuela-Vallejo L, Mantzoros CS. Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD). Metabolism 2022;:155246. [PMID: 35780909 DOI: 10.1016/j.metabol.2022.155246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
510 Ramanathan R, Ali AH, Ibdah JA. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease. IJMS 2022;23:7280. [DOI: 10.3390/ijms23137280] [Reference Citation Analysis]
511 Xu R, Pan J, Zhou W, Ji G, Dang Y. Recent advances in lean NAFLD. Biomed Pharmacother 2022;153:113331. [PMID: 35779422 DOI: 10.1016/j.biopha.2022.113331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
512 Martínez-urbistondo D, San Cristóbal R, Villares P, Martínez-gonzález MÁ, Babio N, Corella D, del Val JL, Ordovás JM, Alonso-gómez ÁM, Wärnberg J, Vioque J, Romaguera D, López-miranda J, Estruch R, Tinahones FJ, Lapetra J, Serra-majem JL, Bueno-cavanillas A, Tur JA, Marcos A, Pintó X, Delgado-rodríguez M, Matía-martín P, Vidal J, Vázquez C, Ros E, Bullón Vela MV, Palau A, Masagué M, Abete I, Moreno-rodríguez A, Candela-garcía I, Konieczna J, García-ríos A, Juárez OL, Martín P, Goday A, Zulet MÁ, Vaquero-luna J, Orea MDCS, Megías I, Baltasar E, Martínez JA, Daimiel L. Role of NAFLD on the Health Related QoL Response to Lifestyle in Patients With Metabolic Syndrome: The PREDIMED Plus Cohort. Front Endocrinol 2022;13:868795. [DOI: 10.3389/fendo.2022.868795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
513 Civelek M, Podszun MC. Genetic Factors Associated with Response to Vitamin E Treatment in NAFLD. Antioxidants 2022;11:1284. [DOI: 10.3390/antiox11071284] [Reference Citation Analysis]
514 Carteri RB, Grellert M, Borba DL, Marroni CA, Fernandes SA. Machine learning approaches using blood biomarkers in non-alcoholic fatty liver diseases. Artif Intell Gastroenterol 2022; 3(3): 80-87 [DOI: 10.35712/aig.v3.i3.80] [Reference Citation Analysis]
515 Monserrat-mesquida M, Quetglas-llabrés M, Bouzas C, Montemayor S, Mascaró CM, Casares M, Llompart I, Gámez JM, Tejada S, Martínez JA, Tur JA, Sureda A. A Greater Improvement of Intrahepatic Fat Contents after 6 Months of Lifestyle Intervention Is Related to a Better Oxidative Stress and Inflammatory Status in Non-Alcoholic Fatty Liver Disease. Antioxidants 2022;11:1266. [DOI: 10.3390/antiox11071266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
516 Tang X, Shi Y, Du J, Hu K, Zhou T, Chen L, Zhang Y, Li F, Zhang H, Liebe R, Meyer C, Dooley S, Zhu Z, Weng HL, Jia J, Huang T. Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study. BMJ Open 2022;12:e054891. [PMID: 35760549 DOI: 10.1136/bmjopen-2021-054891] [Reference Citation Analysis]
517 Jagannathan R, Fiorentino TV, Marini MA, Sesti G, Bergman M. One-hour post-load glucose is associated with severity of hepatic fibrosis Risk. Diabetes Res Clin Pract 2022;189:109977. [PMID: 35772586 DOI: 10.1016/j.diabres.2022.109977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
518 Palma R, Pronio A, Romeo M, Scognamiglio F, Ventriglia L, Ormando VM, Lamazza A, Pontone S, Federico A, Dallio M. The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. JCM 2022;11:3649. [DOI: 10.3390/jcm11133649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
519 Zhang M, Tang L, Cui X, Yu T, Li Z, Li X, Li G. Shear wave elastography in evaluation of carotid elasticity in the type 2 diabetes mellitus patients with nonalcoholic fatty liver disease. Int J Diabetes Dev Ctries. [DOI: 10.1007/s13410-022-01097-w] [Reference Citation Analysis]
520 Duan H, Zhang R, Chen X, Yu G, Song C, Jiang Y, He Y, Wan H, Shen J. Associations of Uric Acid With Liver Steatosis and Fibrosis Applying Vibration Controlled Transient Elastography in the United States: A Nationwide Cross-Section Study. Front Endocrinol 2022;13:930224. [DOI: 10.3389/fendo.2022.930224] [Reference Citation Analysis]
521 Vlasova KY, Ostroverkhov P, Vedenyapina D, Yakimova T, Trusova A, Lomakina GY, Vodopyanov SS, Grin M, Klyachko N, Chekhonin V, Abakumov M. Liposomal Form of 2,4-Dinitrophenol Lipophilic Derivatives as a Promising Therapeutic Agent for ATP Synthesis Inhibition. Nanomaterials 2022;12:2162. [DOI: 10.3390/nano12132162] [Reference Citation Analysis]
522 Chen Y, Lin C, Yen H, Su P, Zeng Y, Huang S, Liu I. Machine-Learning Algorithm for Predicting Fatty Liver Disease in a Taiwanese Population. JPM 2022;12:1026. [DOI: 10.3390/jpm12071026] [Reference Citation Analysis]
523 Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, Panda G, Qian T, Zhu S, Goossens N, Wang X, Liang S, Zhong Z, Lewis S, Taouli B, Schwartz ME, Fiel MI, Singal AG, Marrero JA, Fobar AJ, Parikh ND, Raman I, Li QZ, Taguri M, Ono A, Aikata H, Nakahara T, Nakagawa H, Matsushita Y, Tateishi R, Koike K, Kobayashi M, Higashi T, Nakagawa S, Yamashita YI, Beppu T, Baba H, Kumada H, Chayama K, Baumert TF, Hoshida Y. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Sci Transl Med 2022;14:eabo4474. [PMID: 35731891 DOI: 10.1126/scitranslmed.abo4474] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
524 Hu S, Li X, Sun Y, Wu S, Lan Y, Chen S, Wang Y, Liao W, Wang X, Zhang D, Yuan X, Gao J, Wang L. Short-term weight loss decreased the risk of chronic kidney disease in men with incident nonalcoholic fatty liver disease. Obesity (Silver Spring) 2022. [PMID: 35730626 DOI: 10.1002/oby.23459] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
525 Liu J, Wang C, Xiao Y. The influence and therapeutic effect of dietary pattern on liver diseases in the United State. HSET 2022;2:54-62. [DOI: 10.54097/hset.v2i.555] [Reference Citation Analysis]
526 Attia H, Albekairi N, Albdeirat L, Soliman A, Rajab R, Alotaibi H, Ali R, Badr A. Chrysin Attenuates Fructose-Induced Nonalcoholic Fatty Liver in Rats via Antioxidant and Anti-Inflammatory Effects: The Role of Angiotensin-Converting Enzyme 2/Angiotensin (1-7)/Mas Receptor Axis. Oxid Med Cell Longev 2022;2022:9479456. [PMID: 35720181 DOI: 10.1155/2022/9479456] [Reference Citation Analysis]
527 Yu MM, Tang XL, Zhao X, Chen YY, Xu ZH, Wang QB, Zeng MS. Plaque progression at coronary CT angiography links non-alcoholic fatty liver disease and cardiovascular events: a prospective single-center study. Eur Radiol 2022. [PMID: 35727319 DOI: 10.1007/s00330-022-08904-2] [Reference Citation Analysis]
528 Wang Q, Zhou D, Wang M, Zhu M, Chen P, Li H, Lu M, Zhang X, Shen X, Liu T, Chen L. A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population. Front Med 2022;9:900794. [DOI: 10.3389/fmed.2022.900794] [Reference Citation Analysis]
529 Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, Chen CY, Zuckerman E, Ravussin E, Charatcharoenwitthaya P, Cheng PN, Katchman H, Klein S, Ben-Ari Z, Mendonza AE, Zhang Y, Martic M, Ma S, Kao S, Tanner S, Pachori A, Badman MK, He Y, Ukomadu C, Sicard E. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med 2022. [PMID: 35725922 DOI: 10.1038/s41591-022-01861-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
530 Karlas T, Petroff D, Feisthammel J, Beer S, Blüher M, Schütz T, Lichtinghagen R, Hoffmeister A, Wiegand J. Endoscopic Bariatric Treatment with Duodenal-Jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis. Obes Surg 2022. [PMID: 35713854 DOI: 10.1007/s11695-022-06150-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
531 Ferri S, Stefanini B, Mulazzani L, Alvisi M, Tovoli F, Leoni S, Muratori L, Lotti T, Granito A, Bolondi L, Piscaglia F. Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2022;14:2493. [PMID: 35745223 DOI: 10.3390/nu14122493] [Reference Citation Analysis]
532 Cusi K. A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now. J Clin Endocrinol Metab 2022;107:e3076-7. [PMID: 35333917 DOI: 10.1210/clinem/dgac186] [Reference Citation Analysis]
533 Lan T, Xu T, Fu Y, Jiang S, Liang X, Yu Z, Pan L, Rong X, Guo J. Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis. Front Endocrinol 2022;13:864703. [DOI: 10.3389/fendo.2022.864703] [Reference Citation Analysis]
534 Deng YF, Xu QQ, Chen TQ, Ming JX, Wang YF, Mao LN, Zhou JJ, Sun WG, Zhou Q, Ren H, Zhang YH. Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-κB/NLRP3 signaling pathway. Phytomedicine 2022;104:154241. [PMID: 35749827 DOI: 10.1016/j.phymed.2022.154241] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
535 Androutsakos T, Voulgaris TA, Bakasis A, Koutsompina M, Chatzis L, Argyropoulou OD, Pezoulas V, Fotiadis DI, Papatheodoridis G, Tzioufas AG, Goules AV. Liver Fibrosis in Primary Sjögren’s Syndrome. Front Immunol 2022;13:889021. [DOI: 10.3389/fimmu.2022.889021] [Reference Citation Analysis]
536 Wang X, Mao L, Li C, Hui Y, Yu Z, Sun M, Li Y, Guo G, Yang W, Cui B, Fan X, Sun C. The potential role of FNDC5/irisin in various liver diseases: awakening the sleeping beauties. Expert Rev Mol Med 2022;24:e23. [PMID: 35695040 DOI: 10.1017/erm.2022.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
537 Nassir F. NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules 2022;12:824. [PMID: 35740949 DOI: 10.3390/biom12060824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
538 Nguyen HD, Kim MS. Effects of chemical mixtures on liver function biomarkers in the Korean adult population: thresholds and molecular mechanisms for non-alcoholic fatty liver disease involved. Environ Sci Pollut Res Int 2022. [PMID: 35696061 DOI: 10.1007/s11356-022-21090-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
539 Theel W, Boxma-de Klerk BM, Dirksmeier-Harinck F, van Rossum EFC, Kanhai DA, Apers J, van Dalen BM, de Knegt RJ, Holleboom AG, Tushuizen ME, Grobbee DE, Wiebolt J, Castro Cabezas M. Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. Obes Rev 2022. [PMID: 35692179 DOI: 10.1111/obr.13481] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
540 Hamid O, Eltelbany A, Mohammed A, Alsabbagh Alchirazi K, Trakroo S, Asaad I. The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study. Ann Hepatol 2022;27:100727. [PMID: 35700934 DOI: 10.1016/j.aohep.2022.100727] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
541 Crocker RM, Morrill KE, Villavicencio EA, Garcia DO. How Mexicans' Emotional Responses to Non-Alcoholic Fatty Liver Disease Can Help Inform Culturally Congruent Health Care. J Transcult Nurs 2022;:10436596221101923. [PMID: 35684997 DOI: 10.1177/10436596221101923] [Reference Citation Analysis]
542 Mascaró CM, Bouzas C, Montemayor S, García S, Mateos D, Casares M, Gómez C, Ugarriza L, Borràs PA, Martínez JA, Tur JA. Impact of Physical Activity Differences Due to COVID-19 Pandemic Lockdown on Non-Alcoholic Fatty Liver Parameters in Adults with Metabolic Syndrome. Nutrients 2022;14:2370. [PMID: 35745100 DOI: 10.3390/nu14122370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
543 Leung H, Long X, Ni Y, Qian L, Nychas E, Siliceo SL, Pohl D, Hanhineva K, Liu Y, Xu A, Nielsen HB, Belda E, Clément K, Loomba R, Li H, Jia W, Panagiotou G. Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci Transl Med 2022;14:eabk0855. [PMID: 35675435 DOI: 10.1126/scitranslmed.abk0855] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
544 Rojano-Toimil A, Rivera-Esteban J, Manzano-Nuñez R, Bañares J, Martinez Selva D, Gabriel-Medina P, Ferrer R, Pericàs JM, Ciudin A. When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. J Clin Med 2022;11:3286. [PMID: 35743358 DOI: 10.3390/jcm11123286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
545 Ichikawa K, Miyoshi T, Nakashima M, Nishihara T, Osawa K, Miki T, Toda H, Yoshida M, Ito H. Prognostic value of pericoronary adipose tissue attenuation in patients with non-alcoholic fatty liver disease with suspected coronary artery disease. Heart Vessels. [DOI: 10.1007/s00380-022-02107-x] [Reference Citation Analysis]
546 Ng C, Lee KL, Muthiah MD, Wu KX, Chioh FWJ, Tan K, Soon GST, Shabbir A, Loo WM, Low ZS, Chen Q, Tan NS, Ng HH, Dan YY, Cheung C. Endothelial‐immune crosstalk contributes to vasculopathy in nonalcoholic fatty liver disease. EMBO Reports 2022;23. [DOI: 10.15252/embr.202154271] [Reference Citation Analysis]
547 Ciardullo S, Oltolini A, Cannistraci R, Muraca E, Perseghin G. Sex-related association of nonalcoholic fatty liver disease and liver fibrosis with body fat distribution in the general US population. Am J Clin Nutr 2022;115:1528-34. [PMID: 35244676 DOI: 10.1093/ajcn/nqac059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
548 Kechagias S, Ekstedt M, Simonsson C, Nasr P. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones (Athens) 2022. [PMID: 35661987 DOI: 10.1007/s42000-022-00377-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
549 Pozzan R, Pena RG, Palma CCSSV, Abi-abib RDC, Terra C, Cobas RA. Risk factors associated with nonalcoholic fatty liver disease evaluated by elastography in patients with type 2 diabetes. Archives of Endocrinology and Metabolism 2022. [DOI: 10.20945/2359-3997000000492] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
550 Zhou X, Fu Y, Liu W, Mu Y, Zhang H, Chen J, Liu P. Ferroptosis in Chronic Liver Diseases: Opportunities and Challenges. Front Mol Biosci 2022;9:928321. [DOI: 10.3389/fmolb.2022.928321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
551 Hu M, You Z, Li Y, Huang B, Cui N, Wang R, Wei Y, Li B, Liang J, Liu Q, Li Y, Wang H, Qian Q, Zhang J, Chen R, Lyu Z, Chen Y, Xiao X, Lian M, Tang R, Miao Q, Wang Q, Ma X. Serum Biomarkers for Autoimmune Hepatitis Type 1: the Case for CD48 and a Review of the Literature. Clin Rev Allergy Immunol 2022. [PMID: 35657576 DOI: 10.1007/s12016-022-08935-z] [Reference Citation Analysis]
552 Yamaguchi T, Yoshida K, Murata M, Suwa K, Tsuneyama K, Matsuzaki K, Naganuma M. Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis. Int J Mol Sci 2022;23:6270. [PMID: 35682957 DOI: 10.3390/ijms23116270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
553 Teunis C, Nieuwdorp M, Hanssen N. Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases. Metabolites 2022;12:514. [DOI: 10.3390/metabo12060514] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
554 Sun Y, Chen G, Chen S, Wang Y, Hu Y, Zhao Y. Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial. Trials 2022;23:455. [PMID: 35655225 DOI: 10.1186/s13063-022-06393-8] [Reference Citation Analysis]
555 Matsubayashi Y, Fujihara K, Yamada-harada M, Mitsuma Y, Sato T, Yaguchi Y, Osawa T, Yamamoto M, Kitazawa M, Yamada T, Kodama S, Sone H. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. Cardiovasc Diabetol 2022;21. [DOI: 10.1186/s12933-022-01518-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
556 Ahmad MI, Khan MU, Kodali S, Shetty A, Bell SM, Victor D. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. JHC 2022;Volume 9:477-96. [DOI: 10.2147/jhc.s344559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
557 George ES, Reddy A, Nicoll AJ, Ryan MC, Itsiopoulos C, Abbott G, Johnson NA, Sood S, Roberts SK, Tierney AC. Impact of a Mediterranean diet on hepatic and metabolic outcomes in non-alcoholic fatty liver disease: The MEDINA randomised controlled trial. Liver Int 2022;42:1308-22. [PMID: 35357066 DOI: 10.1111/liv.15264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
558 Kim D, Konyn P, Cholankeril G, Ahmed A. Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan. Clin Gastroenterol Hepatol 2022;20:e1438-55. [PMID: 34214678 DOI: 10.1016/j.cgh.2021.06.029] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
559 Stefan N, Roden M. Diabetes und Fettleber. Diabetologie 2022;18:426-430. [DOI: 10.1007/s11428-022-00906-4] [Reference Citation Analysis]
560 Zhao H, Liu H, Yang Y, Wang H. The Role of Autophagy and Pyroptosis in Liver Disorders. Int J Mol Sci 2022;23:6208. [PMID: 35682887 DOI: 10.3390/ijms23116208] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
561 Mustafina HM, Starchenko II, Fylenko BМ, Koka VМ, Cherniak VV, Roiko NV, Proskurnya SA. MORPHOLOGICAL FEATURES OF THE LIVER PARENCHYMA IN THE EXPERIMENTAL SUPPLEMENTATION OF RATION WITH THE FOOD ADDITIVES. Wiad Lek 2022;75:1525-1528. [DOI: 10.36740/wlek202206117] [Reference Citation Analysis]
562 Younossi ZM, Ong JP, Takahashi H, Yilmaz Y, Eguc Hi Y, El Kassas M, Buti M, Diago M, Zheng MH, Fan JG, Yu ML, Wai-Sun Wong V, Alswat K, Chan WK, Mendez-Sanchez N, Burra P, Bugianesi E, Duseja AK, George J, Papatheodoridis GV, Saeed H, Castera L, Arrese M, Kugelmas M, Romero-Gomez M, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global Nonalcoholic Steatohepatitis Council. A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2022;20:e1456-68. [PMID: 34229038 DOI: 10.1016/j.cgh.2021.06.048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
563 Zhou J, Tripathi M, Ho JP, Widjaja AA, Shekeran SG, Camat MD, James A, Wu Y, Ching J, Kovalik JP, Lim KH, Cook SA, Bay BH, Singh BK, Yen PM. Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis. Thyroid 2022;32:725-38. [PMID: 35317606 DOI: 10.1089/thy.2021.0621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
564 Zhuge A, Li S, Lou P, Wu W, Wang K, Yuan Y, Xia J, Li B, Li L. Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice. Microbiol Spectr 2022;:e0004722. [PMID: 35647690 DOI: 10.1128/spectrum.00047-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
565 Vilar-Gomez E, Nephew LD, Vuppalanchi R, Gawrieh S, Mladenovic A, Pike F, Samala N, Chalasani N. High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. Hepatology 2022;75:1491-506. [PMID: 34668597 DOI: 10.1002/hep.32207] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 21.0] [Reference Citation Analysis]
566 Sonaglioni A, Cerini F, Nicolosi GL, Lombardo M, Rumi MG, Viganò M. Left ventricular strain predicts subclinical atherosclerosis in nonadvanced nonalcoholic fatty liver disease patients. Eur J Gastroenterol Hepatol 2022;34:707-16. [PMID: 35412487 DOI: 10.1097/MEG.0000000000002375] [Reference Citation Analysis]
567 Georgescu D, Ionita I, Lascu A, Hut E, Dragan S, Ancusa O, Ionita M, Calamar-popovici D, Georgescu L, Lighezan D. Gallstone Disease and Bacterial Metabolic Performance of Gut Microbiota in Middle-Aged and Older Patients. IJGM 2022;Volume 15:5513-31. [DOI: 10.2147/ijgm.s350104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
568 Wang Y, Chen C, Chen J, Sang T, Peng H, Lin X, Zhao Q, Chen S, Eling T, Wang X. Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation. Redox Biology 2022;52:102322. [DOI: 10.1016/j.redox.2022.102322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
569 Kahl S, Ofstad AP, Zinman B, Wanner C, Schüler E, Sattar N, Inzucchi SE, Roden M. Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes Obes Metab 2022;24:1061-71. [PMID: 35166009 DOI: 10.1111/dom.14670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
570 Younossi Z, Aggarwal P, Shrestha I, Fernandes J, Johansen P, Augusto M, Nair S. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
571 Rowe IA, Wong VW, Loomba R. Treatment Candidacy for Pharmacologic Therapies for NASH. Clin Gastroenterol Hepatol 2022;20:1209-17. [PMID: 33711479 DOI: 10.1016/j.cgh.2021.03.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
572 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
573 Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, Cohen DE, Horton JD, Pressman GS, Toth PP; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 2022;42:e168-85. [PMID: 35418240 DOI: 10.1161/ATV.0000000000000153] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 17.0] [Reference Citation Analysis]
574 Huh JH, Kim KJ, Kim SU, Cha BS, Lee BW. Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease. Hepatobiliary Pancreat Dis Int. 2022;21:241-247. [PMID: 35365418 DOI: 10.1016/j.hbpd.2022.03.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
575 Vujkovic M, Ramdas S, Lorenz KM, Guo X, Darlay R, Cordell HJ, He J, Gindin Y, Chung C, Myers RP, Schneider CV, Park J, Lee KM, Serper M, Carr RM, Kaplan DE, Haas ME, MacLean MT, Witschey WR, Zhu X, Tcheandjieu C, Kember RL, Kranzler HR, Verma A, Giri A, Klarin DM, Sun YV, Huang J, Huffman JE, Creasy KT, Hand NJ, Liu CT, Long MT, Yao J, Budoff M, Tan J, Li X, Lin HJ, Chen YI, Taylor KD, Chang RK, Krauss RM, Vilarinho S, Brancale J, Nielsen JB, Locke AE, Jones MB, Verweij N, Baras A, Reddy KR, Neuschwander-Tetri BA, Schwimmer JB, Sanyal AJ, Chalasani N, Ryan KA, Mitchell BD, Gill D, Wells AD, Manduchi E, Saiman Y, Mahmud N, Miller DR, Reaven PD, Phillips LS, Muralidhar S, DuVall SL, Lee JS, Assimes TL, Pyarajan S, Cho K, Edwards TL, Damrauer SM, Wilson PW, Gaziano JM, O'Donnell CJ, Khera AV, Grant SFA, Brown CD, Tsao PS, Saleheen D, Lotta LA, Bastarache L, Anstee QM, Daly AK, Meigs JB, Rotter JI, Lynch JA, Rader DJ, Voight BF, Chang KM; Regeneron Genetics Center, Geisinger-Regeneron DiscovEHR Collaboration, EPoS Consortium, VA Million Veteran Program. A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nat Genet 2022;54:761-71. [PMID: 35654975 DOI: 10.1038/s41588-022-01078-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
576 Mikolasevic I, Domislovic V, Ruzic A, Hauser G, Rahelic D, Klobucar-majanovic S, Krznaric Z, Dobrila-dintinjana R, Grgurevic I, Skenderevic N, Lukic A, Targher G. Elastographic parameters of liver steatosis and fibrosis predict independently the risk of incident chronic kidney disease and acute myocardial infarction in patients with type 2 diabetes mellitus. Journal of Diabetes and its Complications 2022. [DOI: 10.1016/j.jdiacomp.2022.108226] [Reference Citation Analysis]
577 Farahat TM, Ungan M, Vilaseca J, Ponzo J, Gupta PP, Schreiner AD, Al Sharief W, Casler K, Abdelkader T, Abenavoli L, Alami FM, Ekstedt M, Jabir MS, Armstrong MJ, Osman MH, Wiegand J, Attia D, Verhoeven V, Amir AAQ, Hegazy NN, Tsochatzis EA, Fouad Y, Cortez-Pinto H. The paradigm shift from NAFLD to MAFLD: A global primary care viewpoint. Liver Int 2022;42:1259-67. [PMID: 35129258 DOI: 10.1111/liv.15188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
578 Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. Clin Gastroenterol Hepatol 2022;20:1354-1361.e7. [PMID: 34329774 DOI: 10.1016/j.cgh.2021.07.039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
579 Bahirwani R, Griffin C. The diagnosis and management of nonalcoholic fatty liver disease: A patient-friendly summary of the 2018 AASLD guidelines. Clin Liver Dis (Hoboken) 2022;19:222-6. [PMID: 35795618 DOI: 10.1002/cld.1216] [Reference Citation Analysis]
580 Teck J. Diabetes-Associated Comorbidities. Primary Care: Clinics in Office Practice 2022;49:275-286. [DOI: 10.1016/j.pop.2021.11.004] [Reference Citation Analysis]
581 Kim KS, Hong S, Ahn HY, Park CY. Triglyceride and glucose index is a simple and easy-to-calculate marker associated with nonalcoholic fatty liver disease. Obesity (Silver Spring) 2022;30:1279-88. [PMID: 35674697 DOI: 10.1002/oby.23438] [Reference Citation Analysis]
582 Kim E, Hwang C, Lee J, Jang E, Kim Y, Lee J. A Case Report of Nonalcoholic Fatty Liver Disease with Obesity and Dyslipidemia. J Int Korean Med 2022;43:184-190. [DOI: 10.22246/jikm.2022.43.2.184] [Reference Citation Analysis]
583 Liu Y, Shuai P, Liu Y, Li D. Association between non-alcoholic fatty liver disease and bone turnover markers in southwest China. J Bone Miner Metab 2022. [PMID: 35639173 DOI: 10.1007/s00774-022-01340-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
584 Wang Y, Chen R, Li J, Zeng G, Yuan J, Su J, Wu C, Lu Z, Zhang F, Ding W. Vanadium(IV)-Chlorodipicolinate Protects against Hepatic Steatosis by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammation. Antioxidants 2022;11:1093. [DOI: 10.3390/antiox11061093] [Reference Citation Analysis]
585 Wen H, Deng H, Yang L, Li L, Lin J, Zheng P, Ji G; Cochrane Hepato-Biliary Group. Vitamin E for people with non-alcoholic fatty liver disease. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd015033] [Reference Citation Analysis]
586 Vélez Aguirre JD, Lepesqueur Guillén LH, Yepes Barreto IDJ. La esteatohepatitis no alcohólica: una causa emergente de cirrosis en Colombia. Rev colomb Gastroenterol 2022;37:136-144. [DOI: 10.22516/25007440.783] [Reference Citation Analysis]
587 Zhang Y, Li J, Liu H. Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function. BMC Endocr Disord 2022;22. [DOI: 10.1186/s12902-022-01050-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
588 Bessho R, Kashiwagi K, Ikura A, Yamataka K, Inaishi J, Takaishi H, Kanai T. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis. PLoS ONE 2022;17:e0269265. [DOI: 10.1371/journal.pone.0269265] [Reference Citation Analysis]
589 Hassen G, Singh A, Belete G, Jain N, De la Hoz I, Camacho-leon GP, Dargie NK, Carrera KG, Alemu T, Jhaveri S, Solomon N. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. Cureus. [DOI: 10.7759/cureus.25495] [Reference Citation Analysis]
590 Fu L, Zhang W, Ao Y, Zheng Z, Hu H. Efficacy of aerobic and resistance exercises in improving visceral adipose in patients with non-alcoholic fatty liver: a meta-analysis of randomized controlled trials. Z Gastroenterol. [DOI: 10.1055/a-1742-4257] [Reference Citation Analysis]
591 Ito T, Nguyen VH, Tanaka T, Park H, Yeh ML, Kawanaka M, Arai T, Atsukawa M, Yoon EL, Tsai PC, Toyoda H, Huang JF, Henry L, Jun DW, Yu ML, Ishigami M, Nguyen MH, Cheung RC. Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00525-0. [PMID: 35654298 DOI: 10.1016/j.cgh.2022.05.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
592 Aghemo A, Alekseeva OP, Angelico F, Bakulin IG, Bakulina NV, Bordin D, Bueverov AO, Drapkina OM, Gillessen A, Kagarmanova EM, Korochanskaya NV, Kucheryavii UA, Lazebnik LB, Livzan MA, Maev IV, Martynov AI, Osipenko MF, Sas EI, Starodubova A, Uspensky YP, Vinnitskaya EV, Yakovenko EP, Yakovlev AA. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. Annals of Medicine 2022;54:1548-60. [DOI: 10.1080/07853890.2022.2069854] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
593 Ndakotsu A, Vivekanandan G. The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review. Cureus 2022. [DOI: 10.7759/cureus.25380] [Reference Citation Analysis]
594 Zhang X, Mou Y, Aribas E, Amiri M, Nano J, Bramer WM, Kavousi M, de Knegt RJ, Asllanaj E, Ghanbari M. Associations of Sex Steroids and Sex Hormone-Binding Globulin with Non-Alcoholic Fatty Liver Disease: A Population-Based Study and Meta-Analysis. Genes 2022;13:966. [DOI: 10.3390/genes13060966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
595 Montemayor S, Bouzas C, Mascaró CM, Casares M, Llompart I, Abete I, Angullo-Martinez E, Zulet MÁ, Martínez JA, Tur JA. Effect of Dietary and Lifestyle Interventions on the Amelioration of NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study. Nutrients 2022;14:2223. [PMID: 35684022 DOI: 10.3390/nu14112223] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
596 Papic N, Samadan L, Vrsaljko N, Radmanic L, Jelicic K, Simicic P, Svoboda P, Lepej SZ, Vince A. Distinct Cytokine Profiles in Severe COVID-19 and Non-Alcoholic Fatty Liver Disease. Life 2022;12:795. [DOI: 10.3390/life12060795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
597 Naimimohasses S, O'Gorman P, Wright C, Ni Fhloinn D, Holden D, Conlon N, Monaghan A, Kennedy M, Gormley J, Beddy P, Finn SP, Lysaght J, O'Sullivan J, Dunne MR, Norris S, Moore JB. Differential Effects of Dietary versus Exercise Intervention on Intrahepatic MAIT Cells and Histological Features of NAFLD. Nutrients 2022;14:2198. [PMID: 35683998 DOI: 10.3390/nu14112198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
598 Liao C, Huang P, Chien H, Lin T, Yeh C, Lin K. Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease. Biomedicines 2022;10:1232. [DOI: 10.3390/biomedicines10061232] [Reference Citation Analysis]
599 Wang Q, Zhu M, Li H, Chen P, Wang M, Gu L, Zhang X, Chen L. Hyperferritinemia Correlates to Metabolic Dysregulation and Steatosis in Chinese Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients. Diabetes Metab Syndr Obes 2022;15:1543-52. [PMID: 35607608 DOI: 10.2147/DMSO.S361187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
600 Derosa G, Guasti L, D’angelo A, Martinotti C, Valentino MC, Di Matteo S, Bruno GM, Maresca AM, Gaudio GV, Maffioli P. Probiotic Therapy With VSL#3® in Patients With NAFLD: A Randomized Clinical Trial. Front Nutr 2022;9:846873. [DOI: 10.3389/fnut.2022.846873] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
601 Baldini F, Khalil M, Bartolozzi A, Vassalli M, Di Ciaula A, Portincasa P, Vergani L. Relationship between Liver Stiffness and Steatosis in Obesity Conditions: In Vivo and In Vitro Studies. Biomolecules 2022;12:733. [PMID: 35625660 DOI: 10.3390/biom12050733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
602 Kanchanasurakit S, Kositamongkol C, Lanoi K, Nunta M, Saetuan T, Chaiyakunapruk N, Saokaew S, Phisalprapa P. Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Front Nutr 2022;9:880014. [DOI: 10.3389/fnut.2022.880014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
603 Tsujita Y, Sofue K, Ueshima E, Ueno Y, Hori M, Murakami T. Clinical Application of Quantitative MR Imaging in Nonalcoholic Fatty Liver Disease. Magn Reson Med Sci 2022. [PMID: 35584952 DOI: 10.2463/mrms.rev.2021-0152] [Reference Citation Analysis]
604 Sun P, Huang L, Shuai P, Wan Z, Liu Y, Xue J, Liu Y. Effect of a High Protein, Low Glycemic Index Dietary Intervention on Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial. Front Nutr 2022;9:863834. [PMID: 35571881 DOI: 10.3389/fnut.2022.863834] [Reference Citation Analysis]
605 Cho IY, Chang Y, Kang JH, Kim Y, Sung E, Shin H, Wild SH, Byrne CD, Ryu S. Long or Irregular Menstrual Cycles and Risk of Prevalent and Incident Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab 2022;107:e2309-17. [PMID: 35238939 DOI: 10.1210/clinem/dgac068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
606 Akuta N, Kawamura Y, Fujiyama S, Saito S, Muraishi N, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kumada H. Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study. Hepatol Commun 2022. [PMID: 35581956 DOI: 10.1002/hep4.2005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
607 Sandoval-Rodriguez A, Torre A, Armendariz-Borunda J. Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2022;9:892495. [PMID: 35573018 DOI: 10.3389/fmed.2022.892495] [Reference Citation Analysis]
608 Yoneda M, Kobayashi T, Honda Y, Ogawa Y, Kessoku T, Imajo K, Nogami A, Taguri M, Kirikoshi H, Saito S, Nakajima A. Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. Hepatol Commun 2022. [PMID: 35578445 DOI: 10.1002/hep4.1993] [Reference Citation Analysis]
609 Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022;28:528-62. [PMID: 35569886 DOI: 10.1016/j.eprac.2022.03.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 25.0] [Reference Citation Analysis]
610 Meng Q, Li X, Xiong X. Identification of Hub Genes Associated With Non-alcoholic Steatohepatitis Using Integrated Bioinformatics Analysis. Front Genet 2022;13:872518. [PMID: 35559030 DOI: 10.3389/fgene.2022.872518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
611 Sugiyama A, Kurisu A, E B, Ouoba S, Ko K, Rakhimov A, Akita T, Harakawa T, Sako T, Koshiyama M, Kumada T, Tanaka J. Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups. BMC Gastroenterol 2022;22:241. [PMID: 35562658 DOI: 10.1186/s12876-022-02290-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
612 Zou Y, Li Q, Gao J, Pan J, Ma J, Chen L, Lin J, Mo Y, Zhang X, Liu P, Dai L. Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort. Front Cardiovasc Med 2022;9:884636. [DOI: 10.3389/fcvm.2022.884636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
613 Kim KE, Lee J, Shin HJ, Jeong EA, Jang HM, Ahn YJ, An HS, Lee JY, Shin MC, Kim SK, Yoo WG, Kim WH, Roh GS. Lipocalin-2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high-fat diet-fed Ob/Ob mice. Hepatology 2022. [PMID: 35560370 DOI: 10.1002/hep.32569] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
614 Shin HS, Hong MH, Moon JY, Sim SJ. Periodontal disease could be a potential risk factor for non-alcoholic fatty liver disease: An 11-year retrospective follow-up study. Clin Oral Investig 2022. [PMID: 35556175 DOI: 10.1007/s00784-022-04518-6] [Reference Citation Analysis]
615 Bikbov MM, Gilmanshin TR, Zainullin RM, Kazakbaeva GM, Iakupova EM, Fakhretdinova AA, Tuliakova AM, Panda-Jonas S, Gilemzianova LI, Khakimov DA, Miniazeva LA, Jonas JB. Prevalence of non-alcoholic fatty liver disease in the Russian Ural Eye and Medical Study and the Ural Very Old Study. Sci Rep 2022;12:7842. [PMID: 35551494 DOI: 10.1038/s41598-022-12004-y] [Reference Citation Analysis]
616 Ducatman A, LaPier J, Fuoco R, DeWitt JC. Official health communications are failing PFAS-contaminated communities. Environ Health 2022;21:51. [PMID: 35538533 DOI: 10.1186/s12940-022-00857-9] [Reference Citation Analysis]
617 Haam J, Lee YK, Suh E, Kim Y. Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults. Diagnostics 2022;12:1199. [DOI: 10.3390/diagnostics12051199] [Reference Citation Analysis]
618 Zhu B, Li H, Lu B, Guo X, Wu C, Wang F, Li Q, Xie L, Glaser S, Francis H, Alpini G, Wu C. Indole Supplementation Ameliorates MCD-induced NASH in mice. J Nutr Biochem 2022;:109041. [PMID: 35568098 DOI: 10.1016/j.jnutbio.2022.109041] [Reference Citation Analysis]
619 Arefhosseini S, Tutunchi H, Nomi-Golzar S, Mahboob S, Pouretedal Z, Ebrahimi-Mameghani M. The effect of hydroxy citric acid supplementation with calorie-restricted diet on metabolic, atherogenic and inflammatory biomarkers in women with non-alcoholic fatty liver disease: a randomized controlled clinical trial. Food Funct 2022;13:5124-34. [PMID: 35416190 DOI: 10.1039/d1fo03685h] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
620 Lee S, Lai H, Chua YJ, Wang MX, Lee G. Endoscopic Bariatric and Metabolic Therapies and Their Effects on Metabolic Syndrome and Non-alcoholic Fatty Liver Disease - A Systematic Review and Meta-Analysis. Front Med 2022;9:880749. [DOI: 10.3389/fmed.2022.880749] [Reference Citation Analysis]
621 Ahmed NR, Kulkarni VV, Pokhrel S, Akram H, Abdelgadir A, Chatterjee A, Khan S. Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review. Cureus. [DOI: 10.7759/cureus.24829] [Reference Citation Analysis]
622 Chen S, Cai X, Liu Y, Shen Y, Guillot A, Tacke F, Tang L, Liu H. The macrophage-associated microRNA-4715-3p / Gasdermin D axis potentially indicates fibrosis progression in nonalcoholic fatty liver disease: evidence from transcriptome and biological data. Bioengineered 2022;13:11740-51. [PMID: 35521691 DOI: 10.1080/21655979.2022.2072602] [Reference Citation Analysis]
623 Zhu C, Huang D, Ma H, Qian C, You H, Bu L, Qu S. High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease. Front Endocrinol 2022;13:848937. [DOI: 10.3389/fendo.2022.848937] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
624 Veltkamp C, Lan S, Korompoki E, Weiss K, Schmidt H, Seitz HK. Hepatic Steatosis and Fibrosis in Chronic Inflammatory Bowel Disease. JCM 2022;11:2623. [DOI: 10.3390/jcm11092623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
625 Digiacomo DV, Shay JE, Crotty R, Yang N, Bloom P, Corey K, Barmettler S, Farmer JR. Liver Stiffness by Transient Elastography Correlates With Degree of Portal Hypertension in Common Variable Immunodeficiency Patients With Nodular Regenerative Hyperplasia. Front Immunol 2022;13:864550. [DOI: 10.3389/fimmu.2022.864550] [Reference Citation Analysis]
626 Doycheva I, Ehrmann DA. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertil Steril 2022;117:897-911. [PMID: 35512974 DOI: 10.1016/j.fertnstert.2022.03.020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
627 Branković M, Jovanović I, Dukić M, Radonjić T, Oprić S, Klašnja S, Zdravković M. Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. Int J Mol Sci 2022;23:5146. [PMID: 35563534 DOI: 10.3390/ijms23095146] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
628 Byeon J, Kang M, Kim M. Association of Low Skeletal Muscle Mass with the Phenotype of Lean Non-Alcoholic Fatty Liver Disease. Healthcare 2022;10:850. [DOI: 10.3390/healthcare10050850] [Reference Citation Analysis]
629 Chen Y, Lian C, Sun Q, Wang T, Liu Y, Ye J, Gao L, Yang Y, Liu S, Shen Z, Liu Y. Ramulus Mori (Sangzhi) Alkaloids Alleviate High-Fat Diet-Induced Obesity and Nonalcoholic Fatty Liver Disease in Mice. Antioxidants 2022;11:905. [DOI: 10.3390/antiox11050905] [Reference Citation Analysis]
630 Martin A, Lang S, Goeser T, Demir M, Steffen HM, Kasper P. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. Curr Atheroscler Rep 2022. [PMID: 35507279 DOI: 10.1007/s11883-022-01028-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
631 Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Curr Atheroscler Rep 2022. [PMID: 35507280 DOI: 10.1007/s11883-022-01027-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
632 Cho Y, Chang Y, Ryu S, Jung HS, Kim CW, Oh H, Kim MK, Sohn W, Shin H, Wild SH, Byrne CD. Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex. Hepatol Commun 2022. [PMID: 35503803 DOI: 10.1002/hep4.1975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
633 Tapper EB, Ufere NN, Huang DQ, Loomba R. Review article: current and emerging therapies for the management of cirrhosis and its complications. Aliment Pharmacol Ther 2022;55:1099-115. [PMID: 35235219 DOI: 10.1111/apt.16831] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
634 Wu H, He X, Li Q, Zheng Y, Rayamajhi S, Thapa A, Meng G, Zhang Q, Liu L, Wu H, Gu Y, Zhang S, Zhang T, Wang X, Zhang J, Cao Z, Dong J, Zheng X, Zhang X, Dong X, Sun S, Wang X, Zhou M, Jia Q, Song K, Chang H, Niu K. Relationship between the consumption of wholegrain and nonalcoholic fatty liver disease: The TCLSIH cohort study. Clinical Nutrition 2022. [DOI: 10.1016/j.clnu.2022.05.009] [Reference Citation Analysis]
635 Li X, Li Y, Zhao W, Yu L, Hu X, Zhao Y, Guo Q, Wang X, Wu X. Dihydroflavonoids as Bioactive Components of Penthorum chinense, a Miao Ethnomedicine, against NAFLD through Bile Acid Metabolism Pathway. Chem Biodivers 2022;19:e202200146. [PMID: 35394106 DOI: 10.1002/cbdv.202200146] [Reference Citation Analysis]
636 Boursier J, Hagström H, Ekstedt M, Moreau C, Bonacci M, Cure S, Ampuero J, Nasr P, Tallab L, Canivet CM, Kechagias S, Sánchez Y, Dincuff E, Lucena A, Roux M, Riou J, Trylesinski A, Romero-Gomez M. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. J Hepatol 2022;76:1013-20. [PMID: 35063601 DOI: 10.1016/j.jhep.2021.12.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
637 Liu J, Oba Y, Yamano S. Chronic ethanol consumption plus an atherogenic diet cause metabolic steatohepatitis with advanced liver fibrosis in apolipoprotein E/low-density lipoprotein receptor double-knockout mice. Alcohol Clin Exp Res 2022. [PMID: 35491473 DOI: 10.1111/acer.14852] [Reference Citation Analysis]
638 Gupta B, Rai R, Oertel M, Raeman R. Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids. Semin Liver Dis 2022;42:122-37. [PMID: 35738255 DOI: 10.1055/s-0042-1748037] [Reference Citation Analysis]
639 Shi YW, Fan JG. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1191-9. [PMID: 34907360 DOI: 10.1038/s41401-021-00822-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
640 Tong XF, Wang QY, Zhao XY, Sun YM, Wu XN, Yang LL, Lu ZZ, Ou XJ, Jia JD, You H. Histological assessment based on liver biopsy: the value and challenges in NASH drug development. Acta Pharmacol Sin 2022;43:1200-9. [PMID: 35165400 DOI: 10.1038/s41401-022-00874-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
641 Shah ND, Barritt AS. Nutrition as Therapy in Liver Disease. Clinical Therapeutics 2022. [DOI: 10.1016/j.clinthera.2022.04.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
642 Yadav Y, Dunagan K, Khot R, Venkatesh SK, Port J, Galderisi A, Cobelli C, Wegner C, Basu A, Carter R, Basu R. Inhibition of 11β-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study. Diabetes Obes Metab 2022;24:881-90. [PMID: 35014156 DOI: 10.1111/dom.14646] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
643 Zhang XL, Wang TY, Targher G, Byrne CD, Zheng MH. Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease. Diabetes Metab J 2022;46:391-401. [PMID: 35656562 DOI: 10.4093/dmj.2022.0048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
644 Harvey BE. NASH: regulatory considerations for clinical drug development and U.S. FDA approval. Acta Pharmacol Sin 2022;43:1210-4. [PMID: 35110697 DOI: 10.1038/s41401-021-00832-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
645 Brunt EM, Clouston AD, Goodman Z, Guy C, Kleiner DE, Lackner C, Tiniakos DG, Wee A, Yeh M, Leow WQ, Chng E, Ren Y, Boon Bee GG, Powell EE, Rinella M, Sanyal AJ, Neuschwander-Tetri B, Younossi Z, Charlton M, Ratziu V, Harrison SA, Tai D, Anstee QM. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol 2022;76:1030-41. [PMID: 35090960 DOI: 10.1016/j.jhep.2022.01.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
646 Lavynenko O, Abdul-Ghani M, Alatrach M, Puckett C, Adams J, Abdelgani S, Alkhouri N, Triplitt C, Clarke GD, Vasquez JA, Li J, Cersosimo E, Gastaldelli A, DeFronzo RA. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). Diabetes Obes Metab 2022;24:899-907. [PMID: 35014145 DOI: 10.1111/dom.14650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
647 Jiao TY, Ma YD, Guo XZ, Ye YF, Xie C. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. Acta Pharmacol Sin 2022;43:1103-19. [PMID: 35217817 DOI: 10.1038/s41401-022-00880-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
648 Bashir A, Duseja A, De A, Mehta M, Tiwari P. Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena. Liver Research 2022. [DOI: 10.1016/j.livres.2022.05.002] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
649 Eguchi A, Iwasa M, Yamada M, Tamai Y, Shigefuku R, Hasegawa H, Hirokawa Y, Hayashi A, Okuno K, Matsushita Y, Nakatsuka T, Enooku K, Sakaguchi K, Kobayashi Y, Yamaguchi T, Watanabe M, Takei Y, Nakagawa H. A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis. Hepatol Commun 2022. [PMID: 35485207 DOI: 10.1002/hep4.1971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
650 Widyasari Wijaya PA, Wihandani DM, Sundari LPR. Prevention of Higher Triglycerides, Malondialdehyde, And Fatty Liver Disease Using the Ethanolic Extract of Sea Lettuce (Ulva lactuca) in Male Wistar Rats (Rattus Norvegicus). Curr Res Nutr Food Sci 2022;10:287-294. [DOI: 10.12944/crnfsj.10.1.23] [Reference Citation Analysis]
651 Shanahan W, Bagwe I, Brassill MJ, O'Regan P. Reduced and more appropriate referrals of patients with type 2 diabetes using liver stiffness measurement compared to FIB-4. Ir J Med Sci 2022. [PMID: 35486350 DOI: 10.1007/s11845-022-03019-5] [Reference Citation Analysis]
652 Moein H, Arteaga EJ, Sarkar S. Using Telehealth for Diagnosis and Management of Non‐Alcoholic Fatty Liver Disease. Clinical Liver Disease 2022;19:171-5. [DOI: 10.1002/cld.1191] [Reference Citation Analysis]
653 Ducatman A, Fenton SE. Invited Perspective: PFAS and Liver Disease: Bringing All the Evidence Together. Environ Health Perspect 2022;130:41303. [PMID: 35475651 DOI: 10.1289/EHP11149] [Reference Citation Analysis]
654 Takemura M, Mochizuki K, Harada Y, Okajima A, Hayakawa M, Dai P, Itoh Y, Tanaka H. Label-free Assessment of the Nascent State of Rat Non-alcoholic Fatty Liver Disease Using Spontaneous Raman Microscopy. Acta Histochem Cytochem 2022;55:57-66. [PMID: 35509867 DOI: 10.1267/ahc.22-00013] [Reference Citation Analysis]
655 Torres S, Segalés P, García-Ruiz C, Fernández-Checa JC. Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. Cells 2022;11:1475. [PMID: 35563780 DOI: 10.3390/cells11091475] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
656 Apostolov R, Gianatti E, Wong D, Kutaiba N, Gow P, Grossmann M, Sinclair M. Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations. World J Hepatol 2022; 14(4): 754-765 [DOI: 10.4254/wjh.v14.i4.754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
657 Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents. Hepatol Commun 2022. [PMID: 35470984 DOI: 10.1002/hep4.1969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
658 Dai L, Xu J, Liu B, Dang Y, Wang R, Zhuang L, Li D, Jiao L, Wang J, Zhang L, Zhong LLD, Zhou W, Ji G. Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach. Front Med 2022. [PMID: 35471471 DOI: 10.1007/s11684-021-0880-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
659 Boonchai P, Kositamongkol C, Jitrukthai S, Phothirat S, Mepramoon E, Nimitpunya P, Srivanichakorn W, Chaisathaphol T, Washirasaksiri C, Auesomwang C, Sitasuwan T, Tinmanee R, Sayabovorn N, Charatcharoenwitthaya P, Phisalprapa P. Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome. J Clin Med 2022;11:2445. [PMID: 35566571 DOI: 10.3390/jcm11092445] [Reference Citation Analysis]
660 Soullane S, Willems P, Lee GE, Auger N. Early life programming of nonalcoholic fatty liver disease in children. Early Hum Dev 2022;168:105578. [PMID: 35489298 DOI: 10.1016/j.earlhumdev.2022.105578] [Reference Citation Analysis]
661 Mascaró CM, Bouzas C, Montemayor S, Casares M, Llompart I, Ugarriza L, Borràs PA, Martínez JA, Tur JA. Effect of a Six-Month Lifestyle Intervention on the Physical Activity and Fitness Status of Adults with NAFLD and Metabolic Syndrome. Nutrients 2022;14:1813. [PMID: 35565780 DOI: 10.3390/nu14091813] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
662 Zhou Y, Li R, Zheng Y, Song M, Zhang S, Sun Y, Wei M, Fan X. Diosgenin Ameliorates Non-alcoholic Fatty Liver Disease by Modulating the Gut Microbiota and Related Lipid/Amino Acid Metabolism in High Fat Diet-Fed Rats. Front Pharmacol 2022;13:854790. [DOI: 10.3389/fphar.2022.854790] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
663 Skvortsov VV, Lunkov MV, Tinaeva RS, Skvortsova EM. Phospholipids in non-alcoholic fatty liver disease. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-6-92-99] [Reference Citation Analysis]
664 Liu N, Yang J, Ma W, Li C, An L, Zhang X, Zou Q. Xiaoyao Powder in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Ethnopharmacol 2022;288:114999. [PMID: 35051605 DOI: 10.1016/j.jep.2022.114999] [Reference Citation Analysis]
665 Prasoppokakorn T, Chan WK, Wong VWS, Pitisuttithum P, Mahadeva S, Nik Mustapha NR, Wong GLH, Leung HHW, Sripongpun P, Treeprasertsuk S. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease . World J Gastroenterol 2022; 28(15): 1563-1573 [DOI: 10.3748/wjg.v28.i15.1563] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
666 López-almada G, Domínguez-avila JA, González-aguilar GA, Mejía-león ME, Salazar-lópez NJ. ABORDAJE PREVENTIVO EN LA ENFERMEDAD POR HÍGADO GRASO NO ALCOHÓLICO. Epistemus 2022;16. [DOI: 10.36790/epistemus.v16i32.185] [Reference Citation Analysis]
667 Woreta TA, Van Natta ML, Lazo M, Krishnan A, Neuschwander-Tetri BA, Loomba R, Mae Diehl A, Abdelmalek MF, Chalasani N, Gawrieh S, Dasarathy S, Vuppalanchi R, Siddiqui MS, Kowdley KV, McCullough A, Terrault NA, Behling C, Kleiner DE, Fishbein M, Hertel P, Wilson LA, Mitchell EP, Miriel LA, Clark JM, Tonascia J, Sanyal AJ; NASH Clinical Research Network. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS One 2022;17:e0266859. [PMID: 35427375 DOI: 10.1371/journal.pone.0266859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
668 Carol M, Pérez-Guasch M, Solà E, Cervera M, Martínez S, Juanola A, Ma AT, Avitabile E, Napoleone L, Pose E, Graupera I, Honrubia M, Korenjak M, Torres F, Ginès P, Fabrellas N; LiverHope Consortium Investigators. Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. PLoS One 2022;17:e0265153. [PMID: 35385510 DOI: 10.1371/journal.pone.0265153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
669 Liang J, Gu L, Liu X, Yan X, Bi X, Fan X, Zhou J, Lu S, Luo L, Yin Z. L-theanine prevents progression of nonalcoholic hepatic steatosis by regulating hepatocyte lipid metabolic pathways via the CaMKKβ-AMPK signaling pathway. Nutr Metab (Lond) 2022;19:29. [PMID: 35428314 DOI: 10.1186/s12986-022-00664-6] [Reference Citation Analysis]
670 Doustmohammadian A, Pishgar E, Clark CCT, Sobhrakhshankhah E, Nikkhah M, Faraji AH, Motamed N, Mansourian MR, Amirkalali B, Maadi M, Kasaii MS, Ebrahimi H, Zamani F. Empirically-Derived Dietary Patterns in Relation to Non-Alcoholic Fatty Liver Diseases Among Adult Participants in Amol, Northern Iran: A Structural Equation Modeling Approach. Front Nutr 2022;9:821544. [PMID: 35419401 DOI: 10.3389/fnut.2022.821544] [Reference Citation Analysis]
671 Khanna S, Wilkins JT, Ning H, Allen NB, Lewis CE, Carr JJ, Lloyd-jones D, Vanwagner LB, Hirata MH. Lipoprotein Levels in Early Adulthood and NAFLD in Midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Journal of Nutrition and Metabolism 2022;2022:1-9. [DOI: 10.1155/2022/1727711] [Reference Citation Analysis]
672 Umemura A, Kataoka S, Okuda K, Seko Y, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Potential Therapeutic Targets and Promising Agents for Combating NAFLD. Biomedicines 2022;10:901. [DOI: 10.3390/biomedicines10040901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
673 Rom O, Liu Y, Finney AC, Ghrayeb A, Zhao Y, Shukha Y, Wang L, Rajanayake KK, Das S, Rashdan NA, Weissman N, Delgadillo L, Wen B, Garcia-Barrio MT, Aviram M, Kevil CG, Yurdagul A Jr, Pattillo CB, Zhang J, Sun D, Hayek T, Gottlieb E, Mor I, Chen YE. Induction of glutathione biosynthesis by glycine-based treatment mitigates atherosclerosis. Redox Biol 2022;52:102313. [PMID: 35447412 DOI: 10.1016/j.redox.2022.102313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
674 Lange NF, Graf V, Caussy C, Dufour JF. PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. Int J Mol Sci 2022;23:4305. [PMID: 35457120 DOI: 10.3390/ijms23084305] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
675 Zelber-Sagi S, O'Reilly-Shah VN, Fong C, Ivancovsky-Wajcman D, Reed MJ, Bentov I. Liver Fibrosis Marker and Postoperative Mortality in Patients Without Overt Liver Disease. Anesth Analg 2022. [PMID: 35417420 DOI: 10.1213/ANE.0000000000006044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
676 Zhang Y, Yin R, Lang J, Fu Y, Yang L, Zhao D. Epigallocatechin-3-gallate ameliorates hepatic damages by relieve FGF21 resistance and promotion of FGF21-AMPK pathway in mice fed a high fat diet. Diabetol Metab Syndr 2022;14:53. [PMID: 35418153 DOI: 10.1186/s13098-022-00823-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
677 Alalwani J, Eljazzar S, Basil M, Tayyem R. The impact of health status, diet and lifestyle on non‐alcoholic fatty liver disease: Narrative review. Clinical Obesity. [DOI: 10.1111/cob.12525] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
678 Sabirin F, Lim SM, Neoh CF, Ramasamy K. Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease in vivo: A Systematic Review. Front Nutr 2022;9:844374. [DOI: 10.3389/fnut.2022.844374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
679 Tavaglione F, Jamialahmadi O, De Vincentis A, Qadri S, Mowlaei ME, Mancina RM, Ciociola E, Carotti S, Perrone G, Bruni V, Gallo IF, Tuccinardi D, Bianco C, Prati D, Manfrini S, Pozzilli P, Picardi A, Caricato M, Yki-Järvinen H, Valenti L, Vespasiani-Gentilucci U, Romeo S. Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00385-8. [PMID: 35421583 DOI: 10.1016/j.cgh.2022.03.044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
680 Peng X, Li J, Zhao H, Lai J, Lin J, Tang S. Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials. BMC Endocr Disord 2022;22. [DOI: 10.1186/s12902-022-01015-5] [Reference Citation Analysis]
681 Yang H, Zhang T, Rayamajhi S, Thapa A, Du W, Meng G, Zhang Q, Liu L, Wu H, Gu Y, Zhang S, Wang X, Li H, Zhang J, Dong J, Zheng X, Cao Z, Zhang X, Dong X, Sun S, Wang X, Zhou M, Jia Q, Song K, Niu K. The longitudinal associations between sweet potato intake and the risk of non-alcoholic fatty liver disease: the TCLSIH cohort study. International Journal of Food Sciences and Nutrition. [DOI: 10.1080/09637486.2022.2050997] [Reference Citation Analysis]
682 Lu Y, Wan H, Wu Y, Yang J, Yu L, He Y, Wan H, Li C. Naoxintong Capsule Alternates Gut Microbiota and Prevents Hyperlipidemia in High-Fat-Diet Fed Rats. Front Pharmacol 2022;13:843409. [PMID: 35387330 DOI: 10.3389/fphar.2022.843409] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
683 Zhang K, Yuan Y, Dawa Z, Liu F, Yao Y, Wang M, Zhu C, Lin C. Integrating metabolomics and network pharmacology to reveal the mechanisms of Delphinium brunonianum extract against nonalcoholic steatohepatitis. J Ethnopharmacol 2022;293:115268. [PMID: 35398502 DOI: 10.1016/j.jep.2022.115268] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
684 Unalp-arida A, Ruhl CE. Prepandemic prevalence estimates of fatty liver disease and fibrosis defined by liver elastography in the United States.. [DOI: 10.1101/2022.04.05.22273458] [Reference Citation Analysis]
685 Lu X, Ding Y, Liu H, Sun M, Chen C, Yang Y, Wang H. The Role of Hydrogen Sulfide Regulation of Autophagy in Liver Disorders. Int J Mol Sci 2022;23:4035. [PMID: 35409395 DOI: 10.3390/ijms23074035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
686 Zhou H, Luo P, Li P, Wang G, Yi X, Fu Z, Sun X, Cui B, Zhu L, Zhu S. Bariatric Surgery Improves Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Obes Surg 2022. [PMID: 35386040 DOI: 10.1007/s11695-022-06011-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
687 Fang X, Wang H, Tan X, Ye T, Xu Y, Fan J. Elevated Serum Regulator of Calcineurin 2 is Associated With an Increased Risk of Non-Alcoholic Fatty Liver Disease. Front Pharmacol 2022;13:840764. [PMID: 35370729 DOI: 10.3389/fphar.2022.840764] [Reference Citation Analysis]
688 Choi HI, Lee MY, Kim H, Oh BK, Lee SJ, Kang JG, Lee SH, Kim BJ, Kim BS, Kang JH, Lee JY, Sung KC. Effect of physical activity on the development and the resolution of nonalcoholic fatty liver in relation to body mass index. BMC Public Health 2022;22:655. [PMID: 35382785 DOI: 10.1186/s12889-022-13128-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
689 Heredia NI, Gaba R, Liu Y, Jain S, Rungta M, Rungta M, El-Serag HB, Kanwal F, Thrift AP, Balakrishnan M. Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. Sci Rep 2022;12:5695. [PMID: 35383229 DOI: 10.1038/s41598-022-09583-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
690 Zhu W, Ding C, Huang P, Ran J, Lian P, Tang Y, Dai W, Huang X. Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway. Sci Rep 2022;12:5639. [PMID: 35379885 DOI: 10.1038/s41598-022-09610-1] [Reference Citation Analysis]
691 Han E, Huh JH, Lee EY, Bae JC, Chun SW, Yu SH, Kwak SH, Park KS, Lee BW. Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial. Diabetes Obes Metab 2022;24:752-6. [PMID: 34918436 DOI: 10.1111/dom.14623] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
692 Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. The Lancet Diabetes & Endocrinology 2022;10:284-96. [DOI: 10.1016/s2213-8587(22)00003-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 45] [Article Influence: 29.0] [Reference Citation Analysis]
693 Pan X, Wu Y, Peng H, Cai X, Hu Z, Lin X, Peng XE. Genome-wide DNA methylation profiling in nonalcoholic fatty liver reveals predictive aberrant methylation in PRKCE and SEC14L3 promoters. Dig Liver Dis 2022;54:521-8. [PMID: 34108094 DOI: 10.1016/j.dld.2021.05.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
694 Priken K, Tapia G, Cadagan C, Quezada N, Torres J, D'espessailles A, Pettinelli P. Higher hepatic advanced glycation end products and liver damage markers are associated with non-alcoholic steatohepatitis. Nutrition Research 2022. [DOI: 10.1016/j.nutres.2022.04.005] [Reference Citation Analysis]
695 Noureddin N, Noureddin M, Singh A, Alkhouri N. Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes. Dig Dis Sci 2022;67:1379-88. [PMID: 33779880 DOI: 10.1007/s10620-021-06955-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
696 Tawfiq RA, Nassar NN, Hammam OA, Allam RM, Elmazar MM, Abdallah DM, Attia YM. Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4/TGF-β1 axis. Chemico-Biological Interactions 2022. [DOI: 10.1016/j.cbi.2022.109953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
697 Thongtan T, Deb A, Vutthikraivit W, Laoveeravat P, Mingbunjerdsuk T, Islam S, Islam E. Antiplatelet therapy associated with lower prevalence of advanced liver fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Indian J Gastroenterol 2022;41:119-26. [PMID: 35318571 DOI: 10.1007/s12664-021-01230-3] [Reference Citation Analysis]
698 Huang DQ, Fowler KJ, Liau J, Cunha GM, Louie AL, An JY, Bettencourt R, Jung J, Gitto Z, Hernandez C, Lopez SJ, Gupta H, Sirlin CB, Marks RM, Loomba R. Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. Aliment Pharmacol Ther 2022;55:820-7. [PMID: 35229334 DOI: 10.1111/apt.16844] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
699 Ding C, Tang Y, Zhu W, Huang P, Lian P, Ran J, Huang X. Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis. Acta Diabetol 2022;59:519-33. [PMID: 34988690 DOI: 10.1007/s00592-021-01830-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
700 Unalp-Arida A, Ruhl CE. Transient Elastography-Assessed Hepatic Steatosis and Fibrosis Are Associated With Body Composition in the United States. Clin Gastroenterol Hepatol 2022;20:e808-30. [PMID: 33549867 DOI: 10.1016/j.cgh.2021.02.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
701 Sun Y, Chen S, Zhao X, Wang Y, Lan Y, Jiang X, Gao X, Wu S, Wang L. Adherence to the dietary approaches to stop hypertension diet and non-alcoholic fatty liver disease. Liver Int 2022;42:809-19. [PMID: 34990079 DOI: 10.1111/liv.15156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
702 Ciardullo S, Grassi G, Mancia G, Perseghin G. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2022;34:365-71. [PMID: 34678858 DOI: 10.1097/MEG.0000000000002299] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 24.0] [Reference Citation Analysis]
703 Sugiyama A, Kurisu A, Kumada T, Tanaka J. Liver biopsy implementation rate for diagnosis of NASH in Japan -analysis of big data of health insurance claims-. Acta hepatologica Japonica 2022;63:211-213. [DOI: 10.2957/kanzo.63.211] [Reference Citation Analysis]
704 Silva-Santisteban A, Agnihotri A, Cruz-Romero C, Nasser IA, Malvar GL, Nsubuga JP, Villafuerte Gálvez JA, Bonder A, Pleskow DK, Berzin TM, Sawhney MS. EUS imaging for the diagnosis of nonalcoholic fatty liver disease. Gastrointest Endosc 2022;95:711-6. [PMID: 34915035 DOI: 10.1016/j.gie.2021.11.048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
705 Lee DH, Sung SU, Lee YK, Lim IH, Jang H, Joo SK, Park JH, Chang MS, So YH, Kim W; Innovative Target Exploration of NAFLD (ITEN) Consortium. A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2022;55:994-1007. [PMID: 35005800 DOI: 10.1111/apt.16766] [Reference Citation Analysis]
706 Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, Ekstedt M, Esmat G, George J, Marchesini G, Novak K, Ocama P, Ratziu V, Razavi H, Romero-Gómez M, Silva M, Spearman CW, Tacke F, Tsochatzis EA, Yilmaz Y, Younossi ZM, Wong VW, Zelber-Sagi S, Cortez-Pinto H, Anstee QM; NAFLD policy review collaborators. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? J Hepatol 2022;76:771-80. [PMID: 34895743 DOI: 10.1016/j.jhep.2021.10.025] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 27.0] [Reference Citation Analysis]
707 Stefan N, Roden M. Diabetes and Fatty Liver. Exp Clin Endocrinol Diabetes 2022. [PMID: 35373310 DOI: 10.1055/a-1624-3541] [Reference Citation Analysis]
708 Noureddin M, Ntanios F, Malhotra D, Hoover K, Emir B, McLeod E, Alkhouri N. Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning. Hepatol Commun 2022. [PMID: 35365931 DOI: 10.1002/hep4.1935] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
709 Barritt AS 4th, Marshman E, Noureddin M. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Aliment Pharmacol Ther 2022;55:944-59. [PMID: 35266164 DOI: 10.1111/apt.16794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
710 Hartleb M, Mastalerz-Migas A, Kowalski P, Okopień B, Popovic B, Proga K, Cywińska-Durczak B. Healthcare practitioners' diagnostic and treatment practice patterns of nonalcoholic fatty liver disease in Poland: a cross-sectional survey. Eur J Gastroenterol Hepatol 2022;34:426-34. [PMID: 34560694 DOI: 10.1097/MEG.0000000000002288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
711 Mcpherson S, Armstrong MJ, Cobbold JF, Corless L, Anstee QM, Aspinall RJ, Barclay ST, Brennan PN, Cacciottolo TM, Goldin RD, Hallsworth K, Hebditch V, Jack K, Jarvis H, Johnson J, Li W, Mansour D, Mccallum M, Mukhopadhya A, Parker R, Ross V, Rowe IA, Srivastava A, Thiagarajan P, Thompson AI, Tomlinson J, Tsochatzis EA, Yeoman A, Alazawi W. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00061-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
712 Zhou H, Zhou Y, Ding J, Chen Y, Wen J, Zhao L, Zhang Q, Jing X. Clinical evaluation of grayscale and linear scale hepatorenal indices for fatty liver quantification: a prospective study of a native Chinese population. Abdom Radiol (NY) 2022;47:1321-32. [PMID: 35150314 DOI: 10.1007/s00261-022-03434-3] [Reference Citation Analysis]
713 Arefhosseini S, Pouretedal Z, Tutunchi H, Ebrahimi-Mameghani M. Serum copper, ceruloplasmin, and their relations to metabolic factors in nonalcoholic fatty liver disease: a cross-sectional study. Eur J Gastroenterol Hepatol 2022;34:443-8. [PMID: 34860704 DOI: 10.1097/MEG.0000000000002325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
714 Lu Y, Shao M, Xiang H, Wang J, Ji G, Wu T. Qinggan Huoxue Recipe Alleviates Alcoholic Liver Injury by Suppressing Endoplasmic Reticulum Stress Through LXR-LPCAT3. Front Pharmacol 2022;13:824185. [DOI: 10.3389/fphar.2022.824185] [Reference Citation Analysis]
715 Xiong G, Huang C, Zou Y, Tao Z, Zou J, Huang J, M.a B. Associations of Urinary Phytoestrogen Concentrations with Nonalcoholic Fatty Liver Disease among Adults. Journal of Healthcare Engineering 2022;2022:1-13. [DOI: 10.1155/2022/4912961] [Reference Citation Analysis]
716 Sun Q, Tang L, Wang M, Zhu P, Li Y, Ma H, Huang O, Hong L, Li G, Byrne CD, Targher G, Liu W, Lu Y, Ding J, Zheng M. Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. Front Med 2022;9:864570. [DOI: 10.3389/fmed.2022.864570] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
717 Huh Y, Cho YJ, Nam GE. Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. J Obes Metab Syndr 2022;31:17-27. [PMID: 35332111 DOI: 10.7570/jomes22021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
718 Wang M, Zhou BG, Zhang Y, Ren XF, Li L, Li B, Ai YW. Association Between Non-alcoholic Fatty Liver Disease and Risk of Stroke: A Systematic Review and Meta-Analysis. Front Cardiovasc Med 2022;9:812030. [PMID: 35345491 DOI: 10.3389/fcvm.2022.812030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
719 Seo JA. Metabolic Syndrome: A Warning Sign of Liver Fibrosis. J Obes Metab Syndr 2022;31:1-3. [PMID: 35332113 DOI: 10.7570/jomes22023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
720 Amin NB, Darekar A, Anstee QM, Wong VW, Tacke F, Vourvahis M, Lee DS, Charlton M, Alkhouri N, Nakajima A, Yunis C. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. BMJ Open 2022;12:e056159. [PMID: 35354614 DOI: 10.1136/bmjopen-2021-056159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
721 Chen S, Jin Y, Xu M, Zhang P, Zhou Y, Qian X, Song Q, Bu S, Sun J, Li L. Relationship Between Thyroid Hormone and Liver Steatosis Analysis Parameter in Obese Participants: A Case-Control Study. Diabetes Metab Syndr Obes 2022;15:887-96. [PMID: 35345544 DOI: 10.2147/DMSO.S356882] [Reference Citation Analysis]
722 Jung J, Han A, Madamba E, Bettencourt R, Loomba RR, Boehringer AS, Andre MP, Erdman JW Jr, O'Brien WD Jr, Fowler KJ, Sirlin CB, Loomba R. Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD. Radiology 2022;:211131. [PMID: 35348378 DOI: 10.1148/radiol.211131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
723 Von-hafe M, Borges-canha M, Vale C, Leite AR, Sérgio Neves J, Carvalho D, Leite-moreira A. Nonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review. Metabolites 2022;12:298. [DOI: 10.3390/metabo12040298] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
724 Pillai A, Bliznashki K, Hutchison E, Kumar C, Challis B, Patel M. Machine Learning Enabled Non-invasive Diagnosis of Nonalcoholic Fatty Liver Disease and Assessment of Abdominal Fat from MRI Data.. [DOI: 10.1101/2022.03.25.22272965] [Reference Citation Analysis]
725 Mirarchi L, Amodeo S, Citarrella R, Licata A, Soresi M, Giannitrapani L. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. IJMS 2022;23:3668. [DOI: 10.3390/ijms23073668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
726 Trifan A, Rotaru A, Stafie R, Stratina E, Zenovia S, Nastasa R, Huiban L, Cuciureanu T, Muzîca C, Chiriac S, Gîrleanu I, Sîngeap A, Sfarti C, Cojocariu C, Stanciu C. Clinical and Laboratory Characteristics of Normal Weight and Obese Individuals with Non-Alcoholic Fatty Liver Disease. Diagnostics 2022;12:801. [DOI: 10.3390/diagnostics12040801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
727 Li G, Peng Y, Chen Z, Li H, Liu D, Ye X, Galani A. Bidirectional Association between Hypertension and NAFLD: A Systematic Review and Meta-Analysis of Observational Studies. International Journal of Endocrinology 2022;2022:1-10. [DOI: 10.1155/2022/8463640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
728 DiStefano JK, Gerhard GS. NAFLD in normal weight individuals. Diabetol Metab Syndr 2022;14:45. [PMID: 35331317 DOI: 10.1186/s13098-022-00814-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
729 Kemas AM, Youhanna S, Lauschke VM. Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development. Expert Review of Precision Medicine and Drug Development 2022;7:39-49. [DOI: 10.1080/23808993.2022.2053285] [Reference Citation Analysis]
730 Tao X, Chen L, Zhao Y, Liu Y, Shi R, Jiang B, Mi Y, Xu L. A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease. Front Med 2022;9:862879. [DOI: 10.3389/fmed.2022.862879] [Reference Citation Analysis]
731 Schmid A, Arians M, Karrasch T, Pons-Kühnemann J, Schäffler A, Roderfeld M, Roeb E. Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy. J Clin Med 2022;11:1756. [PMID: 35407364 DOI: 10.3390/jcm11071756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
732 Akbari S, Sohouli MH, Ebrahimzadeh S, Ghanaei FM, Hosseini AF, Aryaeian N. Effect of rosemary leaf powder with weight loss diet on lipid profile, glycemic status, and liver enzymes in patients with nonalcoholic fatty liver disease: A randomized, double-blind clinical trial. Phytother Res 2022. [PMID: 35318738 DOI: 10.1002/ptr.7446] [Reference Citation Analysis]
733 Kilinç A, Akdevelioğlu Y. Vitaminler ve Non Alkolik Yağlı Karaciğer Hastalığı. Adnan Menderes Üniversitesi Sağlık Bilimleri Fakültesi Dergisi 2022. [DOI: 10.46237/amusbfd.1033604] [Reference Citation Analysis]
734 Yao K, Tarabra E, Sia D, Morotti R, Fawaz R, Valentino P, Santoro N, Caprio S, Liu S, Yimlamai D. Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease. Hepatol Commun 2022. [PMID: 35312185 DOI: 10.1002/hep4.1940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
735 Tunçer AP, Küçükgül A, İşgör MM. İn Vitro Lipopolisakkarit Uyarımlı Karaciğer Yangı Modelinde Alfa-Terpineol’ün Etkinliğinin Araştırılması. Etlik Veteriner Mikrobiyoloji Dergisi 2022. [DOI: 10.35864/evmd.1053710] [Reference Citation Analysis]
736 Akuta N, Kawamura Y, Suzuki F, Kobayashi M, Arase Y, Saitoh S, Muraishi N, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Ikeda K, Kumada H. Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease. Hepatol Int. [DOI: 10.1007/s12072-022-10313-y] [Reference Citation Analysis]
737 Minamikawa T, Hase E, Ichimura-shimizu M, Morimoto Y, Suzuki A, Yasui T, Nakamura S, Tsutsui A, Takaguchi K, Tsuneyama K. Assessment of Ultra-Early-Stage Liver Fibrosis in Human Non-Alcoholic Fatty Liver Disease by Second-Harmonic Generation Microscopy. IJMS 2022;23:3357. [DOI: 10.3390/ijms23063357] [Reference Citation Analysis]
738 Sun L, Deng C, Gu Y, He Y, Yang L, Shi J. Effects of Dapagliflozin in Patients with Nonalcoholic Fatty Liver Disease:A Systematic Review and Meta-Analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 2022;:101876. [PMID: 35321843 DOI: 10.1016/j.clinre.2022.101876] [Reference Citation Analysis]
739 Mahabaleshwarkar R, Liu TL, McKillop IH, Spencer M. The Association Between Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease Diagnosis Varies by Race. Metab Syndr Relat Disord 2022. [PMID: 35319282 DOI: 10.1089/met.2021.0108] [Reference Citation Analysis]
740 Choi JY, Jang TW, Song PH, Choi SH, Ku SK, Song CH. Combination Effects of Metformin and a Mixture of Lemon Balm and Dandelion on High-Fat Diet-Induced Metabolic Alterations in Mice. Antioxidants (Basel) 2022;11:580. [PMID: 35326230 DOI: 10.3390/antiox11030580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
741 Sonaglioni A, Cerini F, Cerrone A, Argiento L, Nicolosi GL, Rigamonti E, Lombardo M, Rumi MG, Viganò M. Liver stiffness measurement identifies subclinical myocardial dysfunction in non-advanced non-alcoholic fatty liver disease patients without overt heart disease. Intern Emerg Med 2022. [PMID: 35302179 DOI: 10.1007/s11739-022-02966-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
742 Schnurr TM, Katz SF, Justesen JM, O'Sullivan JW, Saliba-Gustafsson P, Assimes TL, Carcamo-Orive I, Ahmed A, Ashley EA, Hansen T, Knowles JW. Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD. Hepatol Commun 2022. [PMID: 35293152 DOI: 10.1002/hep4.1932] [Reference Citation Analysis]
743 Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, Kassi E. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int J Mol Sci 2022;23:3107. [PMID: 35328527 DOI: 10.3390/ijms23063107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
744 Babiy B, Ramos-molina B, Ocaña L, Sacristán S, Burgos-santamaría D, Martínez-botas J, Villa-turégano G, Busto R, Perna C, Frutos MD, Albillos A, Pastor Ó. Accumulation of dihydrosphingolipids and neutral lipids is related to steatosis and fibrosis damage in human and animal models of non-alcoholic fatty liver disease.. [DOI: 10.1101/2022.03.10.22271048] [Reference Citation Analysis]
745 Ma Y, Li Q, Chen G, Tan Z, Cao H, Bin Y, Zhou Y, Yi J, Luo X, Tan J, Li J, Si Z. Transcriptomic analysis reveals a novel regulatory factor of ECHDC1 involved in lipid metabolism of non-alcoholic fatty liver disease. Biochem Biophys Res Commun 2022;605:1-8. [PMID: 35305493 DOI: 10.1016/j.bbrc.2022.03.055] [Reference Citation Analysis]
746 Verhaegen A, Van Gaal LF. Obesity, Ectopic Fat and Type 2 Diabetes. Clinical Obesity in Adults and Children 2022. [DOI: 10.1002/9781119695257.ch10] [Reference Citation Analysis]
747 Ceci L, Zhou T, Lenci I, Meadows V, Kennedy L, Li P, Ekser B, Milana M, Zhang W, Wu C, Sato K, Chakraborty S, Glaser SS, Francis H, Alpini G, Baiocchi L. Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development. Cancers 2022;14:1442. [DOI: 10.3390/cancers14061442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
748 Deo R, Panigrahi S. Explainability Analysis of Black Box SVM models for Hepatic Steatosis Screening. 2022 IEEE Healthcare Innovations and Point of Care Technologies (HI-POCT) 2022. [DOI: 10.1109/hi-poct54491.2022.9744067] [Reference Citation Analysis]
749 Czarnecka P, Czarnecka K, Tronina O, Baczkowska T, Durlik M. Utilization of HCV viremic donors in kidney transplantation: a chance or a threat? Ren Fail 2022;44:434-49. [PMID: 35260039 DOI: 10.1080/0886022X.2022.2047069] [Reference Citation Analysis]
750 Vidal‐cevallos P, Torre A, Mendez‐sanchez N, Uribe M, Chavez‐tapia NC. Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico. Clinical Liver Disease 2022;19:68-72. [DOI: 10.1002/cld.1167] [Reference Citation Analysis]
751 Han B, Lee GB, Yim SY, Cho K, Shin KE, Kim J, Park Y, Han K, Kim Y. Non-Alcoholic Fatty Liver Disease Defined by Fatty Liver Index and Incidence of Heart Failure in the Korean Population: A Nationwide Cohort Study. Diagnostics 2022;12:663. [DOI: 10.3390/diagnostics12030663] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
752 Machida T, Obara T, Miyazaki M, Inoue J, Mano N. Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. Ann Hepatol 2022;27:100699. [PMID: 35278680 DOI: 10.1016/j.aohep.2022.100699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
753 Berry P, Kotha S. The Challenging Ethical Landscape of Non-alcoholic Fatty Liver Disease. EMJ Hepatol 2022. [DOI: 10.33590/emjhepatol/21-00217] [Reference Citation Analysis]
754 Lee YS, Lee JE, Yi HS, Jung YK, Jun DW, Kim JH, Seo YS, Yim HJ, Kim BH, Kim JW, Lee CH, Yeon JE, Lee J, Um SH, Byun KS. MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatol Int 2022. [PMID: 35254642 DOI: 10.1007/s12072-022-10300-3] [Reference Citation Analysis]
755 Lee S, Kim KW, Lee J, Park T, Koo K, Song GW, Lee SG. Visceral Fat Area Is an Independent Risk Factor for Overweight or Obese Nonalcoholic Fatty Liver Disease in Potential Living Liver Donors. Transplant Proc 2022:S0041-1345(22)00091-4. [PMID: 35256204 DOI: 10.1016/j.transproceed.2021.10.032] [Reference Citation Analysis]
756 Wang M, Wang M, Zhang R, Zhang L, Ding Y, Tang Z, Fan H, Wang H, Zhang W, Chen Y, Wang J. A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study. PeerJ 2022;10:e13022. [PMID: 35265397 DOI: 10.7717/peerj.13022] [Reference Citation Analysis]
757 Kosmalski M, Ziółkowska S, Czarny P, Szemraj J, Pietras T. The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. J Clin Med 2022;11:1375. [PMID: 35268466 DOI: 10.3390/jcm11051375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
758 Souza CAD, Rocha R, Costa PRDF, Almeida NS, Cotrim HP. Probiotic, prebiotic or symbiotic supplementation impacts on intestinal microbiota in patients with nonalcoholic fatty liver disease: A systematic review. Arq Gastroenterol 2022;59:123-8. [DOI: 10.1590/s0004-2803.202200001-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
759 de Vries M, Westerink J, El-morabit F, Karin Kaasjager H, de Valk HW. Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109827] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
760 Park H, Yoon EL, Kim M, Lee J, Kim JH, Cho S, Jun DW, Nah EH. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era. Hepatol Res 2022;52:247-54. [PMID: 34841632 DOI: 10.1111/hepr.13737] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
761 Gluvic Z, Tomasevic R, Bojovic K, Obradovic M, Isenovic ER. Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approach—the institutional adaptation to existing Clinical Practice Guidelines. Emergency and Critical Care Medicine 2022;2:12-22. [DOI: 10.1097/ec9.0000000000000016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
762 Ji J, Feng M, Huang Y, Niu X. Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro. Bioengineered 2022;13:5091-102. [PMID: 35164657 DOI: 10.1080/21655979.2022.2036902] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
763 Venkatesh SK, Torbenson MS. Liver fibrosis quantification. Abdom Radiol (NY) 2022;47:1032-52. [PMID: 35022806 DOI: 10.1007/s00261-021-03396-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
764 Akam EY, Nuako AA, Daniel AK, Stanford FC. Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention. Curr Diab Rep 2022;22:129-36. [PMID: 35175453 DOI: 10.1007/s11892-022-01451-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
765 Bamburowicz-klimkowska M, Ruzycka-ayoush M, Cieszanowski A, Szeszkowski W, Bialek M, Malkowska A, Grudzinski IP. New insights into NAFLD based on preclinical MRI studies. Chemistry and Physics of Lipids 2022. [DOI: 10.1016/j.chemphyslip.2022.105192] [Reference Citation Analysis]
766 Gong L, Wang G, Ma Q, Hao W, Xian M, Wu Y, Kurihara H, He R, Chen J. Novel insights into the effect of Xiaoyao san on corticosterone-induced hepatic steatosis: inhibition of glucocorticoid receptor/perilipin-2 signaling pathway. Acupuncture and Herbal Medicine 2022;2:49-57. [DOI: 10.1097/hm9.0000000000000011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
767 Rinella ME, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol 2022;76:536-48. [PMID: 34793868 DOI: 10.1016/j.jhep.2021.10.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
768 Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, Ma Z, Bruno MJ, de Knegt RJ, Cao W, Peppelenbosch MP, Ghanbari M, Li Z, Pan Q. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clin Gastroenterol Hepatol 2022;20:e573-82. [PMID: 33618024 DOI: 10.1016/j.cgh.2021.02.030] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 39.0] [Reference Citation Analysis]
769 Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal N, Lai M. Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2022;117:453-61. [PMID: 35041626 DOI: 10.14309/ajg.0000000000001606] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
770 Eriksen PL, Thomsen KL, Sørensen M, Vilstrup H, Hvas A. Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease. Thrombosis Research 2022. [DOI: 10.1016/j.thromres.2022.02.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
771 Kuchay MS, Misra A. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis. Diabetes Metab Syndr 2022;16:102446. [PMID: 35259705 DOI: 10.1016/j.dsx.2022.102446] [Reference Citation Analysis]
772 Meneses D, Olveira A, Corripio R, Méndez MDC, Romero M, Calvo-viñuelas I, Herranz L, Vicent D, de-Cos-Blanco AI. Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity. Endocrinología, Diabetes y Nutrición (English ed ) 2022;69:178-188. [DOI: 10.1016/j.endien.2022.02.017] [Reference Citation Analysis]
773 Yuan L, Hanlon CL, Terrault N, Alqahtani S, Tamim H, Lai M, Saberi B. Portrait of Regional Trends in Liver Transplantation for Nonalcoholic Steatohepatitis in the United States. Am J Gastroenterol 2022;117:433-44. [PMID: 35083985 DOI: 10.14309/ajg.0000000000001591] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
774 Yasar O, Long P, Harder B, Marshall H, Bhasin S, Lee S, Delegge M, Roy S, Doyle O, Leavitt N, Rigg J. Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH). BMJ Health Care Inform 2022;29:e100510. [DOI: 10.1136/bmjhci-2021-100510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
775 Wan H, Wang Y, Zhang H, Zhang K, Chen Y, Chen C, Zhang W, Xia F, Wang N, Lu Y. Chronic lead exposure induces fatty liver disease associated with the variations of gut microbiota. Ecotoxicology and Environmental Safety 2022;232:113257. [DOI: 10.1016/j.ecoenv.2022.113257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
776 Fernández T, Viñuela M, Vidal C, Barrera F. Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One 2022;17:e0263931. [PMID: 35176096 DOI: 10.1371/journal.pone.0263931] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
777 Park H, Park K, Kim M, Park H, Hwang H. Association between serum uric acid level and non-alcoholic fatty liver disease in Koreans. Asian Biomedicine 2022;16:15-22. [DOI: 10.2478/abm-2022-0003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
778 Núñez F P, Castro F, Mezzano G, Quera R, Diaz D, Castro L. Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. World J Hepatol 2022; 14(2): 319-337 [DOI: 10.4254/wjh.v14.i2.319] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
779 Fassio E, Barreyro FJ, Pérez MS, Dávila D, Landeira G, Gualano G, Ruffillo G. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations? WJH 2022; 14(2):354-71. [DOI: 10.4254/wjh.v14.i2.354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
780 Xue J, Liang S, Ma J, Xiao Y. Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease. BMC Endocr Disord 2022;22:49. [PMID: 35216556 DOI: 10.1186/s12902-022-00967-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
781 Boulouta A, Aggeletopoulou I, Kanaloupitis S, Tsounis EP, Issaris V, Papantoniou K, Apostolos A, Tsaplaris P, Pastras P, Sotiropoulos C, Tsintoni A, Diamantopoulou G, Thomopoulos K, Michalaki M, Triantos C. The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience. Clin Res Hepatol Gastroenterol 2022;:101896. [PMID: 35227957 DOI: 10.1016/j.clinre.2022.101896] [Reference Citation Analysis]
782 Baldin P, Carrasco J, Beniuga G, Jouret-Mourin A, Demolin G, Roland S, D'Hondt L, Vergauwe P, Van Daele D, Mailleux M, Sinapi I, De Cuyper A, Blétard N, Massart B, Delos M, Castella ML, van Maanen A, Van den Eynde M. Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial). Cancers (Basel) 2022;14:1183. [PMID: 35267491 DOI: 10.3390/cancers14051183] [Reference Citation Analysis]
783 Zhang Y, Liu X, Zhang H, Wang X. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Endocrinol 2022;13:836455. [DOI: 10.3389/fendo.2022.836455] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
784 Abou Seada N, El Hamamsy M, Shaheen S, Elwakil R, Barakat A, El‐sayed Mansy A. The impact of clinical pharmacist-led health education on the disease course of non-alcoholic fatty liver disease patients: an interventional study. F1000Res 2022;11:234. [DOI: 10.12688/f1000research.77415.1] [Reference Citation Analysis]
785 Moylan CA, Mavis AM, Jima D, Maguire R, Bashir M, Hyun J, Cabezas MN, Parish A, Niedzwiecki D, Diehl AM, Murphy SK, Abdelmalek MF, Hoyo C. Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children. Epigenetics 2022;:1-16. [PMID: 35188871 DOI: 10.1080/15592294.2022.2039850] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
786 He K, Li J, Xi W, Ge J, Sun J, Jing Z. Dapagliflozin for nonalcoholic fatty liver disease: a systematic review and meta-analysis. Diabetes Res Clin Pract 2022;:109791. [PMID: 35202771 DOI: 10.1016/j.diabres.2022.109791] [Reference Citation Analysis]
787 Mazi TA, Borkowski K, Fiehn O, Bowlus CL, Sarkar S, Matsukuma K, Ali MR, Kieffer DA, Wan YY, Stanhope KL, Havel PJ, Newman JW, Medici V. Plasma Oxylipin Profile Discriminates Ethnicities in Subjects with Non-Alcoholic Steatohepatitis: An Exploratory Analysis. Metabolites 2022;12:192. [DOI: 10.3390/metabo12020192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
788 Zhang Q, Zhang L, Liu K, Shang H, Ruan J, Yu Z, Meng S, Liang F, Wang T, Zhang H, Peng W, Wang Y, Chen J, Xiao T, Wang B. A Network Pharmacology Study on the Active Components and Targets of the Radix Ginseng and Radix Bupleuri Herb Pair for Treating Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2022;2022:1638740. [PMID: 35178098 DOI: 10.1155/2022/1638740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
789 Chen C, Li H, Song J, Zhang C, Li M, Mao Y, Liu A, Du J, Drew PD. Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease. PPAR Research 2022;2022:1-7. [DOI: 10.1155/2022/4709300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
790 Maevskaya M, Kotovskaya Y, Ivashkin V, Tkacheva O, Troshina E, Shestakova M, Breder V, Geyvandova N, Doschitsin V, Dudinskaya E, Ershova E, Kodzoeva K, Komshilova K, Korochanskaya N, Mayorov A, Mishina E, Nadinskaya M, Nikitin I, Pogosova N, Tarzimanova A, Shamkhalova M. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii arkhiv. [DOI: 10.26442/00403660.2022.02.201363] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
791 Chahal D, Sharma D, Keshavarzi S, Arisar FAQ, Patel K, Xu W, Bhat M. Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank. Hepatol Int 2022. [PMID: 35178663 DOI: 10.1007/s12072-022-10304-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
792 Yang C, He Q, Chen Z, Qin J, Lei F, Liu Y, Liu W, Chen M, Sun T, Zhu Q, Wu Y, Zhuo M, Cai J, Mao W, Li H. A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease. Front Endocrinol 2022;13:821689. [DOI: 10.3389/fendo.2022.821689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
793 Hasin-Brumshtein Y, Sakaram S, Khatri P, He YD, Sweeney TE. A robust gene expression signature for NASH in liver expression data. Sci Rep 2022;12:2571. [PMID: 35173224 DOI: 10.1038/s41598-022-06512-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
794 Boehlig A, Gerhardt F, Petroff D, van Boemmel F, Berg T, Blank V, Karlas T, Wiegand J. Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. Biomedicines 2022;10:451. [DOI: 10.3390/biomedicines10020451] [Reference Citation Analysis]
795 Attia IM. Novel Approach of Multistate Markov Chains to Evaluate Progression in the Expanded Model of Non-alcoholic Fatty Liver Disease. Front Appl Math Stat 2022;7:766085. [DOI: 10.3389/fams.2021.766085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
796 De Rosa L, Salvati A, Bonino F, Brunetto MR, Faita F. Effects of Different Scan Projections on the Quantitative Ultrasound-Based Evaluation of Hepatic Steatosis. Healthcare 2022;10:374. [DOI: 10.3390/healthcare10020374] [Reference Citation Analysis]
797 Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-peralta F. Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. JCM 2022;11:968. [DOI: 10.3390/jcm11040968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
798 Quinn C, Rico MC, Merali C, Merali S. Dysregulation of S-adenosylmethionine Metabolism in Nonalcoholic Steatohepatitis Leads to Polyamine Flux and Oxidative Stress. Int J Mol Sci 2022;23:1986. [PMID: 35216100 DOI: 10.3390/ijms23041986] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
799 Xing Y, Chen J, Liu J, Song G, Ma H. Relationship Between Serum Uric Acid-to-Creatinine Ratio and the Risk of Metabolic-Associated Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes 2022;15:257-67. [PMID: 35140486 DOI: 10.2147/DMSO.S350468] [Reference Citation Analysis]
800 Šmíd V, Dvořák K, Šedivý P, Kosek V, Leníček M, Dezortová M, Hajšlová J, Hájek M, Vítek L, Bechyňská K, Brůha R. Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD. Hepatol Commun 2022. [PMID: 35147302 DOI: 10.1002/hep4.1906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
801 Georgescu D, Caraba A, Ionita I, Lascu A, Hut EF, Dragan S, Ancusa OE, Suceava I, Lighezan D. Dyspepsia and Gut Microbiota in Female Patients with Postcholecystectomy Syndrome. Int J Womens Health 2022;14:41-56. [PMID: 35136356 DOI: 10.2147/IJWH.S342882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
802 Bhat N, Esteghamat F, Chaube BK, Gunawardhana K, Mani M, Thames C, Jain D, Ginsberg HN, Fernandes‐hernando C, Mani A. TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut‐liver crosstalk. The FASEB Journal 2022;36. [DOI: 10.1096/fj.202101607r] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
803 Mohammad Rahimi GR, Attarzadeh Hosseini SR. Effect of Aerobic Exercise Alone or in Conjunction With Diet on Liver Function, Insulin Resistance and Lipids in Non-Alcoholic Fatty Liver Disease. Biol Res Nurs 2022;:10998004211068026. [PMID: 35130757 DOI: 10.1177/10998004211068026] [Reference Citation Analysis]
804 Farrell AM, Magliano DJ, Shaw JE, Thompson AJ, Croagh C, Ryan MC, Howell J. A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study. Sci Rep 2022;12:1956. [PMID: 35121749 DOI: 10.1038/s41598-022-05168-0] [Reference Citation Analysis]
805 Martinou E, Pericleous M, Stefanova I, Kaur V, Angelidi AM. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics (Basel) 2022;12:407. [PMID: 35204498 DOI: 10.3390/diagnostics12020407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
806 Furthner D, Anderwald C, Bergsten P, Forslund A, Kullberg J, Ahlström H, Manell H, Ciba I, Mangge H, Maruszczak K, Koren P, Schütz S, Brunner SM, Schneider AM, Weghuber D, Mörwald K. Single Point Insulin Sensitivity Estimator in Pediatric Non-Alcoholic Fatty Liver Disease. Front Endocrinol 2022;13:830012. [DOI: 10.3389/fendo.2022.830012] [Reference Citation Analysis]
807 Zhao Y, Zhang C, Xu S, Zhang H, Wei S, Huang P, Zhang L, Wong YN, Xu W, Huang P. Quantitative evaluation of hepatic steatosis using novel ultrasound technology normalized local variance (NLV) and its standard deviation with different ROIs in patients with metabolic-associated fatty liver disease: a pilot study. Abdom Radiol (NY) 2022;47:693-703. [PMID: 34958409 DOI: 10.1007/s00261-021-03394-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
808 Hajifathalian K, Tafesh Z, Rosenblatt R, Kumar S, Homan EA, Sharaiha RZ, Cohen DE, Brown RS Jr, Fortune BE. Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease: A Prospective United States Cohort Study. J Clin Gastroenterol 2022;56:173-80. [PMID: 33606428 DOI: 10.1097/MCG.0000000000001503] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
809 Gao F, Chen M, Yu J, Xu L, Yu L, Jiang H, Gu Z. Tetrahydrocurcumin protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis. Journal of Functional Foods 2022;89:104957. [DOI: 10.1016/j.jff.2022.104957] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
810 Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications 2022;36:108101. [PMID: 34922811 DOI: 10.1016/j.jdiacomp.2021.108101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
811 Smirne C, Croce E, Di Benedetto D, Cantaluppi V, Comi C, Sainaghi PP, Minisini R, Grossini E, Pirisi M. Oxidative Stress in Non-Alcoholic Fatty Liver Disease. Livers 2022;2:30-76. [DOI: 10.3390/livers2010003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
812 Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 2022;76:446-57. [PMID: 34555422 DOI: 10.1016/j.jhep.2021.09.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 38.0] [Reference Citation Analysis]
813 Kim MN, Ahn SH. Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma? Authors' reply. Aliment Pharmacol Ther 2022;55:481-2. [PMID: 35092057 DOI: 10.1111/apt.16765] [Reference Citation Analysis]
814 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO), Members of the guidelines panel, Coordinator, AISF Members, SID Members, SIO Members, Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 2022;54:170-82. [PMID: 34924319 DOI: 10.1016/j.dld.2021.04.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
815 Tavaglione F, De Vincentis A, Bruni V, Gallo IF, Carotti S, Tuccinardi D, Spagnolo G, Ciociola E, Mancina RM, Jamialahmadi O, D'Alessio R, Bottazzi B, Manfrini S, Picardi A, Perrone G, Pozzilli P, Caricato M, Vespasiani-Gentilucci U, Romeo S. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery. Liver Int 2022;42:374-83. [PMID: 34890093 DOI: 10.1111/liv.15127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
816 Sebastiani G, Patel K, Ratziu V, Feld JJ, Neuschwander-tetri BA, Pinzani M, Petta S, Berzigotti A, Metrakos P, Shoukry N, Brunt EM, Tang A, Cobbold JF, Ekoe J, Seto K, Ghali P, Chevalier S, Anstee QM, Watson H, Bajaj H, Stone J, Swain MG, Ramji A. Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). CanLivJ 2022;5:61-90. [DOI: 10.3138/canlivj-2021-0030] [Reference Citation Analysis]
817 Lan T, Hu Y, Hu F, Li H, Chen Y, Zhang J, Yu Y, Jiang S, Weng Q, Tian S, Ma T, Yang G, Luo D, Wang L, Li K, Piao S, Rong X, Guo J. Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling. J Hepatol 2022;76:407-19. [PMID: 34656650 DOI: 10.1016/j.jhep.2021.09.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
818 Lake JE, Overton T, Naggie S, Sulkowski M, Loomba R, Kleiner DE, Price JC, Chew KW, Chung RT, Corey KE. Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. Clin Gastroenterol Hepatol 2022;20:256-68. [PMID: 33069882 DOI: 10.1016/j.cgh.2020.10.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
819 Yang S, Cheng J, Zhang R, Sun H, Zhang H, Lyu S, Duan W. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. Hepatol Res 2022;52:176-86. [PMID: 34751487 DOI: 10.1111/hepr.13728] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
820 Cariou B. The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. Diabetes Obes Metab 2022;24 Suppl 2:15-27. [PMID: 35014161 DOI: 10.1111/dom.14651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
821 Rabbitt LA, McNally M, Reynolds L, Hinchion K, Simpkin A, Scarry M, Bohan-Keane M, Goulding C. A prospective cohort study of the use of the fatty liver index and Fibroscan to determine the prevalence of fatty liver disease in an Irish population. Eur J Gastroenterol Hepatol 2022;34:200-5. [PMID: 33079776 DOI: 10.1097/MEG.0000000000001951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
822 Kim MN, Lo CH, Corey KE, Luo X, Long L, Zhang X, Chan AT, Simon TG. Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: Evidence from mediation analysis. Clin Nutr 2022;41:356-64. [PMID: 34999330 DOI: 10.1016/j.clnu.2021.12.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
823 Huang Z, Ng K, Chen H, Deng W, Li Y. Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement. Front Endocrinol 2022;12:739875. [DOI: 10.3389/fendo.2021.739875] [Reference Citation Analysis]
824 Zou H, Ge Y, Lei Q, Ung COL, Ruan Z, Lai Y, Yao D, Hu H. Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review. Hepatol Int. [DOI: 10.1007/s12072-021-10286-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
825 Meister FA, Lurje G, Verhoeven S, Wiltberger G, Heij L, Liu WJ, Jiang D, Bruners P, Lang SA, Ulmer TF, Neumann UP, Bednarsch J, Czigany Z. The Role of Sarcopenia and Myosteatosis in Short- and Long-Term Outcomes Following Curative-Intent Surgery for Hepatocellular Carcinoma in a European Cohort. Cancers (Basel) 2022;14:720. [PMID: 35158988 DOI: 10.3390/cancers14030720] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
826 Tang H, Li J, Zinker B, Boehm S, Mauer A, Rex-Rabe S, Glaser KJ, Fronheiser M, Bradstreet T, Nakao Y, Petrone T, Pena A, Villano M, Chow P, Malhi H, Charles ED, Hayes W, Ehman RL, Du S, Yin M. Evaluation of a PEGylated Fibroblast Growth Factor 21 Variant Using Novel Preclinical Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Mouse Model of Nonalcoholic Steatohepatitis. J Magn Reson Imaging 2022. [PMID: 35092323 DOI: 10.1002/jmri.28077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
827 Duseja ADA. Future pharmacotherapy for non-alcoholic steatohepatitis. NMJI 2022;34:225-227. [DOI: 10.25259/nmji_103_21] [Reference Citation Analysis]
828 Tsay CJ, Lim JK. NASH and the Gut Microbiome: Implications for New Therapies. Clinical Liver Disease. [DOI: 10.1002/cld.1170] [Reference Citation Analysis]
829 Han S, Sung GH, Lee S, Han KJ, Han HJ. Serum cadmium is associated with hepatic steatosis and fibrosis: Korean national health and nutrition examination survey data IV-VII. Medicine (Baltimore) 2022;101:e28559. [PMID: 35089193 DOI: 10.1097/MD.0000000000028559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
830 Devi J, Raees A, Butt AS. Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible? World J Hepatol 2022; 14(1): 158-167 [DOI: 10.4254/wjh.v14.i1.158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
831 Prikhodko VA, Bezborodkina NN, Okovityi SV. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines 2022;10:274. [DOI: 10.3390/biomedicines10020274] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
832 Duseja A, Singh SP, Mehta M, Shalimar, Venkataraman J, Mehta V, Devadas K, Kar SK, Goyal O, Nagral A, Saigal S, Nijhawan S, Praharaj D, Shukla A, Sharma B, Narayanasamy K, Kumar P, Rao PN, Arora A, Mehta R, Asati P, Ranjan P, Koshy A, Alam S, Mukewar S, Mukewar S, Mohan Prasad VG, Rastogi M, Sanyal AJ. Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease. Metab Syndr Relat Disord 2022. [PMID: 35085026 DOI: 10.1089/met.2021.0104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
833 Ferraioli G, Kumar V, Ozturk A, Nam K, de Korte CL, Barr RG. US Attenuation for Liver Fat Quantification: An AIUM-RSNA QIBA Pulse-Echo Quantitative Ultrasound Initiative. Radiology 2022;:210736. [PMID: 35076304 DOI: 10.1148/radiol.210736] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
834 Garcia DO, Morrill KE, Lopez-Pentecost M, Villavicencio EA, Vogel RM, Bell ML, Klimentidis YC, Marrero DG, Thomson CA. Nonalcoholic Fatty Liver Disease and Associated Risk Factors in a Community-Based Sample of Mexican-Origin Adults. Hepatol Commun 2022. [PMID: 35076162 DOI: 10.1002/hep4.1896] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
835 Hu C, Zhuang X, Zhang J, Wang T, Du S, Wang J, Peng X, Cao Q, Zhang M, Jiang Y. Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatography-Mass Spectrometry. Lab Med 2022:lmab118. [PMID: 35075477 DOI: 10.1093/labmed/lmab118] [Reference Citation Analysis]
836 Wong WJ, Emdin C, Bick A, Zekavat SM, Niroula A, Pirruccello J, Dichtel L, Griffin G, Uddin MM, Gibson CJ, Kovalcik V, Lin AE, Mcconkey ME, Vromman A, Sellar RS, Kim PG, Agrawal M, Weinstock J, Long MT, Yu B, Banerjee R, Nicholls RC, Kelly M, Loh P, Mccarroll S, Boerwinkle E, Vasan R, Jaiswal S, Johnson A, Chung RT, Corey K, Levy D, Ballantyne C, Ebert BL, Natarajan P, NHLBI TOPMed Hematology Working Group. Clonal hematopoiesis and risk of chronic liver disease.. [DOI: 10.1101/2022.01.17.22269409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
837 Heredia NI, Zhang X, Balakrishnan M, Hwang JP, Thrift AP. Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among Hispanic/Latinos adults in the U.S. Ethn Health 2022;:1-14. [PMID: 35067116 DOI: 10.1080/13557858.2022.2027883] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
838 Herrington GJ, Peterson JJ, Cheng L, Allington BM, Jensen RD, Healy HS, Correia MLG. The use of very low‐calorie diets in subjects with obesity complicated with nonalcoholic fatty liver disease: A scoping review. Obesity Science & Practice. [DOI: 10.1002/osp4.589] [Reference Citation Analysis]
839 Alrasheed M, Guo JJ, Lin AC, Wigle PR, Hardee A, Hincapie AL. The effect of polypharmacy on quality of life in adult patients with nonalcoholic fatty liver disease in the United States. Qual Life Res. [DOI: 10.1007/s11136-022-03090-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
840 Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022;28:310-31. [PMID: 35110952 DOI: 10.3748/wjg.v28.i3.310] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
841 Liu L, Xie S, Teng Y, Deng Z, Chen K, Liu H, Huo R, Liang X, Guo P, Yang D, Ma L, Xiang B, Li L, Zhong J. Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. Front Oncol 2022;11:783339. [DOI: 10.3389/fonc.2021.783339] [Reference Citation Analysis]
842 Xue W, Zhang L, Liu C, Gao Y, Li S, Huai Z, Dai J, Wang Y. Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2032661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
843 Schreiner AD, Moran WP, Zhang J, Livingston S, Marsden J, Mauldin PD, Koch D, Gebregziabher M. The Association of Fibrosis-4 Index Scores with Severe Liver Outcomes in Primary Care. J GEN INTERN MED. [DOI: 10.1007/s11606-021-07341-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
844 Bernstein D, Kovalic AJ. Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]. Metabol Open 2022;13:100158. [PMID: 35036892 DOI: 10.1016/j.metop.2021.100158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
845 Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. J Am Coll Cardiol 2022;79:180-91. [PMID: 35027111 DOI: 10.1016/j.jacc.2021.11.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
846 Rustgi VK, Duff SB, Elsaid MI. Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease. J Med Econ 2022;:1-29. [PMID: 35034553 DOI: 10.1080/13696998.2022.2026702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
847 Horiuchi K, Kogiso T, Sagawa T, Taniai M, Kotera Y, Egawa H, Tokushige K. Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors. Ann Hepatol 2022;27:100670. [PMID: 35051631 DOI: 10.1016/j.aohep.2022.100670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
848 Lima ÉC, Passos MDCF, Ferolla SM, Costa RSND, Lisboa QC, Pereira LID, Nardelli MJ, Arantes VN, Ferrari TCA, Couto CA. High prevalence of functional dyspepsia in nonalcoholic fatty liver disease: a cross-sectional study. Sao Paulo Med J 2022:S1516-31802022005001201. [PMID: 35043829 DOI: 10.1590/1516-3180.2021.0015.R1.14062021] [Reference Citation Analysis]
849 Lesmana CRA, Kencana Y, Rinaldi I, Kurniawan J, Hasan I, Sanityoso Sulaiman A, Gani RA. Diagnostic Value of Neutrophil to Lymphocyte Ratio in Non-Alcoholic Fatty Liver Disease Evaluated Using Transient Elastography (TE) with Controlled Attenuated Parameter (CAP). Diabetes Metab Syndr Obes 2022;15:15-22. [PMID: 35023936 DOI: 10.2147/DMSO.S330526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
850 Angelidi AM, Papadaki A, Nolen-Doerr E, Boutari C, Mantzoros CS. The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials. Metabolism 2022;:155136. [PMID: 35032545 DOI: 10.1016/j.metabol.2022.155136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
851 Gatzios A, Rombaut M, Buyl K, De Kock J, Rodrigues RM, Rogiers V, Vanhaecke T, Boeckmans J. From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights. Biomedicines 2022;10:161. [DOI: 10.3390/biomedicines10010161] [Reference Citation Analysis]
852 Raeman R. Inflammation: The Straw That Broke the NAFLD Liver! Cell Mol Gastroenterol Hepatol 2022;13:1273-4. [PMID: 35031516 DOI: 10.1016/j.jcmgh.2022.01.006] [Reference Citation Analysis]
853 Um YJ, Chang Y, Jung H, Cho IY, Shin JH, Shin H, Wild SH, Byrne CD, Ryu S. Decrease in Sleep Duration and Poor Sleep Quality over Time Is Associated with an Increased Risk of Incident Non-Alcoholic Fatty Liver Disease. JPM 2022;12:92. [DOI: 10.3390/jpm12010092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
854 Kumari B, Sharma S, Kumar R, Dipankar S, Naik BN, Banerjee A, Kumar S. Efficacy of Lipid Ratios and Platelet Distribution Width for Assessment of Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. Cureus 2022. [DOI: 10.7759/cureus.21110] [Reference Citation Analysis]
855 Liu Y, Li D, Liu Y, Shuai P. Association Between Helicobacter Pylori Infection and Non-alcoholic Fatty Liver Disease, Hepatic Adipose Deposition and Stiffness in Southwest China. Front Med (Lausanne) 2021;8:764472. [PMID: 35004736 DOI: 10.3389/fmed.2021.764472] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
856 Xu J, Shen J, Yuan R, Jia B, Zhang Y, Wang S, Zhang Y, Liu M, Wang T. Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-alcoholic Fatty Liver Disease. Front Pharmacol 2021;12:796207. [PMID: 35002729 DOI: 10.3389/fphar.2021.796207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
857 Köylü B. Biyopsi tanılı nonalkolik steatohepatit hastalarında fibrozis evrelerine göre metabolik sendrom komponentlerinin sıklıklarının karşılaştırılması: Metabolik bozukluk sayısındaki artış fibrozis progresyonunda etkili mi? Akademik Gastroenteroloji Dergisi 2022. [DOI: 10.17941/agd.1055288] [Reference Citation Analysis]
858 Jia S, Zhao Y, Liu J, Guo X, Chen M, Zhou S, Zhou J. Magnetic Resonance Imaging-Proton Density Fat Fraction vs. Transient Elastography-Controlled Attenuation Parameter in Diagnosing Non-alcoholic Fatty Liver Disease in Children and Adolescents: A Meta-Analysis of Diagnostic Accuracy. Front Pediatr 2022;9:784221. [DOI: 10.3389/fped.2021.784221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
859 Al-Karaghouli M, Fuentes S, Davyduke T, Ma M, Abraldes JG. Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD. BMJ Open Gastroenterol 2022;9:e000798. [PMID: 34992072 DOI: 10.1136/bmjgast-2021-000798] [Reference Citation Analysis]
860 Ben-Assuli O, Jacobi A, Goldman O, Shenhar-Tsarfaty S, Rogowski O, Zeltser D, Shapira I, Berliner S, Zelber-Sagi S. Stratifying individuals into non-alcoholic fatty liver disease risk levels using time series machine learning models. J Biomed Inform 2022;126:103986. [PMID: 35007752 DOI: 10.1016/j.jbi.2022.103986] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
861 Ma Z, Zhu Y, Wang Q, Deng M, Wang J, Li D, Gu L, Zhao R, Yan S. Y-box binding protein 1 regulates liver lipid metabolism by regulating the Wnt/β-catenin signaling pathway. Ann Transl Med 2021;9:1693. [PMID: 34988202 DOI: 10.21037/atm-21-5767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
862 Moran S. Prevalence of non alcoholic fatty liver disease and associated factors? Ann Hepatol 2022;27:100659. [PMID: 35007769 DOI: 10.1016/j.aohep.2022.100659] [Reference Citation Analysis]
863 Yang N, Lu Y, Cao L, Lu M. The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults. J Clin Lab Anal 2022;:e24225. [PMID: 34997649 DOI: 10.1002/jcla.24225] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
864 Ciardullo S, Pizzi M, Pizzi P, Oltolini A, Muraca E, Perseghin G. Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States. Obes Surg 2022;32:712-9. [PMID: 34988895 DOI: 10.1007/s11695-021-05885-x] [Reference Citation Analysis]
865 Xing M, Gao M, Li J, Han P, Mei L, Zhao L. Characteristics of peripheral blood Gamma-glutamyl transferase in different liver diseases. Medicine (Baltimore) 2022;101:e28443. [PMID: 35029891 DOI: 10.1097/MD.0000000000028443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
866 Thomas KL, Root CL, Peterson JM. Transgenic overexpression of CTRP3 does not prevent alcohol induced hepatic steatosis in female mice. PLoS ONE 2022;17:e0258557. [DOI: 10.1371/journal.pone.0258557] [Reference Citation Analysis]
867 Anstee QM, Hallsworth K, Lynch N, Hauvespre A, Mansour E, Kozma S, Marino JP, Bottomley J, Piercy J, Higgins V. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions. JHEP Rep 2022;4:100411. [PMID: 34977520 DOI: 10.1016/j.jhepr.2021.100411] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
868 Luo Y, Decato BE, Charles ED, Shevell DE, McNaney C, Shipkova P, Apfel A, Tirucherai GS, Sanyal AJ. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis. JHEP Rep 2022;4:100392. [PMID: 34977519 DOI: 10.1016/j.jhepr.2021.100392] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
869 Andreev KA, Skirdenko YP, Nikolaev NA, Livzan MA, Gorbenko AV, Fedorin MM, Krolevets TS. Adherence to lifestyle modification in patients with nonalcoholic fatty liver disease. Bûll sib med 2022;20:112-122. [DOI: 10.20538/1682-0363-2021-4-112-122] [Reference Citation Analysis]
870 Chang WH, Mueller SH, Chung SC, Foster GR, Lai AG. Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost. J Transl Med 2022;20:2. [PMID: 34980174 DOI: 10.1186/s12967-021-03210-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
871 Garbuzenko DV. Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2022;31:16-24. [DOI: 10.22416/1382-4376-2021-31-5-16-24] [Reference Citation Analysis]
872 Muzurović EM, Volčanšek Š, Tomšić KZ, Janež A, Mikhailidis DP, Rizzo M, Mantzoros CS. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence. J Cardiovasc Pharmacol Ther 2022;27:10742484221146371. [PMID: 36546652 DOI: 10.1177/10742484221146371] [Reference Citation Analysis]
873 Kaya E, Yilmaz Y. Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease. Therapeutic Advances in Endocrinology 2022;13:204201882211396. [DOI: 10.1177/20420188221139650] [Reference Citation Analysis]
874 Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol 2022;76:195-201. [PMID: 34508791 DOI: 10.1016/j.jhep.2021.08.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
875 F. Lange N, Dufour J. Spezifische Therapie – neue Medikamente. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_21] [Reference Citation Analysis]
876 An L, Wirth U, Koch D, Schirren M, Drefs M, Koliogiannis D, Nieß H, Andrassy J, Guba M, Bazhin AV, Werner J, Kühn F. The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. J Gastrointest Surg 2022;26:671-83. [PMID: 34734369 DOI: 10.1007/s11605-021-05188-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
877 Stokes CS. Therapie: Diät. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_19] [Reference Citation Analysis]
878 Howell J, Samani A, Mannan B, Hajiev S, Motedayen Aval L, Abdelmalak R, Tam VC, Bettinger D, Thimme R, Taddei TH, Kaplan DE, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therap Adv Gastroenterol 2022;15:175628482211001. [DOI: 10.1177/17562848221100106] [Reference Citation Analysis]
879 Aggarwal S, Agarwal L, Chekuri R, Singla V, Kumar A, Shalimar. Impact of metabolic and bariatric surgery on liver diseases: Current evidence. J Bariatr Surg 2022;0:0. [DOI: 10.4103/jbs.jbs_9_22] [Reference Citation Analysis]
880 Salvador S, Oje A, Sarker S. Obesity and its impact on gastrointestinal health. Obesity and Esophageal Disorders 2022. [DOI: 10.1016/b978-0-323-98365-5.00006-1] [Reference Citation Analysis]
881 Hydes TJ, Cuthbertson DJ, Graef S, Berhane S, Teng M, Skowronska A, Singh P, Dhanaraj S, Tahrani A, Johnson PJ. The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall Survival. Clinical Therapeutics 2022. [DOI: 10.1016/j.clinthera.2021.12.011] [Reference Citation Analysis]
882 Bergram M, Nasr P, Iredahl F, Kechagias S, Rådholm K, Ekstedt M. Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. Scand J Gastroenterol 2022;57:60-9. [PMID: 34618619 DOI: 10.1080/00365521.2021.1984572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
883 Roeb E. Diagnostik: Algorithmus und Leberbiopsie. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_16] [Reference Citation Analysis]
884 Plaz MC, Tsochatzis EA. Metabolic Complications Before and After Liver Transplantation. Textbook of Liver Transplantation 2022. [DOI: 10.1007/978-3-030-82930-8_20] [Reference Citation Analysis]
885 Kawashita E, Ozaki T, Ishihara K, Kashiwada C, Akiba S. Endothelial group IVA phospholipase A2 promotes hepatic fibrosis with sinusoidal capillarization in the early stage of a non-alcoholic steatohepatitis in mice. Life Sciences 2022. [DOI: 10.1016/j.lfs.2022.120355] [Reference Citation Analysis]
886 Fearon N, Pournaras D. Effect of Metabolic Surgery on Non-Alcoholic Steatohepatitis. Obesity, Bariatric and Metabolic Surgery 2022. [DOI: 10.1007/978-3-030-54064-7_107-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
887 Wang M, Guo W, Yang Z, Chen F, Lin T, Li W, Lv X, Rao P, Ai L, Ni L. Intestinal microbiomics and liver metabolomics insights into the preventive effects of chromium (III)-enriched yeast on hyperlipidemia and hyperglycemia induced by high-fat and high-fructose diet. Current Research in Food Science 2022;5:1365-1378. [DOI: 10.1016/j.crfs.2022.08.015] [Reference Citation Analysis]
888 Holanda NCP, Oliveira ARL, Carvalho NNC, Souza BL. Nonalcoholic Fatty Liver Disease. Endocrinology and Diabetes 2022. [DOI: 10.1007/978-3-030-90684-9_42] [Reference Citation Analysis]
889 Elsaid MI, Bridges JF, Li N, Rustgi VK. Metabolic Syndrome Severity Predicts Mortality in Nonalcoholic Fatty Liver Disease. Gastro Hep Advances 2022;1:445-56. [DOI: 10.1016/j.gastha.2022.02.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
890 Natarajan Y, Loomba R. Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD. J Clin Exp Hepatol 2022;12:174-9. [PMID: 35068797 DOI: 10.1016/j.jceh.2021.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
891 Anand A, Singh AA, Elhence A, Vaishnav M, Biswas S, Gunjan D, Gamanagatti SR, Nayak B, Kumar R, Shalimar. Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol 2022;12:362-71. [PMID: 35535086 DOI: 10.1016/j.jceh.2021.07.013] [Reference Citation Analysis]
892 Huber Y, Schattenberg JM. Epidemiologie. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_1] [Reference Citation Analysis]
893 Imajo K, Honda Y, Yoneda M, Saito S, Nakajima A. Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. Jpn J Med Ultrasonics 2022;49:411-425. [DOI: 10.3179/jjmu.jjmu.r.203] [Reference Citation Analysis]
894 Asgharpour A, Sanyal AJ. Generation of a Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease. Methods in Molecular Biology 2022. [DOI: 10.1007/978-1-0716-2128-8_2] [Reference Citation Analysis]
895 Stickel F, Datz C. Nicht-alkoholische Fettlebererkrankung und Alkoholkonsum. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_32] [Reference Citation Analysis]
896 Jaffe A, Strazzabosco M. Metabolic Syndrome and Liver Cancer. Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_51] [Reference Citation Analysis]
897 Georgescu CE. Polycystic ovary syndrome and nonalcoholic fatty liver disease. Polycystic Ovary Syndrome 2022. [DOI: 10.1016/b978-0-12-823045-9.00007-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
898 Gao W, Li Z, Chu H, Yuan H, Hu L, Yao L, Zhang L, Wang W, Lin R, Yang L. Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective. Pharmacotherapy for Liver Cirrhosis and Its Complications 2022. [DOI: 10.1007/978-981-19-2615-0_6] [Reference Citation Analysis]
899 Fitzpatrick E. Nonalcoholic Fatty Liver Disease. In Clinical Practice 2022. [DOI: 10.1007/978-3-030-98808-1_10] [Reference Citation Analysis]
900 Tada T, Iijima H, Kumada T. Ultrasound diagnosis of fatty liver disease. Jpn J Med Ultrasonics 2022;49:313-327. [DOI: 10.3179/jjmu.jjmu.r.207] [Reference Citation Analysis]
901 Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00261-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 19.0] [Reference Citation Analysis]
902 Xie J, Huang H, Chen Y, Xu L, Xu C. Skipping breakfast is associated with an increased long-term cardiovascular mortality in metabolic dysfunction-associated fatty liver disease (MAFLD) but not MAFLD-free individuals. Aliment Pharmacol Ther 2022;55:212-24. [PMID: 34877669 DOI: 10.1111/apt.16727] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
903 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO), Members of the guidelines panel, Coordinator, AISF Members, SID Members, SIO Members, Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis 2022;32:1-16. [PMID: 34924246 DOI: 10.1016/j.numecd.2021.04.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
904 Yoneda M, Honda Y, Nogami A, Imajo K, Nakajima A. Advances in ultrasound elastography for nonalcoholic fatty liver disease. Jpn J Med Ultrasonics 2022;49:397-410. [DOI: 10.3179/jjmu.jjmu.r.202] [Reference Citation Analysis]
905 Govaere O, Anstee QM. Non-Alcoholic Fatty Liver Disease and Steatohepatitis. Reference Module in Life Sciences 2022. [DOI: 10.1016/b978-0-12-821618-7.00265-0] [Reference Citation Analysis]
906 Weber SN, Lammert F. Pathophysiologie: Genetik. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_8] [Reference Citation Analysis]
907 Rojas Á, Lara-romero C, Muñoz-hernández R, Gato S, Ampuero J, Romero-gómez M. Emerging pharmacological treatment options for MAFLD. Therapeutic Advances in Endocrinology 2022;13:204201882211424. [DOI: 10.1177/20420188221142452] [Reference Citation Analysis]
908 Pepin KM, Welle CL, Guglielmo FF, Dillman JR, Venkatesh SK. Magnetic resonance elastography of the liver: everything you need to know to get started. Abdom Radiol (NY) 2022;47:94-114. [PMID: 34725719 DOI: 10.1007/s00261-021-03324-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
909 Heredia NI, Zhang X, Balakrishnan M, Daniel CR, Hwang JP, McNeill LH, Thrift AP. Physical activity and diet quality in relation to non-alcoholic fatty liver disease: A cross-sectional study in a representative sample of U.S. adults using NHANES 2017-2018. Prev Med 2022;154:106903. [PMID: 34861339 DOI: 10.1016/j.ypmed.2021.106903] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
910 Bu SY. Association of energy intake with handgrip strength in Korean adults with non-alcoholic fatty liver disease. J Nutr Health 2022;55:684. [DOI: 10.4163/jnh.2022.55.6.684] [Reference Citation Analysis]
911 Mandelia C, Worley S, Kabbany MN, Selvakumar PKC. Performance Characteristics, Intra- & Inter-Operator Agreement of Transient Elastography in Pediatric NAFLD. J Pediatr Gastroenterol Nutr 2022;74:e19-20. [PMID: 34321426 DOI: 10.1097/MPG.0000000000003255] [Reference Citation Analysis]
912 Montaño-loza AJ. Evaluación de la fibrosis en pacientes con enfermedad de hígado graso no alcohólico. Revista de Gastroenterología de México 2022;87:1-3. [DOI: 10.1016/j.rgmx.2021.04.004] [Reference Citation Analysis]
913 Thompson J, Karnsakul W. Liver disorders: nutritional management. Reference Module in Food Science 2022. [DOI: 10.1016/b978-0-12-821848-8.00171-2] [Reference Citation Analysis]
914 Paulino do Nascimento LC, Cruz Neto JPR, Callou KRDA, Dejani NN, de Brito Alves JL. Probiotics for liver disease prevention and treatment. Probiotics for Human Nutrition in Health and Disease 2022. [DOI: 10.1016/b978-0-323-89908-6.00009-1] [Reference Citation Analysis]
915 Maksimova E, Kliaritskaia I, Stilidi E, Grigorenko E, Moshko Y. Influence of changes in the intestinal microbiome on the course and progression of metabolically associated fatty liver disease. NAMJ 2022. [DOI: 10.56936/18290825-2022.16.2-38] [Reference Citation Analysis]
916 De A, Keisham A, Mishra S, Mehta M, Verma N, Premkumar M, Taneja S, Das A, Singh V, Duseja A. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort. J Clin Exp Hepatol 2022;12:440-7. [PMID: 35535068 DOI: 10.1016/j.jceh.2021.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
917 Al-Omary A, Byth K, Weltman M, George J, Eslam M. The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C. J Dig Dis 2022;23:33-43. [PMID: 34902220 DOI: 10.1111/1751-2980.13071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
918 Giashuddin S, Alawad M. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH). Methods in Molecular Biology 2022. [DOI: 10.1007/978-1-0716-2128-8_1] [Reference Citation Analysis]
919 Lu X, Wang F. MicroRNA targeted therapy in hepatitis. MicroRNA 2022. [DOI: 10.1016/b978-0-323-89774-7.00009-1] [Reference Citation Analysis]
920 Heidari Z, Sheikhi V. Association of subclinical hypothyroidism with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A cross-sectional study. Adv Biomed Res 2022;11:124. [DOI: 10.4103/abr.abr_15_21] [Reference Citation Analysis]
921 Hussain F. Psychiatric Aspects of Obesity in Transplantation. Transplant Psychiatry 2022. [DOI: 10.1007/978-3-031-15052-4_9] [Reference Citation Analysis]
922 Chhabra S, Singh SP, Singh A, Mehta V, Kaur A, Bansal N, Sood A. Diabetes Mellitus Increases the Risk of Significant Hepatic Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol 2022;12:409-16. [PMID: 35535092 DOI: 10.1016/j.jceh.2021.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
923 Chandra Kumar CV, Skantha R, Chan W. Non-invasive assessment of metabolic dysfunction–associated fatty liver disease. Therapeutic Advances in Endocrinology 2022;13:204201882211396. [DOI: 10.1177/20420188221139614] [Reference Citation Analysis]
924 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 28.0] [Reference Citation Analysis]
925 Apostolopoulou M, Roden M. Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_20] [Reference Citation Analysis]
926 Cheng X, Tu P, Dong W, Yu B, Xia S, Muskat MN, Guan B. Electrophilic thymol isobutyrate from Inula nervosa Wall. (Xiaoheiyao) ameliorates steatosis in HepG2 cells via Nrf2 activation. Journal of Functional Foods 2022;88:104895. [DOI: 10.1016/j.jff.2021.104895] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
927 American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45:S46-59. [PMID: 34964869 DOI: 10.2337/dc22-S004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 41.0] [Reference Citation Analysis]
928 Fitzpatrick E. Nonalcoholic Fatty Liver Disease. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition 2022. [DOI: 10.1007/978-3-030-80068-0_69] [Reference Citation Analysis]
929 Baba HA. Pathologie. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_3] [Reference Citation Analysis]
930 S Daud N, Akram N, Hidayah N, Jayanti S, Handayani I, Massi M. Gut microbiome profiling in nonalcoholic fatty liver disease and healthy individuals in Indonesian population. J Med Sci 2022;42:166. [DOI: 10.4103/jmedsci.jmedsci_25_21] [Reference Citation Analysis]
931 Bantel H, Bahr MJ. Diagnostik: Blutbasierte Marker. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_14] [Reference Citation Analysis]
932 Bergasa NV. Nonalcoholic Fatty Liver Disease. Clinical Cases in Hepatology 2022. [DOI: 10.1007/978-1-4471-4715-2_9] [Reference Citation Analysis]
933 Witkowski M, Moreno SI, Fernandes J, Johansen P, Augusto M, Nair S. The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review. Pharmacoeconomics 2022;40:751-76. [PMID: 35789987 DOI: 10.1007/s40273-022-01140-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
934 Weiss J. Therapie: Bewegung. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_18] [Reference Citation Analysis]
935 Ramos-tovar E, Muriel P. Free radicals, antioxidants, nuclear factor-E2-related factor-2 and liver damage. Vitamins and Hormones 2022. [DOI: 10.1016/bs.vh.2022.09.006] [Reference Citation Analysis]
936 李 红. Progress in the Treatment of Metabolism-Related Fatty Liver Disease. ACM 2022;12:8647-8654. [DOI: 10.12677/acm.2022.1291249] [Reference Citation Analysis]
937 胡 盛. Association between Non-Alcoholic Fatty Liver Disease and the Risk of Colorectal Polyp. ACM 2022;12:2996-3004. [DOI: 10.12677/acm.2022.124432] [Reference Citation Analysis]
938 . Fatty Liver Disease. Non-Neoplastic Diseases of the Liver 2022. [DOI: 10.55418/9781933477183-9] [Reference Citation Analysis]
939 Shen MC, Chiou SS, Chou SC, Weng TF, Lin CY, Wang JD, Lee SW, Peng CT. Prevalence of non-Alcoholic Fatty Liver Disease and Associated Factors in Patients with Moderate or Severe Hemophilia: A Multicenter-Based Study. Clin Appl Thromb Hemost 2022;28:10760296221128294. [PMID: 36163682 DOI: 10.1177/10760296221128294] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
940 Wang YL, Zhou X, Li DL, Ye JM. Role of the mTOR-autophagy-ER stress pathway in high fructose-induced metabolic-associated fatty liver disease. Acta Pharmacol Sin 2022;43:10-